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ABSTRACT 
The effects of ingesting a ready-to-drink pre-workout supplement (RTD) on 
exercise performance were assessed in this dissertation.  Resistance-trained 
participants (n=25, 24 ± 4 y) ingested in a double-blind, crossover study a: (1) Dextrose 
placebo (PLA, 12 g) and, (2) RTD containing caffeine (200 mg), β-alanine (2.1 g), niacin 
(65 mg), folic acid (325 mcg), Vitamin B12 (45 mcg), and arginine nitrate (1.3 g) for 7 d, 
interspersed by 7 d washout.  Data were analyzed by univariate, multivariate, and 
repeated measures general linear models (GLM), adjusted for gender and relative 
caffeine intake. Data are presented as mean change (95% CI). An overall multivariate 
time × treatment interaction was observed on strength performance variables (p = 
0.01). Acute RTD ingestion better maintained LP 1-RM (PLA: −0.285 (−0.49, −0.08); 
RTD: 0.23 (−0.50, 0.18) kg/kgFFM, p = 0.30); increased LP RtF (PLA: −2.60 (−6.8, 1.6); 
RTD: 4.00 (−0.2, 8.2) repetitions, p = 0.031); increased BP lifting volume (PLA: 0.001 
(−0.13, 0.16); RTD: 0.03 (0.02, 0.04) kg/kgFFM, p = 0.007); and, increased total lifting 
volume (PLA: −13.12 (−36.9, 10.5); RTD: 21.06 (−2.7, 44.8) kg/kgFFM, p = 0.046). 
Short-term RTD ingestion maintained baseline LP 1-RM (PLA: −0.412 (−0.08, −0.07);  
RTD: 0.16 (−0.50, 0.18) kg/kgFFM, p = 0.30); LP RtF (PLA: 0.12 (−3.0, 3.2); RTD: 3.6 
(0.5, 6.7) repetitions, p = 0.116); and, LP lifting volume (PLA: 3.64 (−8.8, 16.1); RTD: 
16.25 (3.8, 28.7) kg/kgFFM, p = 0.157) to a greater degree than PLA. No significant 
differences were observed between treatments in cycling TT performance, 
hemodynamic assessment, fasting blood panels, or self-reported side effects.  Within 
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the confines of this study, the RTD examined appears to be safe and provides an 
ergogenic benefit for total lifting volume by enhancing muscular endurance; however, 
it does not appear to be ergogenic to 4 km time trial performance in non-trained 
cyclists.  
iv 
 
DEDICATION 
I would like to dedicate this dissertation work to my family and many friends.  My 
wife Kristen has been mostly patient and very supportive with me throughout the 
program and my 2-year old daughter, Adelynn Aeris, never fails to make me smile even 
in the stressful times.  I also dedicate this dissertation to my parents, Brent & Patricia, 
and my brothers Logan and Carson as well as Logan’s wife Audra. 
 v 
 
ACKNOWLEDGEMENTS 
I would like to thank my committee chair, Dr. Kreider, and my committee 
members, Dr. Massett, Dr. Smith, and Dr. Woodman.  Their guidance expertise 
throughout my PhD provided a great deal of support.  I give special thanks to the 
Exercise and Sports Nutrition Laboratory for making it possible to perform this study.  I 
would also extend special thanks to Dr. Conrad Earnest whom was instrumental in 
consolidating the statistical analysis and helping to clarify my understanding of SPSS as 
well as providing substantial feedback on my dissertation.  Additionally, I thank Dr. 
Lightfoot for his tutelage and feedback during the first half of my PhD. 
I would also thank my wife, Kristen Deanne Collins, RN, BSN, and daughter for 
being pillars throughout my PhD program.  Kristen was instrumental in honest feedback 
on the writing as well as helping me to organize and my completion of PhD would not 
have been possible without her.  In addition, I wish to thank Dr. Josh Avila, Ayland 
Letsinger, and Jorge Granados for their friendship and constructive criticism throughout 
the program. 
  
 vi 
 
CONTRIBUTORS AND FUNDING SOURCES 
This work was supervised by a dissertation committee consisting of Drs. Kreider, 
Massett, and Woodman of the Department of Health and Kinesiology and Dr. Smith of 
the Department of Animal Sciences.   
The data analyzed in Chapter 4 were collected primarily by the Candidate with 
help from members of the Exercise and Sports Nutrition Laboratory of the Department 
of Health and Kinesiology.  The analysis completed in Chapter 4 was primarily done by 
the Candidate with direction from Dr. Earnest as a research associate and Dr. Kreider as 
principle investigator.  All remaining work for the dissertation was completed 
independently by the Candidate. 
This work was funded by Nutrabolt through a research grant provided to Dr. 
Kreider as Principal Investigator (Bryan, TX).  The contents of this work are solely the 
responsibility of the authors and do not necessarily represent the official views of 
Nutrabolt or Texas A&M University. 
  
 vii 
 
NOMENCLATURE 
ESNL Exercise and Sports Nutrition Laboratory 
ISSN International Society of Sports Nutrition 
FAM Familiarization Session 
RTD Ready-to-Drink pre-workout supplement 
PLA Placebo 
TLVC Total Lifting Volume Combined 
TBPV Total Bench Press Volume 
TLPV Total Leg Press Volume 
BP Bench Press 
LP Leg Press 
1-RM One-repetition maximum 
kg/kgFFM Weight lifted normalized by fat-free mass 
RtF Repetitions to failure 
TT 4-km Time Trial 
HR Heart Rate 
SBP Systolic Blood Pressure 
DBP Diastolic Blood Pressure 
MAP Mean Arterial Pressure 
RPP Rate Pressure Product 
DXA Dual x-ray absorptiometry 
VO2 Volume of Oxygen Consumption 
PCr Phosphocreatine, Phosphagen System 
MVC Maximum voluntary contraction 
EMG Electromyography 
RPE Borg Ratings of Perceived Exertion 
NO Nitric Oxide 
NO2 Nitrite 
NO3 Nitrate 
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CHAPTER I 
INTRODUCTION AND RATIONALE 
 
1.1. Introduction 
 Many athletes and recreational weightlifters will try almost anything if they 
perceive a benefit to performance [1].  The estimate as of 2014 yields a range of 48- to 
53% of those in the United States utilize some form of nutritional supplementation to 
enhance well-being and performance [2] with some estimates going as high as 70% [3].  
These supplements often contain multiple ingredients and it is important new 
combinations of ingredients are properly tested for safety and efficacy.  Pre-workout 
drinks containing combinations of caffeine, β-alanine, and vasodilators (e.g., nitrates, L-
citrulline, L-arginine) [4-6] have become commonplace to both recreational and 
competitive lifters with the goal of enhanced mental acuity [7-10] and performance 
[11-20]. 
According to the International Society of Sports Nutrition (ISSN), consuming 
energy drinks primarily containing caffeine, glucose, taurine, or citrulline an improve 
acute exercise performance, cognitive function, and/or training adaptations [14, 21, 
22].  Additionally, ingestion of nitrates prior to exercise has been reported to improve 
endurance exercise efficiency and high-intensity exercise performance [23-27].  
Consequently, there has been interest in examining the individual and synergistic 
effects of ingesting pre-workout supplements and/or energy drinks prior to exercise 
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and during training [21, 28].  The acute and short-term safety of adding these types of 
supplements to the normal diet must be assessed at the absolute doses recommended; 
as this is the typical way consumers take these supplements.  This study examined the 
use of an RTD version of a market leading pre-workout supplement containing caffeine 
anhydrous (200 mg), beta-alanine (2.1 g), arginine nitrate (1.3 g), niacin (65 mg), folic 
acid (325 mcg) and cobalamin (45 mcg) on indices of muscular strength and endurance. 
 Caffeine acts through multiple mechanisms with the resultant effect of 
enhancing intercellular cyclic AMP (cAMP) via allosteric modification of adenosine.  In 
practice, caffeine is associated with mental acuity, maximal strength, maximal power, 
and increased muscular endurance [29, 30].  Various studies have evidenced an 
ergogenic effect in doses as low as 3 mg/kg up to 9 mg/kg, with the ceiling to the 
ergogenic effect occurring with 3 mg/kg and 6 mg/kg and a slight decrease at 9 mg/kg 
[30, 31].  It should also be noted that higher doses also exhibit increases in physiological 
responses such as heart rate, blood lactate levels, and circulating free fatty acids (FFA) 
[31, 32] while low to moderate doses provided an ergogenic effect without the 
aforementioned physiological responses [33]. 
Nitrates (NO3) function via reduction to nitrites (NO2) and further reduction to 
the vasodilator nitric oxide (NO).  The initial conversion takes place in the mouth and 
absorption into the blood stream occurs in the stomach where nitrites then act on 
endothelial smooth muscle to promote a vasodilatory response.  Hypoxia appears to be 
the main signal for the action of nitrates/nitrates on endothelial tissue, which fits with 
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the physiological responses to exercise, particularly in the primarily glycolytic exercises 
employed in this study [34, 35].  Nitrates are shown to be effective at doses of 5 mmol 
(310 mg) to as high as 20 mmol (1240 mg) in enhancing exercise efficiency, improving 
recovery, and maintaining muscular strength and endurance in the later stages of 
exhaustive exercise [23, 36, 37]. 
Arginine serves as a precursor to a variety of proteins and cellular signaling 
molecules, most notably nitric oxide (NO).  Given the increased protein synthesis, the 
conceptual understanding of arginine is that it enhances the recovery of damages 
tissues.  Arginine activates the nitric oxide synthase pathway which results in 
vasodilation and therefore enhanced blood flow to working tissues.  Arginine is a 
supplement which is shown to enhance nitric oxide activity following acute doses of 3 
to 9 mg/d, thereby enhancing nutrient supply to muscles via vasodilation-induced 
increases in blood flow; however, there is inconclusive evidence of any ergogenic effect 
in healthy populations [38, 39].  The proposed rationale of combining L-arginine and 
nitrate postulates the nitrate attached to the arginine enhances the bioavailability of L-
arginine to increase the ergogenic effect.  
The function of β-alanine is to convert to L-carnitine where it then acts as a pH 
buffer in skeletal muscle; intramuscular L-carnitine is regulated by the amount of 
present β-alanine.  In practice, chronic, but not acute use, of β-alanine has been shown 
to enhance muscular strength and power as well as muscular endurance [40, 41].  β-
alanine, when taken daily for several in doses of 4 to 6 g/d, has also been evidenced to 
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be a promising ergogenic aid, being classified as “Apparently Effective” in performance 
enhancement by the ISSN [14].  Of note, PWS often contain less than the ergogenic 
amount of some compounds as a “maintenance dose”, primarily for convenience in 
supplementing normal diet. 
 
1.2. Purpose of the Study 
 The aim of this study was to assess the effects of consuming a “ready to drink” 
(RTD) version of a market-leading pre-workout supplement.  Our primary outcome was 
the assessment of exercise performance recovery following acute and short-term 
supplementation.  The secondary outcome was the assessment of safety following 
acute and short-term use. 
 
1.3. Hypotheses 
H1: RTD ingestion will promote significant improvements in measures of muscular 
strength and performance in comparison to a ingesting a placebo. 
H2: RTD ingestion will promote significant improvements in measures of 4 km time 
trial performance compared to placebo. 
H3: There will be no statistically significant differences observed between placebo 
and RTD in measurements of safety assessed by hemodynamic response or 
serum and whole blood chemistries. 
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H4: There will be no statistically significant differences observed between placebo 
and RTD in hemodynamic response, blood chemistry, or frequency or severity of 
self-reported side effects. 
 
1.4. Research Design 
 This study was conducted in a double-blind, placebo-controlled manner 
following a randomized crossover model.  The independent variable in this work was 
nutritional supplementation of a RTD caffeine anhydrous (200 mg), beta-alanine (2.1 g), 
arginine nitrate (1.3 g), niacin (65 mg), folic acid (325 mcg) and cobalamin (45 mcg) and 
the dependent variables were performance measured as total volume (bench press, leg 
press, combined), one repetition maximum and repetitions to failure on bench press 
and leg press, time trial average power and time to completion, hemodynamic 
response (heart rate, blood pressure, mean arterial pressure, and rate pressure 
product), blood chemistry, and self-reported side effects.   
The primary outcome was the assessment of exercise performance recovery after 
acute and short-term supplementation, while the secondary outcome was 
assessment of acute and short-term safety. We hypothesized that the RTD studied 
would improve muscular strength and endurance as well as 4 km time trial performance 
without undue alterations in hemodynamic response to a hemodynamic challenge, 
hepatorenal and muscle enzyme function, or the frequency and severity of self-reported 
side effects. 
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 Following recruitment and screening, subjects underwent a familiarization 
session.  During the familiarization session, demographic data and anthropometrics 
including gender, height, weight, race, resting systolic and diastolic blood pressure 
(SBP, DBP), resting heart rate, and body composition analyzed by dual x-ray 
absorptiometry (DXA) were recorded.  In addition, subjects underwent a familiarization 
testing protocol on bench press, leg press, and 4 km time trial (TT).  
 For the strength measurements, subjects were instructed to perform 3 warm-up 
sets followed by progressively increased weight until a one-rep maximum (1-RM) was 
determined.  Following determination of 1-RM, subjects performed two sets of ten 
repetitions on each lift followed by one set to volitional fatigue.  Following strength 
measurements, subjects were adjusted for comfort on the bicycle, followed by a short 
warm-up, and finally the TT.  Subjects also provided one 10 mL fasting blood sample at 
the onset of each testing session in addition to the side effects questionnaire and 
resting blood pressure and heart rate using a tilt table protocol for added control and 
safety. 
 Following the four testing sessions for the initial treatment (or placebo), 
subjects completed a 7 to 10 d washout period prior to beginning the alternate 
treatment.  The order in which they took treatment or placebo were randomized prior 
to allocation.  Participants were randomized using random number generation in SPSS 
to provide a random order relative to each participant number (RTD then PLA or PLA 
then RTD). 
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The scope of this study involved college-aged males and females from a local 
Tier 1 University located in East Texas.  The results of this study should reasonably be 
readily extrapolated to similar populations undergoing similar training regimens in 
other geographical areas. 
 
1.5. Limitations 
1. Participants were recruited locally as a function of convenience and logistics.  
Therefore, there was some limitation to the degree of randomization. 
2. Participants were instructed to maintain their current training protocol; 
however, there did exist the possibility of altering training routines during the 
three week study period. 
3. All laboratory equipment was calibrated according to manufacturer prior to 
each testing day. 
4. Dietary food logs were not collected or controlled for. 
 
1.6. Assumptions 
1. Participants answered the screening forms honestly. 
2. Participants gave maximum effort during testing. 
3. Participants adhered to the supplementation protocol. 
4. Participants maintained a consistent dietary intake and exercise regimen 
throughout the duration of the study. 
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1.7. Delimitations 
The current study was conducted under the following guidelines: 
1. IRB approval was for 40 participants consisting of both males and females.  
Intake was limited to a maximum of 20 males and 20 females. 
2. Participants were required to have been involved in a resistance/cardiovascular 
exercise combination training program for at least the prior six months 
3. Eligible participants took part in a familiarization session during which time they 
were informed of the study protocol, filled out necessary forms including an 
informed consent form and a general screening form, and established baseline 
data for leg press, bench press, and 4 km time trial. 
4. Participants were advised to maintain a consistent workout and dietary regimen 
throughout the duration of the study. 
5. Participants were instructed to abstain from exercise, caffeine, and use of over-
the-counter stimulants for 48- h prior to each testing session. 
6. Participants were instructed to be fasted for at least 8 h prior to each testing 
session. 
7. Participants were instructed to perform to their maximal ability on all strength 
and fatigue tests as well as the time trial. 
8. Participants were instructed to consume all supplements and report any 
disorder(s) in weekly side-effects questionnaires. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
2.1. Review of Literature 
 The literature under review was gathered using the PubMed database and 
keywords: caffeine, nitrate(s), beta-alanine, L-arginine, exercise, performance, time 
trial, strength, endurance, and safety.  No date restrictions were set.  Citations were 
maintained using EndNote X8 and Journal of Nutrients referencing style. 
 
2.2. Prevalence of Ergogenic Aid Usage 
According to the ISSN position stand on caffeine and energy drinks, an energy 
drink can be defined as having a dose of caffeine between 2 and 6 mg/kg with the 
addition of carbohydrates, electrolytes, and proprietary mixtures of other compounds 
[22].  Pre-workout supplements are typically found in powder form and include 
caffeine, creatine, and other substances with the purpose of improving exercise 
performance.  Conversely, in ready-to-drink pre-workout supplements (RTD) caffeine 
exists in the ergogenic range and is accompanied by a proprietary blend of proposed 
ergogenic substances with the exclusion of creatine as creatine becomes the inert 
creatinine when left suspended in water.  These proprietary blends may include 
vitamins, herbal extracts, and other compounds and are not regulated by the FDA, 
indicating a need for research to determine efficacy and safety. 
 10 
 
2.3. Ergogenic Assessment of Primary Nutrients 
In this review, primary focus was placed on the active ingredients found in the 
present RTD.  The RTD in this study contains caffeine (200 mg), arginine nitrate, 1.3 g), 
and β-alanine (2.1 g).  The arginine nitrate compound exists as 73% arginine and 27% 
nitrate (950 mg and 350 mg, respectively), indicating a nitrate dose of 5.7 mmol.  The 
individual effects of these ingredients were compared with respect to dose, timing, and 
performance. 
 
2.3.1. Caffeine 
Caffeine is structurally similar to adenosine and allosterically modifies 
adenosine receptors to attenuate the response.  Activation of adenosine receptors by 
their main ligand adenosine has various effects throughout the body including 
reduction of core temperature and decreases in dopamine release [42-45].  Adenosine 
Receptor Type 1 (AR1), found throughout the body, initiates a G-protein signaling 
cascade which results in a decrease in cyclic AMP (cAMP) and ultimately a relaxation 
effect of the muscle.  In the brain, caffeine has been found to antagonize adenosine 
receptors, leading to increased metabolism at the expense of decreased blood flow 
[46].  According to Nehlig, et al., [46] caffeine also promotes the release of dopamine 
via arousal of norepinephrine neurons to facilitate increases in learning, memory, 
coordination, and memory. 
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In the heart, adenosine activation of AR1 leads to decreased chronotropy or 
decreased rate of contraction.  By contrast, caffeine activation of AR1 serves an 
excitatory role to cAMP which results in increased Ca++ influx and thus increased 
chronotropy [42].  AR2a/b, and AR3 also follow this pattern of adenosine and caffeine 
having opposite effects on cell function via inhibition or excitation of cAMP.  In addition 
to the allosteric modification of adenosine, caffeine also serves to modulate insulin 
receptor substrate-1 (IRS-1) and impairs insulin signal transduction [47].  These insulin-
related mechanisms bay serve to increase fat oxidation and spare glucose [48, 49]. 
Caffeine is classified by the International Society of Sports Nutrition (ISSN) as 
“apparently effective” in a variety of areas [22]; it yields measurable improvements 
most of the time in most populations.  Caffeine is purported to not only enhance 
strength [11, 16-20, 50-54] and endurance [50, 55-59] but also to increase and maintain 
cognition [7-9, 60] and higher executive functions following a fatiguing bout of exercise.  
Much of the research has involved moderate to high doses (5 to 13 mg/kg) [30, 32, 61-
63] but there is evidence showing low doses of caffeine (<3 mg/kg) to yield similar 
ergogenic results to those of the moderate and high doses with lower incidence of side 
effects [22, 30, 64-69].  The key points put forth by the ISSN position stand state 
caffeine is regarded as ergogenic in doses of 3 to 9 mg/kg, yields a greater effect when 
consumed as caffeine anhydrous, reduces perceptions of pain, and the evidence is 
consistent in regards to caffeine and strength [22].  An overview of caffeine’s ergogenic 
potential is found in TABLE 2.1. 
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 In a study by Dekker, et al. [70], twelve caffeine-naïve young males were 
recruited to analyze the effects of caffeine on insulin, glucose, epinephrine, and 
response to the glucose tolerance test.  Caffeine dose was maintained at 5 mg/kg in 
unlabeled gel capsules for the duration of the study for a total of 6 total doses.  The 
results of the glucose tolerance test found insulin and blood glucose to be elevated in 
the caffeine group versus placebo at Day 7 and on Day 14 the caffeine group still 
yielded elevated insulin concentration however the effect was blunted compared to 
Day 7.  This study found a pertubatory effect of caffeine on glucose homeostasis that 
slowly corrected after chronic use of caffeine. 
Beaudoin, et al. [71] further elucidated the possible mechanism found in 
Dekker, et al. using a protocol to assess the effects of caffeine on insulin sensitivity.  
The study sought to further analyze the response of glucose homeostasis as a function 
of both gender and caffeine dose.  This placebo-controlled, double-blind, randomized, 
crossover study used 24 participants (12 M, 12 F) provided with either 1, 3, or 5 mg/kg 
caffeine or dextrose placebo.  One hour after ingestion, participants underwent a 
glucose tolerance test in addition to analysis of blood glucose, insulin, and C-peptide.  
The results yielded no evidence of a gender effect; however, insulin and C-peptide were 
both increased with increasing doses of caffeine.  Despite elevated insulin, glucose also 
elevated with increasing amounts of caffeine.  Caffeine increases fat oxidation, and 
these data provide a more accurate view of caffeine and glucose sparing.
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Table 2.1. Caffeine      
Author (year) 
Study 
Design 
Sample Dosing Protocol 
Assessment 
Protocol 
Significant Findings 
Beaudoin, et al. (2013) 
[71] 
P, R, DB 
n = 24 (12 M, 12 
F) 
1, 3, or 5 mg/kg 1 h prior 
to testing 
Oral glucose 
tolerance test 
Elevated plasma insulin and glucose in 
dose response manner with return to 
baseline after 2 weeks; No effect of 
gender 
Hendrix, et al. (2010) [20] 
P, R, DB, 
CO 
n = 21 untrained 
men (23 ± 2.6 y) 
400 mg in gel capsule 
(4.9 mg kg) 1 h prior to 
exercise, 7 d w/o  
1RM, time to 
exhaustion on 
CE  
No difference noted 
Collier, et al (2016) [72] P, R, DB,  
n = 15 healthy 
participants (26.1 
± 3.5 y) 
100 mg (~1.7 mg/kg) 
caffeine in energy drink 1 
h pre-exercise,  7 d w/o 
MVC, EMG 
Increase MVC in caffeine group with 
no difference in EMG 
Goldstein, et al. (2010) 
[73]  
P, R, DB, 
CO  
n = 15 resistance-
trained women 
(24.6 ± 6.9 y) 
6 mg/kg 1 h pre-exercise, 
7 d w/o 
Bench Press 
1RM, RtF at 60% 
Increased 1RM in caffeine group; 
Increased SBP in caffeine group was 
still within normal limits 
Duncan, et al. (2012) [74] 
P, R, DB, 
CO 
n = 11 resistance-
trained 
participants (26.4 
± 6.4 y) 
5 mg/kg 1 h pre-exercise, 
3 d w/o 
RtF at 60% 
Increased RtF in caffeine group; 
Decreased RPE in caffeine group 
Ivy, et al. (2009) [67] P, R, DB 
n = 12 trained 
cyclists(6 M, 6 F, 
27.3 ± 1.7 y)) 
~2 mg/kg 40 min pre-
exercise 
Time trial at 70% 
Wmax 
Time trial time to completion 
improved in caffeine group, RPE 
decreased 
Pai, et al. (2015) [66] 
P, R, DB, 
CO 
n = 20 students 
~2 mg/kg 1 h pre-
exercise, 7 d w/o 
MVC, EMG 
Increased time to fatigue on MVC in 
caffeine group with no difference in 
EMG readings 
Forbes, et al. (2007) [68] 
P, R, DB, 
CO 
n = 15 healthy 
adults (21 ± 5 y) 
~2 mg/kg 30 min pre-
exercise, 7 d w/o 
RtF, Wingate 
exercise test 
Caffeine group increased RtF with no 
difference in Wingate performance 
Overview of literature reviewed.  P = Placebo controlled, R = Randomized, DB = Double-blind, CO = Crossover, w/o = Washout, 1 RM = one repetition maximum, RtF = repetitions to failure, 
CE = cycle ergometer, MVC = maximal voluntary contraction, SBP = systolic blood pressure, DBP = diastolic blood pressure, RPE = ratings of perceived exertion 
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 Graham and Spriet [75] analyzed a high dose of caffeine in relation to prolonged 
exercise relative to performance and metabolism.  The study analyzed seven 
competitive runners (28.3 ± 2.3 y, 67.2 ± 3.4 kg) with average 10-km run times of 
00:31:36: ± 00:00:36 (n=7) and marathon times of 02:33:00 ± 00:00:03 (n=5).  
Incremental VO2max tests were conducted on treadmill and cycle ergometer, yielding 
values of 72.6 ± 1.5 mL/kg/min and 61.9 ± 2.7 mL/kg/min, respectively.  Participants 
were then assigned to either caffeine or placebo group in a double-blind, crossover 
manner involving a one week washout between treatments.  The subjects were 
administered either a dextrose placebo or caffeine at a dose of 9 mg/kg in an unlabeled 
capsule 1 h prior to testing.  Of the four following visits, separated by 1 w between each 
visit, two visits were completed on the treadmill and two on the cycle ergometer, all 
four to exhaustion at 85% VO2max.  Prior to each test, each participant provided a urine 
sample as well as establishment of IV access for 15 min blood draws; within 15 min of 
test completion, a second urine sample was collected. 
 The caffeine group yielded a greater time to exhaustion, improving from 49.2 ± 
7.2 min at baseline to 71.0 ± 11.0 min following treatment on the treadmill and 39.2 ± 
6.5 min to 59.3 ± 9.9 min on the cycle ergometer.  Urinalysis revealed a caffeine 
content of 8.7 ± 1.2 µg/ml on the treadmill and 10.0 ± 0.8 µg/ml on the cycle, both 
below the International Olympic Committee arbitrary ceiling of 12 µg/ml.  The caffeine 
group also yielded an approximate twofold increase in epinephrine in both tests while 
placebo remained constant.  No effect was reported in relation to free fatty acids at 
 15 
 
rest or during exercise, though, there was a trend in the caffeine group.  No effect was 
reported on blood lactate or glucose in either group.  Furthermore, there was no report 
of any side effects even at the high dose of 9 mg/kg. 
 Caffeine has long been thought to be ergogenic to strength and power.  In a 
meta-analysis by Warren, et al. [76], the authors set out with the aim to assess 
caffeine’s effects on maximal strength and muscular endurance.  Covering studies from 
1939 to 2008, the authors reviewed a total of 34 studies investigating the effects of 
caffeine on maximal voluntary contraction (MVC) and muscular endurance.  There was 
an overall effect size of 0.19 for caffeine on MVC (p < 0.001) with a lower-body specific 
effect size of 0.37 in the knee extensors.  Analyzing studies that focused on percent 
muscle activation measured by EMG, the overall effect size of caffeine was found to be 
0.67 (p < 0.001), evidencing a role of caffeine in the central nervous system (CNS).  The 
overall effect size of caffeine on muscular endurance was 0.28 versus placebo (p < 
0.001) demonstrating a small beneficial effect of caffeine on muscular endurance. 
 Hendrix, et al. [20] analyzed the effects of caffeine on strength and time to 
exhaustion in both the bench press, leg extension, and cycle ergometry at a constant 
work load of 80% VO2peak.  This study involved 21 untrained men (23 ± 2.6 y, 81 ± 12.1 
kg, 180.2 ± 4.8 cm) on either a supplement containing 400 mg caffeine and 66.7 mg 
capsaicin extract or cellulose placebo separated by a one week washout.  This amount 
of caffeine yielded an average dose of 4.9 mg/kg, well within the accepted ergogenic 
range.  One hour following ingestion, participants underwent a one-repetition 
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maximum (1-RM) protocol on bench press and knee extension prior to undergoing a 
time to exhaustion protocol on a cycle ergometer.  The authors reported no significant 
difference of the supplement on any of the metrics. 
Collier, et al. [72] analyzed the effects of caffeine in the form of an energy drink 
on MVC, electrically stimulated force production, and percent muscle activation during 
MVC.  The study involved 15 healthy participants (26.1 ± 3.5 y, 70.7 ± 12.1 kg, 174.6 ± 
6.0 cm) in a placebo-controlled, double-blind, repeated-measures, crossover design 
with a 1 w washout between treatments.  The energy drink used in this study contained 
100 mg caffeine, 29 g carbohydrate, and other non-ergogenic ingredients which 
equates to 1.7 mg/kg of caffeine.  These metrics were followed by EMG recording of 
electrical activity following MVC testing.  The caffeine group yielded an improvement of 
5 ± 1.7% versus -0.5 ± 1.5% in placebo on MVC (p = 0.015) with no differences in any 
other metric. 
Goldstein, et al. [73] studied the effects of caffeine on upper body strength in 
resistance-trained women.  Fifteen women were recruited for this study (24.6 ± 6.9 y, 
63.6 ± 8.3 kg, 166.2 ± 9.0 cm) wherein either caffeine at 6 mg/kg or placebo was 
consumed for each study session with a 7 d washout period between sessions.  Prior to 
ingestion, heart rate and blood pressure were assessed, as well as at 60 min post-
ingestion and following repetitions to failure.  One hour post-ingestion, the participants 
were assessed for 1-RM and repetitions to failure (RtF) at 60% baseline 1-RM, similar to 
the protocol in the present study.  The caffeine group yielded a greater 1-RM compared 
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to placebo and no difference in RtF.  The caffeine group demonstrated higher systolic 
blood pressure (116.8 ± 5.3 mmHg against 112.9 ± 4.9 mmHg for placebo); however, 
SBP remained within normal limits.   
Duncan, et al. [74] studied 11 resistance trained participants (9 male, 2 female; 
26.4 ± 6.4 y) in a double-blind, placebo controlled, randomized study which used a 
crossover model wherein the treatment and placebo were separated by a 72 h 
washout.  After establishing 1RM on bench press, rows, deadlifts, and back squat at the 
familiarization session, participants waited 48 to 72 h before performing their first 
study session.  Upon arrival, they ingested a measured dose of either dextrose placebo 
or 5mg/kg caffeine followed by a 60 min waiting period.  After a 5 min warm-up on a 
cycle ergometer, participants performed RtF at 60% 1-RM on each of the 
aforementioned lifts with 3 min separating each exercise.  Caffeine increased RtF (p = 
0.049).  Across all exercises, caffeine yielded a lower rating of perceive exertion (RPE) (p 
= 0.027). 
In a separate study by Bloms, et al. [77], power as a function of jump height was 
measured in response to acute caffeine ingestion at a dose of 5 mg/kg.  No 
familiarization session was noted by the authors; however, the participants were 
allowed practice attempts prior to the actual testing.  In this study, NCAA Division I 
athletes were recruited (16 males, 21 ± 1.5 y; 9 females, 20 ± 1.3 y) and study sessions 
were built around the athletes’ training schedules.  Each athlete completed two study 
sessions separated by one week; the study sessions were completed prior to training.  
 18 
 
Participants ingested the caffeine anhydrous or placebo, waited a period of 1 h, and 
then began the exercise protocol.  Participants completed three squat jumps and three 
countermovement jumps with 30 sec rests separating each attempt.  Following data 
collection, there was an improvement in the caffeine group in jump height for both the 
squat jump (p = 0.001) and the countermovement jump (p = 0.001).  Also of interest, 
there was increased efficiency of movement in the caffeine group (p = 0.017). 
 In a similar study by Ribeiro, et al. [78], acute caffeine ingestion was analyzed in 
relation to leg power measured by vertical jumps.  In contrast to the multiple single 
attempts seen in Bloms, et al., Ribeiro, et al. offered continuous jumping to measure 
both power and endurance.  Six male handball athletes were recruited for this study 
(21.6 ± 2.9 y).  Participants ingested the caffeine (6 mg/kg) or placebo treatment, 
waited 1 h and, after a brief warm-up, completed four sets of 30 sec continuous vertical 
jumps interspersed by 60 sec rests.  Leg power was recorded by a force plate and 
plotted.  After a one week washout, participants returned to the lab to repeat testing.  
The caffeine group yielded no change from start to finish; however, the placebo group 
had a lower end power (p < 0.05) and decreased time to fatigue (p < 0.001). 
 Shearer & Graham [79] completed a review of energy drinks on performance 
and metabolism.  In this review, articles involving human models after 1990; double-
blind, placebo controlled, randomized studies; and articles not using coffee as the 
caffeine source were included in the analysis.  The aims of the review were to elucidate 
the effects of caffeine on timed performance, endurance/performance time, power 
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related to performance, and glucose tolerance.  This amounted to 38 relevant studies 
which was then reduced to 24 after further review.  Many of the studies used set 
amounts of caffeine of between 75 and 160 mg in pre-packaged products.  The authors 
attempted to extrapolate this number based on an average male weight of 65 kg, 
providing a dose of between 1.15 to 2.26 mg/kg of caffeine.   
The results of the combined analysis showed an overall timed performance 
increase of 3.6% with caffeine use.  Overall, the studies in the review ranged from 2 to 
7 mg/kg and closer inspection revealed an increase in performance of 7% for doses of 2 
to 5 mg/kg with a maintained improvement of 7% at doses greater than 5 mg/kg.  The 
authors noted a plateau effect to occur at approximately 6 mg/kg of caffeine in hepatic 
metabolism resulting in an increase of caffeine metabolites; however, the metabolism 
of caffeine can be affected by a variety of individual factors including liver cytochrome 
p450 and CYP1A2 as well as variation in adenosine receptors.  Caffeine was also found 
to increase insulin resistance in sedentary populations but this does not appear to hold 
true in trained populations, suggesting a safety issue and increased risk of the 
development of Type II Diabetes in sedentary populations.  In trained populations, this 
mechanism appears to enhance reliance on fat oxidation, possibly lending to the 
ergogenic effect on performance by sparing muscle glycogen and decreasing lactate 
accumulation. 
 Souza, et al. [80] analyzed the effects of caffeinated energy drinks on physical 
performance in a systematic literature review.  This review covered studies from 1998 
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to 2015 (n=34) and calculated overall effect sizes of caffeinated energy drinks on 
muscle strength and endurance, endurance exercise, sport-specific actions, and 
sprinting.  The authors found an effect size of 0.49 in muscular strength and endurance 
(p < 0.001), 0.53 in endurance testing (p < 0.001), 0.29 in jumping actions (p = 0.01), 
and 0.51 in sport-specific actions (p < 0.001); however, the 0.14 effect size in sprinting 
was not significant (p = 0.06).  When data were adjusted for taurine content, taurine 
was more closely associated with increased performance than caffeine.  The studies 
under review contained between 40 and 325 mg of caffeine  as an absolute dose; the 
authors did not calculate relative dose.  Taurine content ranged from 71.2 to 3105.8 mg 
and higher content of taurine correlated with performance improvement unrelated to 
total caffeine content. 
 Analyzing the lower end of the dosing spectrum, Spriet, et al. [81] conducted a 
review on low doses of caffeine to analyze for ergogenic effect as well as safety.  There 
does appear to be a ceiling effect to ergogenic potential as doses exceed 5 mg/kg with 
a concomitant increase in side effects [79].  These side effects include increased 
catecholamine levels [32], higher blood lactate concentrations [82], and increased free 
fatty acids [31].  Spriet, et al. [30] hypothesized a similar ergogenic effect from a lower 
dose without the side effects.  In one of the reviewed studies, endurance-trained 
participants received either 3, 6, or 9 mg/kg of caffeine and were tested using a run to 
exhaustion protocol at 85% VO2max with a 1 w washout between treatments.  Compared 
to placebo, the 3 and 6 mg/kg groups yielded a 22% increase in time to exhaustion, 
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whereas the 9 mg/kg showed an 11% increase.  Further investigation found a moderate 
dose of 4.5 mg/kg spread out during exercise provided the largest ergogenic benefit 
[56].  Returning to the low dose (<3 mg/kg), a study by Jenkins, et al. [83] utilized either 
placebo or 1, 2, or 3 mg/kg caffeine on trained cyclists.  The cyclists ingested the 
treatment 1 h prior to a 20 min steady state cycle test at 80% VO2max, followed by 5 min 
of light pedaling, and then a 15 min time trial.  Those on placebo of 1 mg/kg yielded no 
evidence of an ergogenic effect however 2 and 3 mg/kg increased overall work in the 
15 min time trial by 4% and 3%, respectively.   
 A study by Santos, et al. investigated the effects of caffeine on reaction time in 
simulated Tae-Kwon-Do matches [84].  This study involved 10 competitive Tae-Kwon-
Do practitioners (24.9 ± 7.3 y, 77.2 ± 12.3 kg, 175 ± 0.06 cm) whom were recruited due 
to familiarization with the testing procedures involved.  For baseline testing, the 
athletes received a dose of caffeine at 5 mg/kg or a cellulose placebo.  After two 
consecutive testing days, the athletes completed a 7 d washout period followed by 
follow-up testing on the other treatment.  Fifty minutes post-ingestion, participants 
completed a reaction time test; at 1 h post-ingestion, a combat drill was completed.  At 
70 min, the two tests were repeated followed by one final reaction time test at 100 
min.  Blood was collected at regular intervals between testing.   
The reaction time test utilized a series of 5 roundhouse kicks to abdomen-height 
following a visual stimulus.  Of the 5 kicks, the best and worst were excluded and the 
average of the remaining three was used in the analysis.  For the combat drills, athletes 
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participated in a 2 min round against the other participants under World Tae-Kwon-Do 
Federation rules, full protective gear, and a referee.  Three rounds were completed 
separated by 1 min rests.  During the first reaction time test, the caffeine group yielded 
an 11.9% lower time compared to placebo (p = 0.004) but there was no significance in 
the second or third reaction time test.  During the first combat drill, the caffeine group 
committed fewer errors than the placebo group in the first round (p = 0.036) and 
second round (p = 0.005) with no significance being found in the third round.  During 
the second combat drill, the caffeine group again performed better during the first and 
second rounds (p = 0.012 and 0.018, respectively); however, there was again no 
significance in the third round.  There were no differences between the first and second 
combat drills in relation to the treatment; however, overall performance decreased for 
both groups (p = 0.036).  Despite lactate concentration being higher in the caffeine 
group during first combat drill rounds 2 and 3 (p = 0.29 and 0.014, respectively), there 
were no differences in RPE or HR.  The results of this study demonstrate an ergogenic 
effect of caffeine on reaction time and increased intensity during the combat drills. 
 Caffeine has a role in the brain via antagonizing adenosine receptors and 
promoting an increase in dopamine [46].  The impact on performance is equivocal [22]; 
however, there are some who believe the ergogenic effect has its foundation in the 
brain and central nervous system, not the peripheral tissues.  The putative effects on 
fatigue reduction and increased alertness are accepted but the mechanisms need to be 
expanded upon.  Meeusen, et al. [85] sought to further elucidate the mechanisms in a 
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review article.  The authors hypothesized the increase in dopamine enhances the 
signaling within the motor coordination and somatosensory centers of the brain, 
providing a potential mechanism by which caffeine may increase performance from a 
neurological frame.   
The nucleus accumbens, the “pleasure and reward center” of the brain, contains 
an abundance of adenosine receptors.  When adenosine is elevated these receptors are 
activated and fatigue is enhanced, when caffeine allosterically modifies these receptors 
fatigue is reduced.  One article in the review involved direct cranial injections of either 
placebo, caffeine, an adenosine analog, or a combination of caffeine and adenosine 
analog [86].  After injection, the rats performed a forced treadmill to exhaustion.  The 
placebo and combination groups completed 80 min, the caffeine only group completed 
120 min, and the adenosine only group completed 25 min.  These findings support the 
CNS-mediated ergogenic effect of caffeine. 
Caffeine also has a putative role in decreasing perception of pain, allowing for 
increased time to fatigue or repetitions to failure.  Richardson & Clarke [87] found 
caffeine to significantly improve total volume lifted in bench press and squats, 
specifically with a significant increase to total squat volume.  Nine resistance trained 
men (24 ± 2 y) participated in a randomized, crossover, double-blind, placebo-
controlled study wherein caffeine was administered by itself (5 mg/kg), with 
decaffeinated coffee, as caffeinated coffee, or none at all.  Each participant participated 
in each condition with a 2 d washout between each condition.  At the onset of each 
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testing session, participants consumed the treatment, waited 45 min, and performed 
RtF on squat and bench press.  Caffeine added to decaffeinated coffee improved RtF 
compared to decaffeinated coffee (p < 0.01), caffeinated coffee (p < 0.05), and placebo 
(p < 0.05).  Coffee alone performed better than both the decaffeinated coffee and 
placebo (p < 0.05). 
Mets, et al. [65] conducted a study on a popular caffeinated energy drink and its 
effect on cognition.  In this study, 24 participants were given Red Bull with or without 
the active ingredients and put through a simulated driving test.  The driving test 
consisted of a 2 h “highway” drive, a 15 min break and treatment or placebo ingestion, 
and a second 2 h “highway” drive.  The primary endpoint of the study was to assess 
how well the driver kept the car in a straight path and secondary analyses were 
conducted to examine the effects of the treatment on subjective driving quality and 
alertness.  Red Bull significantly improved performance over placebo during both Hour 
Three and Hour Four (p = 0.046 and 0.011, respectively) as well as every secondary 
endpoint (ie. Sleepiness, mental effort, speed maintenance; p = 0.001, 0.024, 0.004, 
respectively).  It is likely that the caffeine was responsible for the increase in 
performance. 
 In a separate study by Ivy, et al. [67, 88], also investigating Red Bull, twelve 
trained cyclists were assigned to either a Red Bull or flavored placebo in a randomized, 
double-blind manner.  The participants (n = 12, 6 M, 6 F, 27.3 ± 1.7 y, 68.9 ± 3.2 kg) fasted 
for 12 h, ingested the supplement, and then after a 40 min wait performed a time trial 
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at 70% Wmax.  The Red Bull group yielded better performance (p < 0.01).  However, 
rating of perceived exertion and metabolism were unaffected by the treatment.  To 
clarify, those in the Red Bull group exhibited enhanced performance with no difference 
in subjective difficulty compared to placebo. 
Red bull is a popular energy drink containing 80 mg of caffeine and assorted B-
vitamins in 250 mL of carbonated water.  Assuming a 65 kg (143 lb) individual, this 
equates to a relative caffeine dose of 1.23 mg/kg, well under the putative ergogenic 
range.  Despite the “low” dose, ergogenic effects have been associated with Red Bull by 
other researchers.  Pai, et al. [66] conducted a crossover design using a sample of 
medical students (n = 20, 10 M and 10 F) which demonstrated a calculated relative 
caffeine dose of 2 mg/kg.  The findings evidence decreased rate of fatigue with no 
difference in EMG readings or MVC 1 h after ingestion of Red Bull.  Goel, et al. [89] 
conducted a cross over study analyzing a cohort (n = 20, 10 M and 10 F) that yielded a 
mean relative dose of 2 mg/kg.  The findings evidenced an ergogenic role in reaction 
time but no difference in maximal voluntary contraction.  Forbes, et al. [68]analyzed a 
sample of healthy young adults (n = 15, 11 M and 4 F, 21 ± 5 y) in a randomized, 
crossover model.  The average relative dose of the sample was 2 mg/kg.  Participants 
underwent a modified RtF protocol on bench press at 70% 1-RM as well as a modified 
Wingate stress test.  The modified RtF protocol used the total repetitions of 3 
consecutive sets to failure to calculate total volume and the modified Wingate included 
3 separate 30 sec Wingate bouts separated by 2 min active recovery.  The Red Bull 
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group demonstrated significantly increased total volume with no effect on the Wingate.  
Of note, Red Bull contains taurine which has been found to potentially increase the 
effects of caffeine[90-93]  
 In the studies reviewed, there were many trends and commonalities.  The 
current understanding is caffeine yields ergogenic benefit in doses of 3 to 9 mg/kg [22, 
30, 32, 61, 62].  However, there exists sufficient evidence of low doses (<3 mg/kg) of 
caffeine having an ergogenic effect on performance with a lower incidence of side 
effects [56, 65, 66, 71, 72, 79, 81, 83, 89, 94].  The amount of caffeine in the current 
treatment is 200 mg.  Assuming an average mass of 65 kg, an approximate average 
dose of 3 mg/kg seems to be a fair estimate.  Considering the literature reviewed, it 
seems likely caffeine could still be effective even if the average dose is slightly less than 
3 mg/kg, as multiple studies found ergogenic effects as low as 2 mg/kg [68, 72, 83]. 
 
2.3.2. Nitrates 
 Nitrates (NO3) act by reducing from NO3 to nitrites (NO2) and then to nitric oxide 
(NO) which then induces vasodilation [95, 96].  Aside from its actions within the 
endothelium, nitrate has also been found to have effects within muscle tissue and have 
a role in glucose homeostasis [97] leading to it becoming a popular addition in many 
PWS [25-27, 98-100]. 
A review by Affourtit, et al. [35] illustrates a general overview of the role of 
nitrates in skeletal muscle.  In one of the reviewed studies, Bailey, et al. [34] 
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demonstrated VO2 during low-intensity cycling was lower in the nitrate-rich beetroot 
treatment group at a given intensity compared to the nitrate-depleted beetroot group.  
The authors also suggest a dose dependent response of nitrate on the decreased VO2 
cost during low-intensity exercise, showing the decrease to be greater at 4.2, 8.4, and 
16.8 mmol NO3 [101, 102].  Further work in that same study found 4.2 mmol (260 mg) 
to have no effect on high-intensity exercise whereas 8.4 and 16.8 mmol (521 and 1042 
mg, respectively) improved exercise tolerance similar to low-intensity.  The review by 
Affourtit, et al. also suggests the effects of nitrates may be muscle fiber specific, 
perhaps through increased removal of metabolites or enhancement of GLUT4 as 
previously discussed.  
One other proposed mechanism in this review shows that nitrate ingestion may 
actually reduce ATP cost of contraction by increasing phosphocreatine (PCr) synthesis, 
thus providing an avenue for more ‘free’ ATP production [103].  The authors explicitly 
state they are unaware of the exact mechanism by which the ATP cost and subsequent 
decrease in VO2 cost is employed.  In addition, there is some evidence that nitrate 
supplementation may enhance the contractile properties of skeletal muscle [104]. 
During incremental exercise, pulmonary VO2 uptake increases to meet need 
within a few minutes of arriving at a given intensity.  At steady state, ATP use and 
production are equal, providing a snap shot of metabolism at a given exercise intensity.  
As was shown in the studies by Bailey, et al. [34, 105], nitrates decrease VO2 at varying 
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intensities, indicating a potentially large role of the metabolically active skeletal muscle 
tissue in the ergogenic effects of nitrates. 
Bailey, et al. [106] investigated the effects of dietary nitrate supplementation in 
muscle contractile efficiency.  They hypothesized nitrates may act to reduce the O2 cost 
of mitochondrial ATP synthesis, improves the coupling of ATP hydrolysis in the cross-
bridge cycle, and/or potentially inhibits mitochondrial ATP production which would 
shift energy production to other systems. 
Seven recreationally active males were recruited for this study (28 ± 7 y, 81 ± 7 
kg, 180 ± 2 cm).  Participants were randomly assigned to either a nitrate-rich beetroot 
juice group or a nitrate-depleted beetroot juice group separated by a 10 d washout; the 
nitrate content was not specified however other studies in the same lab report 10.2 
mmol (632 mg) for nitrate-rich and 0.17 mmol (10.5 mg) for nitrate-depleted beetroot 
juice [34, 37].  Participants underwent seven total testing sessions over the course of 
four weeks: a familiarization session where plasma nitrite and blood pressure were 
measured, MVC of the quadriceps followed by an incremental exercise test on the knee 
extension ergometer on days 1 through 3, and step test on days 4 through 6, and a 7 d 
washout between 3 and 4.  The MVC was conducted for 3 sec and the incremental leg 
extension was conducted at 40 repetitions per min starting at 4 kg and increasing by 1 
kg each increment.  Electromyography (EMG) was recorded from the beginning of MVC 
testing to completion of the incremental knee extension.  The step testing involved two 
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4 min bouts of low cadence stepping and one 6 min bout of high cadence stepping with 
6 min rests between bouts.  Pulmonary gases were measured throughout. 
There were no side effects reported and the nitrates were tolerated.  Blood 
analysis showed an increase of 137% in NO2 with the nitrate group compared to 
placebo (p < 0.05).  There was no difference in blood pressure or heart rate between 
groups.  During low-intensity exercise, there was no difference in the EMG recordings. 
Further evidencing the effects of nitrates ergogenic role in skeletal muscle, 
Haider & Folland [104] recruited 19 healthy untrained men (21 ± 3 y) to participate in a 
double-blind, randomized, crossover study to elucidate the effects of nitrate 
supplementation on contractile function.  Participants supplemented on either 9.7 
mmol (601 mg) of nitrate-rich beetroot juice or nitrate-depleted placebo for a period of 
7 d, after which they returned to the lab for testing and subsequent 7 d washout.  
Testing included voluntary and involuntary contractions as well as measurements of 
force production.  The nitrate group significantly improved maximal twitch, submaximal 
contractions, and demonstrated a significant 3 to 15% increase on explosive force 
production evoked by electric stimulation.  No change was seen in voluntary force 
production.  The authors speculate enhanced excitation-contraction coupling efficiency 
may have been the underlying mechanism to increased submaximal voluntary force 
and increased maximal involuntary force. 
With regards to VO2, the nitrate group yielded lower VO2 at the peak (Nitrate: 
362 ± 30 mL/min, Placebo: 484 ± 41 mL/min) and end points (Nitrate: 778 ± 38 mL/min, 
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Placebo: 870 ± 42 mL/min) of low-intensity exercise, consistent with previous findings 
in their lab.  During high-intensity exercise, nitrate supplementation revealed lower VO2 
at 360 sec of exercise (1460 ± 54 mL/min, Placebo: 1692 ± 70 mL/min) as well as the 
slow component following termination of the test (100 ± 26 mL/min, Placebo: 209 ± 30 
mL/min) which is indicative of faster recovery.  In addition, degradation of 
phosphocreatine (PCr) during low-intensity exercise was blunted in the nitrates group 
(5.2 ± 0.8 mmolPCr, Placebo: 8.1 ± 1.2 mmolPCr) indicating either increased re-synthesis 
of PCr or reduced energy cost.  In addition, the nitrate group had lower increases in 
inorganic phosphate (3.5 ± 0.8 mmolPi against 4.4 ± 0.8 mmolPi for placebo).  Free ADP 
was also decreased in the nitrates group at all time points, indicating increased ATP 
production from ADP + Pi.  Relative to ATP production, the nitrate group had 
significantly lower total ATP (p < 0.05), ATP from oxidative pathways (p < 0.05), and ATP 
from phosphagen system (p < 0.05); however, there was no difference in ATP from 
glycolytic pathways.  These data evidence an increased exercise tolerance from the 
nitrate group.  Coupled with the decreased ATP and VO2, it is a logical leap to assume 
nitrates reduced the energy requirements of the testing. 
Fulford, et al. [37] examined the effect of nitrate supplementation on skeletal 
muscle metabolism as well as force production.  Despite findings showing decreased 
ATP turnover rate and reduced VO2 cost, there have been studies showing an ergolytic 
effect of nitrate supplementation on force production [107, 108].
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Table 2.2: Nitrates 
Author 
(year) 
Study 
Design 
Sample Dosing Protocol 
Assessment 
Protocol 
Significant Findings 
Haider & 
Folland (2014) 
[104] 
P, R, 
DB, CO 
n = 19 untrained males (28 
± 7 y) 
9.7 mmol/d (601 
mg/d) NO3 for 7 d 
with 7 d w/o 
MVC, electrically 
stimulated force 
production 
Increased force production and twitch 
speed in nitrate group, lower VO2 
Bailey, et al. 
(2010) [106]  
P, R, 
DB, CO 
n = 7 recreationally active 
males (28 ± 7 y)  
10.2 mmol/d (632 
mg/d) NO3 for 15 d, 
10 d w/o 
MVC, incremental 
exercise test, EMG, 
VO2 
Lower VO2 at peak and increased 
metabolic efficiency from oxidative 
pathways in NO3 group 
Fulford, et al. 
(2013) [37] 
P, R, 
DB, CO 
n = 8 recreationally-active 
males (24 ± 4 y) 
10.2 mmol/d (632 
mg/d) NO3 for 15 d, 
14 d w/o 
MVC No difference in MVC 
Bailey, et al. 
(2015) [109] 
P, R, 
DB, CO 
n = 7 recreationally-active 
males (21 ± 2 y) 
6.2 mmol/d (384 
mg/d) NO3 for 9 d, 10 
d w/o 
TTE on step test, 
VO2 
Lower VO2 at high intensity and decreased 
MAP in NO3 as well as increased 
oxygenation of myoglobin 
Thompson, et 
al. (2016) [110] 
P, R, 
DB, CO 
n = 16 recreationally-active 
males (24 ± 4 y) 
5 mmol (310 mg) NO3 
acute dose, 7 d w/o 
Incremental CE, 
cognitive testing 
Increased TTE, decreased cerebral blood 
flow, increased muscle blood flow, 
decreased VO2 at lower intensities, and 
increased RER in NO3 
Porcelli, et al. 
(2016) [111] 
P, R, 
DB, CO 
n = 7 recreationally-active 
males (25 ± 2 y) 
8.2 mmol/d (508 
mg/d) or 2 mmol/d 
(124 mg/d) NO3 for 6 
d, 20 d w/o 
Incremental CE, 
MVC, RtF, Wingate 
Decreased VO2 during CE, increased RtF, 
improved maintenance of power during 
Wingate for NO3 
Thompson, et 
al. (2015) [112] 
P, R, 
DB, CO 
n = 18 recreationally-active 
males (27 ± 8 y) and 
females (n = 18, 23 ± 4 y) 
6.5 mmol/d (403 
mg/d) NO3 for 5 d, 7 d 
w/o 
Incremental ST and 
CE, Wingate 
Increased TTE and work rate in NO3 as 
well as lower VO2 and lactate at 
exhaustion with higher pH 
Thompson, et 
al. (2016) [23] 
P, R, 
DB, CO 
n = 35 male athletes ( 
6.4 mmol/d (397 
mg/d) NO3 for 5 d, 7 d 
w/o 
20 m sprints, Yo-Yo 
shuttle 
Decreased sprint times and increased 
distance in YoYo in NO3 
Callahan, et al. 
(2016) [113] 
P, R, 
DB, CO 
N = 8 trained male cyclists 
(34 ± 7 y) 
5 mmol (310 mg) NO3 
Incremental CE, 4 
min TT, 4 km TT 
NO3 and NaNO3 demonstrated increased 
lactate at exhaustion 
P = Placebo controlled, R = Randomized, DB = Double-blind, CO = Crossover, w/o = washout, VO2 = volume of oxygen consumption, MVC = maximal voluntary contraction, TT = time trial, 
TTE = time to exhaustion, CE = cycle ergometer, ST = step test  
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Eight recreationally active males (24 ± 4 y, 76 ± 8 kg) were recruited.  Following 
familiarization, they were divided into either nitrate-rich or nitrate-depleted beetroot 
juice supplement groups separated by a 14 d washout.  They were instructed to drink 
0.5 L daily and on testing days to ingest the supplement 2.5 h prior.  For each of the six 
visits, a blood sample was collected at the onset of testing for nitrite analysis.  PCr 
kinetics were analyzed using short bouts of high-intensity exercise and, after a short 
recovery, repeated measures of MVC were completed.  The protocols for PCr and MVC 
were similar to the incremental knee extension test used previously in this lab [106].  
No side effects were reported.  The nitrate group showed increased levels of plasma 
nitrate compared to placebo (p < 0.01).  but no difference at any time point in force 
production between nitrates and placebo.  The authors noted a trend towards PCr 
depletion in the nitrate group and acknowledge a larger sample (n = 18) would likely 
yield significance. 
Continuing to investigate the influence of nitrate supplementation on 
bioenergetics, specifically the role of nitrates in glucose homeostasis [35], Shepherd, et 
al. [114] analyzed hepatic blood flow and glucose homeostasis.  In this study, 31 
participants were recruited and divided into a young (11 males, 5 females, 26.6 ± 6 y, 
76.2 ± 13 kg, 175 ± 1 cm) and an old group (8 males, 7 females, 59.2 ± 6 y, 75.3 ± 12 kg, 
169 ± 1 cm).  Following familiarization, participants were randomly assigned to a 
nitrate-rich beetroot group with 11.91 mmol (738 mg) of nitrate or a nitrate-depleted 
beetroot group containing 0.01 mmol of nitrate (6.2 mg) with a 7 d washout between 
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treatments.  Supplements were provided with a meal totaling 76 g of carbohydrate.  
Following ingestion, blood collection, and blood pressure analysis, the participants 
were positioned in an MRI to evaluate hepatic blood flow.  Blood was analyzed for 
glucose, glucagon-like peptide-1 (GLP-1) and C-peptide.  As expected, plasma nitrate 
and nitrite were higher in the nitrate group (p < 0.001).  With regards to hepatic blood 
flow, the older participants yielded a significantly higher flux and velocity at baseline 
compared to the younger participants; the differences remained throughout the study.  
Relative to glucose, the older individuals again yielded higher concentrations at 
baseline with no treatment or time effect from supplementation.  There were also no 
differences reported in GLP-1, C-peptide, or resting blood pressure.  The results 
indicate no effect of dietary nitrate supplementation on glucose homeostasis which 
further strengthens the findings of Bailey, et al. [106]. 
The role of nitrates in various muscle fiber types has been mentioned and the 
underlying mechanisms were further elucidated by Jones, et al. [115].  In this 
systematic literature review, it was hypothesized that the ergogenic role of nitrates is 
more pronounced in the less oxidative, high glycolytic, fast twitch Type II fibers.  The 
authors speculate nitrates to locally alter PO2 in working muscle tissue.  Analyzing PO2 
provides a clearer picture of the physiological effects of nitrates. Normally, PO2 is 
around 40 mmHg at rest and can be as low as 2 mmHg during intense exercise.  Jones, 
et al. sought to investigate whether the perfusion would be altered in varying fiber 
types with nitrate supplementation.  This aim was based on previous studies in rats 
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where nitrate supplementation increased blood flow up to 66% in Type II fibers with 
minimal change in Type I fibers [116-118].  Furthermore, nitrate supplementation has 
been shown to decrease the O2 cost of exercise by an average of 5.5% [119, 120].  The 
authors also state much of the ergogenic effect of nitrate supplementation is found in 
low- to moderately trained individuals with little to no effect in elite athletes.  Given 
that the elite athletes in reviewed studies are primarily endurance trained athletes, 
they should have a lower proportion of Type II fibers, providing circumstantial evidence 
that Type II fibers are the primary target of nitrates.  De Smet, et al. [121] found the 
addition of sprint training and hypoxia with ingestion of nitrates (6.45 mmol, 400 mg) 
produced a favorable shift towards increased Type IIa muscle fibers. 
 The studies reviewed thus far evidence a robust role of nitrate within the body 
ranging from endothelial vasodilation to increased efficiency of muscular contraction 
TABLE 2.2.  Bailey, et al. [109] investigated the effect of inorganic nitrate on muscle 
oxygenation and O2 kinetics at varying intensities.  Seven recreationally active healthy 
male subjects (21 ± 2 y, 86 ± 10 kg, 182 ± 8 cm) were recruited.  Over the course of five 
to seven weeks, participants completed ten visits.  During the first two baseline 
sessions, participants completed a cadence-specific incremental cycle test at 35 and 
115 rpm.  They were then divided into a beetroot juice (6.2 mmol, 384 mg NO3) or 
placebo group separated by a 10 d washout.  For days 2,3, 6, and 7, participants 
completed either the 35 rpm or 115 rpm test wherein they pedaled to exhaustion with 
exhaustion being defined as dropping >10 rpm under the specified range for > 3 sec.  
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On days 4, 5, 8, and 9, participants completed a step test using the same cadence as the 
cycle ergometer.  Pulmonary gasses were measured throughout each test and 
oxygenation was assessed using a near-infrared spectroscopy system applied to the 
vastus lateralis of the right leg. 
Plasma nitrite, SBP, and mean arterial pressure (MAP) were all significantly 
different in the nitrate group (p < 0.05) and there was no difference in DBP.  Systolic 
blood pressure decreased by 8 mmHg and MAP decreased by 4 mmHg in the nitrate 
group; however, these values were still within normal limits.  No difference was noted 
in oxygen kinetics for any time point during the 35 rpm conditions.  In the 115 rpm, the 
nitrate group yielded a significantly lower resting VO2 (1.89 ± 0.25 L/min compared to 
1.93 ± 0.34 L/min, p < 0.05), 120 sec VO2 (3.68 ± 0.47 L/min compared to 3.65 ± 0.49 
L/min, p < 0.05), and higher VO2 at exhaustion (4.32 ± 0.75 L/min compared to 4.24 ± 
0.61 L/min, p < 0.05).  In addition, the nitrate group evidenced an increase in 
oxygenated myoglobin at 115 rpm at baseline (3.4 ± 4.9 AU compared to -1.1 ± 3.5 AU), 
120 sec (-1.0 ± 6.3-AU compared to -6.1 ± 3.7 AU for placebo), and at exhaustion (-0.6 ± 
7.8 AU compared to -6.0 ± 5.4 AU for placebo).  The authors concluded the reduction of 
NO3 to NO to be augmented as pH decreases with strenuous exercise which pulls the 
reaction towards NO.  In addition, there was an increase in proteins associated with 
mitochondrial [108] and calcium function [122]. 
In a study by Thompson, et al., [110] the influence of nitrate supplementation 
on incremental cycle exercise performance as well as cognition were investigated using 
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a placebo-controlled, double-blind, cross-over study.  Sixteen recreationally active 
healthy males (24 ± 4 y, 75.6 ± 9.2 kg, 177 ± 7 cm) were recruited and, upon completing 
familiarization, participants were assigned to either a nitrate group (5 mmol or 310 mg 
from beetroot juice) or a 450 mL placebo developed to match in appearance and flavor.  
Treatments were separated by a 7 d washout.  Prior to exercise testing, 
muscle/cerebral oxygenation, blood pressure, blood lactate, and pulmonary gas were 
assessed.  Participants completed a cycle ergometer test separated into 20 min 
increments beginning at 50% VO2peak followed by 70% and 90% VO2peak.  Pulmonary 
gasses and EMG readings were assessed throughout testing as was HR. 
In addition, blood lactate was assessed via finger stick at regular intervals.  
Cognition was assessed using the Computerized Mental Performance Assessment 
System (COMPASS) at baseline, prior to exercise, during the 50% VO2peak portion, during 
the 70% VO2peak portion, and 6 min after the exercise test.  Finally, RPE were assessed 
during the exercise protocol. 
The nitrate group again yielded higher plasma nitrite compared to placebo (p < 
0.001) and no differences were reported for SBP or DBP.  The change in cerebral blood 
flow was blunted in the nitrate group (p < 0.05) prior to exercise and the effect 
remained up to the 90% VO2peak portion of the cycle test.  Following the exercise test, 
cerebral blood flow was restored faster in the nitrate group (p < 0.05).  The change in 
muscle blood flow was also blunted in the nitrate group (p = 0.038) and muscle blood 
flow increased to a higher degree during exercise in the nitrate group (p = 0.001). 
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VO2 was reduced in the nitrate group; however, this effect was only seen during 
the 50% VO2peak portion.  Additionally, respiratory exchange ratio was found to be 
significantly higher in the nitrate group (p < 0.001).  There was no treatment effect for 
EMG, HR, cognitive metrics, or blood lactate.  Finally, the nitrate group lasted 16% 
longer during the 90% VO2peak stage to exhaustion while VO2 at exhaustion remained 
similar between the two groups. 
Porcelli, et al. [111] studied nitrate-heavy diets in seven recreationally active 
males (25 ± 2 y, 66.3 ± 6.0 kg, 174 ± 5 cm).  After informed consent, baseline data was 
determined using an incremental cycle ergometer test until volitional fatigue with peak 
oxygen consumption and work rate being recorded.  Participants supplied the 
researchers with a seven-day food log which a nutritionist then used to create 
standardized diets based on individual normal intake and activity level, with the high-
nitrate group having 8.2 mmol/d (508 mg/d) nitrates and the control diet having 
approximately 2 mmol/d (124 mg/d) nitrates, all from plant sources.  This diet was 
maintained for six days, performance analyzed, and switched to the other diet after a 
20 d washout period where the measures were tested once more.  The exercise tests 
conducted in this study included moderate intensity constant-work rate cycling at a 
frequency of 80 ± 5 rpm and a work rate of 50% peak work rate. 
Also, isometric knee extensions were employed to determine MVC as well as 
submaximal knee extension to volitional fatigue.  Finally, repeated sprints were 
conducted using a Wingate protocol repeated for six bouts at 0.74 N/kg with 24 sec 
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rests between bouts.  VO2 and VCO2 were analyzed throughout testing, as were force, 
EMG, and blood samples to assess for nitrate/nitrite. 
The authors did not include p-values; however, the authors noted statistically 
significant difference in nitrate or nitrite concentration between groups at baseline and 
a significant increase in both plasma nitrate and nitrite following a high nitrate diet.  
The high nitrate diet yielded lower VO2 and VE values during the moderate intensity 
cycle test with no difference in HR or blood lactate.  The nitrate group saw no 
difference in MVC on the knee extension portion although the high nitrate group did 
see a significant increase in the number of repetitions prior to fatigue.  Additionally, 
while there was no difference on the repeated sprint bouts for the first or second bout, 
the high nitrate group yielded significantly higher power output in the third, fourth, and 
fifth bouts, indicating a role of nitrates in maintaining exercise intensity in line with 
current research. 
Thompson, et al. [112] also investigated the effect of nitrate supplementation 
on sprint performance.  Using a double-blind, randomized crossover design, the 
authors recruited 16 male athletes.  The protocol involved 7 d of supplementation and 
7 d washout using either nitrate-rich (12.8 mmol, 794 mg) or nitrate-depleted beet root 
juice (0.08 mmol, 4.96 mg) mixed in 140 mL of juice.  On the last day of the 
supplementation period, the participants completed a test wherein 20 sprints were 
done over the course of 40 minutes.  Each sprint consisted of a 6 sec sprint, 100 sec 
active recovery, and 20 sec rest on a cycle ergometer.  The 40 min test was completed 
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twice, with the second time including cognitive testing during exercise.  The nitrate-rich 
group yielded significantly increased total work and higher cognitive function as the 
exhaustive exercise continued. 
 The majority of the studies thus far have involved incremental or steady state 
exercise to exhaustion.  Thompson, et al. [112] investigated the role of nitrates in 
interval training.  Eighteen recreationally active young adults (Males n=18, 27± 8 y, 80 ± 
13 kg, 179 ± 8 cm; Females n=18, 23 ± 4 y, 65 ± 9 kg, 166 ± 5 cm) were recruited for this 
investigation.  During familiarization, participants completed an incremental treadmill 
protocol to determine VO2peak and work rates were determined for moderate and 
severe exercise.  Participants were randomly assigned to either nitrate-rich beetroot 
juice (6.5 mmol, 403 mg) or nitrate-depleted beetroot juice (0.04 mmol, 2.48 mg).  
Participants then underwent a 4 week standardized exercise and supplementation 
period followed by follow-up testing before being moved to the other treatment in a 
crossover manner after a 7 d washout.  Blood pressure and HR were assessed at the 
beginning, middle, and ending of each session followed by calculation of MAP.  Blood 
was collected at baseline, 1 min into exercise, 3 min into exercise, and following 
exhaustion.  Muscle biopsies were collected to analyze muscle metabolites, muscle 
glycogen, pH, and fiber types prior to testing.  In addition, oxygen uptake was 
measured throughout the testing using indirect calorimetry.  Exercise testing included 
step tests and incremental cycle tests similar to prior research from this lab [123] and 
the standardized training involved repeated Wingate tests against a resistance of 7.5% 
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body mass (in kg).  Wingate bouts were separated by 4 min rest periods and were done 
four times, three times a week during the first two weeks and five bouts, four days per 
week during the final two weeks. 
 Plasma nitrites were elevated in the nitrate group at all time points.  Blood 
pressure decreased in the nitrate group by 6 ± 4 mmHg by the fourth week while MAP 
was reduced by 3 ± 5 mmHg.  Work rate on the incremental test was significantly 
higher for the nitrate group (p < 0.001) following four weeks of treatment.  Consistent 
with other studies under review, VO2 at exhaustion was lower in the nitrate group (p < 
0.05).  Time to failure was higher in the nitrate group (170 ± 90 sec) compared to 
placebo (163 ± 144 sec, p < 0.05).  The trained nitrate group also yielded lower blood 
lactate than placebo or sedentary supplemented group at both 1 min and 3 min (p < 
0.05).  There were no changes in ATP, pH, or PCr at baseline; however, the trained 
nitrate group yielded lower blood/muscle lactate and higher pH at 3 min of severe 
exercise (p < 0.05).  The trained nitrate group also showed evidence of a decrease of 
Type IIx fibers and increase in Type IIa fibers, indicating a potential effect of nitrates in 
training adaptations.  The results of this study showed that nitrate supplementation in 
conjunction with sprint training, but not nitrate alone, caused favorable changes to pH, 
fiber types, and performance.  Nitrate supplementation also caused lower VO2 at 
exhaustion in addition to increased work rate. 
With focus on time trial performance, Callahan, et al. [124] recruited eight 
trained male cyclists (34 ± 7 y, 73.8 ± 10.1 kg) were enrolled in a placebo-controlled, 
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double-blind, randomized, crossover study.  In this study, participants were randomized 
into four groups: nitrate in the form of beet root crystals (5 mmol, 310 mg), nitrate + 
sodium bicarbonate, sodium bicarbonate, and placebo.  Diets were standardized 
throughout the study in pre-packaged meals and participants were instructed to fast 
overnight prior to testing sessions.  During familiarization, participants completed an 
incremental cycling protocol beginning at 150 W and increasing 50 W in 5 min intervals 
until peak power was achieved.  In addition, blood samples were taken via the ear lobe 
during the final 30 seconds of each increment and exercise was terminated when 
lactate concentration eclipsed 7 mmol/L, indicating the onset of blood lactate 
accumulation had been passed.  Following the incremental test, participants completed 
a 10 min steady state cycle test at 150 W followed by a 10 min seated rest.  Once blood 
lactate had returned to less than 2.5 mmol/L, participants underwent a 4 km time trial 
to determine VO2peak.  Upon completion of the time trial, blood lactate was again 
assessed.  Following that test, a 4 km time trial was completed.  For the entirety of the 
familiarization testing, participants were analyzed for pulmonary gas exchange.   
At 72 h pre-baseline testing, participants presented to the lab for baseline blood 
draw.  At baseline testing, participants ingested the supplement as well as a 
standardized meal containing 2 g/kg carbohydrate as well as completing a 
gastrointestinal distress questionnaire.  This questionnaire was completed 65 min prior, 
5 min prior, 6 min post, and 81 min post-time trial.  Sixty minutes post-ingestion, 
participants began to warm-up on the cycle at 50% (8 min), 70% (5 min), 85% (3 min), 
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and 100% (3 min) lactate threshold determined from familiarization.  Following this 
test, participants were given a sports gel containing 27 g carbohydrate followed by the 
4 km time trial.  Blood was collected at 72 h pre-testing and five times during the 
testing day to analyze for glucose, lactate, and nitrate/nitrite concentration. 
There was no effect of treatment order on any metric.  The nitrate containing 
groups (beetroot + bicarbonate, beetroot + placebo) yielded higher nitrate and nitrite 
concentrations compared to bicarbonate + placebo and placebo alone (p < 0.01).  The 
beetroot + bicarbonate and bicarbonate + placebo groups yielded higher blood lactate 
following the time trial compared to beetroot + placebo and placebo (p < 0.01).  No 
significance was found in the responses to the GI questionnaire. 
To assess the effects of acute and chronic supplementation of nitrates, Jo, et al. 
[125] employed a randomized, double blind, placebo-controlled study assessing the 
effect of nitrates on time trial performance.  Participants (n = 29, 15 M, 14 F, ) were 
assigned to either a multi-day nitrate supplementation group or a single pre-exercise 
dose group.  Both groups completed 14 d of supplementation with either a nitrate (MD, 
8 mmol NO3, 500 mg) or placebo (SD) with both consuming nitrates on Day 15 at 180 
min prior to exercise testing.  The exercise testing days consisted of collection of 
anthropometric and hemodynamic data, infrared muscle oxygenation and the 8 km 
time trial.  Resistance was not specified.  The MD group demonstrated a significant 
decrease of 5.6% in time to completion (p = 0.01) as well as a significant increase of 
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4.2% in average power (p = 0.04); no acute effect was noted in SD.  No differences were 
noted in hemodynamic responses or muscle oxygenation. 
Thompson, et al. [110] opted to analyze nitrates in a pure sprint protocol.  
Thirty-six male athletes (24 ± 4 y, 80 ± 10 kg, 180 ± 7 cm) involved in team sports such 
as football, rugby, and hockey were introduced to a sprint based study protocol with 
the aim of demonstrating a positive benefit in both sprint performance and cognition.  
After a familiarization session, participants were randomized to receive either nitrate-
enriched beetroot juice (6.4 mmol, 397 mg) or nitrate-depleted beetroot juice.  
Participants ingested the supplement for five consecutive days, followed by the first 
testing session, 7 d washout, and alteration to the other treatment in a crossover 
manner.  Dietary food logs were maintained throughout the study. During the testing 
protocol, participants underwent five 20 m sprints as a warm-up, followed by the YoYo 
Intermittent Recovery Level 1 test.  In this test, participants would sprint 20 m, 
immediately turn around, and sprint back to the start.  These 40 m sprints were 
interspersed by 10 second rest periods and increased in speed until time ceased to 
decrease.  Following the Yo-Yo test, participants took the Stroop Color-Word test for 
cognition and the study session was complete.  In addition to the performance and 
cognitive tests, blood chemistry and blood pressure were also assessed.   
Plasma nitrate increased eight-fold from baseline to testing in the nitrate group 
compared to no change in placebo (p < 0.01).  The nitrate group also boasted a 
reduction in SBP (117 ± 7 mmHg against 119 ± 8 mmHg, p < 0.05) as well as a trend in 
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MAP (79 ± 15 mmHg compared to 81 ± 15 mmHg, p = 0.08).  Despite significance or 
trend toward significance, these values were still well within normal limits.  There also 
was a decrease in 20 m sprint time of 1.2% in the nitrate group (p < 0.05) as well as a 
2.3% and 1.6% decrease in sprint time in the 5- and 10 m sprints, respectively.  In 
addition, the results of the Yo-Yo test evidence an increase in distance covered of 3.9% 
for the nitrate group (p < 0.05).  Finally, cognition was enhanced in the nitrate group on 
the Stroop Color-Word test (p < 0.05). 
In a study by Kramer, et al. [126], twelve male cross-training athletes (23 ± 5 y) 
were recruited to test the effects of nitrate supplementation on high intensity interval 
training. After a familiarization period where VO2peak was measured on a graded 
treadmill test, participants partook in two consecutive study days followed by six days 
of sodium nitrate (8 mmol NO3 or 496 mg potassium nitrate) or nitrate-free potassium 
chloride placebo supplementation, and follow-up testing using the baseline protocol.  
Supplements were pre-packaged as unmarked gel capsules by a third party and 
consumed in the morning and in the evening.  After a 10 d washout, the protocol was 
repeated using the alternative treatment in a crossover design.  Testing Day 1 included 
isokinetic testing of the quadriceps and hamstrings, a Wingate cycle ergometer test, 
and a time trial on a cycle ergometer.  Testing Day 2 included a specific cross-training 
workout wherein time to completion was measured.   
There was no difference in quadriceps or hamstring isokinetic force.  There was 
a significant increase in peak power on the Wingate protocol for the nitrate group (p = 
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0.01).  Time to completion for the workout was not different between groups.  In 
addition, supplementation yielded complaints of nausea and gastrointestinal 
discomfort in both the nitrate group (n=5) and placebo group (n=3), indicating 
something other than the nitrates may have had an effect. 
Similar to Kramer, et al., Nyakayiru, et al. [25] investigated the effects of nitrate 
supplementation on high-intensity interval training (HIIT).  This study involved 32 
amateur league soccer players (23 ± 1 y, 77 ± 1 kg, 181 ± 1 cm) in a double blind, 
randomized, placebo-controlled, crossover design investigating the effects of short-
term (6 d) use of nitrates on high intensity interval training.  At baseline, participants 
completed the Yo-Yo intermittent exercise test, followed by random allotment of either 
nitrate-rich beetroot juice (12.9 mmol NO3, 800 mg) or depleted beetroot juice.  
Participants were instructed to consume the assigned treatment at approximately the 
same time daily and at 3 h pre-exercise at follow-up testing. 
Short-term treatment resulted in a significant elevation in plasma nitrate and 
nitrite at all time points in the nitrate group.  Performance on the Yo-Yo was 
significantly improved in the nitrate group compared to PLA (p = 0.027), demonstrating 
an average increase in distance completed of 3.4 ± 1.3%.  Additionally, HR was 
significantly lower in the nitrate group compared to PLA during the Yo-Yo test (p = 
0.014).  Finally, there were no differences in side effects reported or RPE. 
There is some debate regarding differing effects related to training status [127-
131].  Muggeridge, et al. [26] conducted a double-blind, placebo-controlled, 
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randomized study analyzing the effects of nitrates on adaptation to sprint training in 
untrained males.  In this study, untrained males (n = 27, 28 ± 7 y, 82.3 ± 17.1 kg, 177 ± 5 
cm).  At familiarization, baseline measurements on an incremental exercise test on a 
cycle ergometer were determined as VO2max, ventilatory threshold, and maximal work 
rate.  The cycle test began at 50 W for 1 min and increased by 15 W/min until volitional 
fatigue.  Participants were then randomly assigned to an exercise condition (normal 
activity, sprint interval training) and a treatment condition (no treatment, placebo, 
nitrates).  The nitrate group received 8 mmol/d NO3 (496 mg/d).  Sprint interval training 
(SIT) took place on a cycle ergometer over 9 training sessions across 3 weeks of 
supplementation prior to follow-up testing. 
The PLA + SIT and NIT + SIT yielded significant ergogenic effects compared to the 
control group; however, there were no differences between PLA and NIT in regards to 
VO2max.  Analysis of 95% confidence intervals showed NIT to significantly improve 
VO2max, while both PLA and NIT significantly improved ventilator threshold and maximal 
work rate.  Interestingly, PLA demonstrated increased power in sprint bouts 2 through 
9 compared sprint bout 1 whereas NIT demonstrated no difference in power in any 
sprint bout. 
 A review by Lara, et al. [132] analyzed studies involving humans over the age of 
18 with or without any co-morbidities to assess the difference, if any, of organic and 
inorganic nitrates.  This review specifically analyzed studies utilizing flow-mediated 
dilation, pulse wave velocity, and augmentation index to assess blood flow.  The review 
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began with 9,684 articles and was eventually narrowed down to 12 articles that fit the 
criteria.  Of these 12 studies, five assessed young and healthy participants, two 
assessed participants with hypertension, and one assessed patients with Type 2 
diabetes.  Beetroot juice (organic nitrate, 1.1 to 22 mmol/dose or 6.82 to 1364 
mg/dose) was used in nine of the studies whereas inorganic nitrate salts were used in 
four (8.0 to 24 mmol/dose or 496 to 1488 mg/dose).  Lara, et al. concluded inorganic 
and organic nitrates to not be different with regards to efficacy (p = 0.001). 
 In a balanced crossover study by Wylie, et al. [133], the dose response of 
nitrates were examined.  The study involved 10 healthy men whom received either 4.2 
mmol (260 mg), 8.4 mmol (521 mg), or 16.8 mmol (1042 mg) of concentrated beetroot 
juice or nitrate-depleted beetroot juice as a placebo.  The protocol consisted of seven 
visits over a 4 to 5 week period (separated by 3 d w/o) where acute supplementation of 
the randomly assigned treatment was analyzed relative to hemodynamics, blood 
chemistries, oxygen kinetics and work done during the cycle ergometer testing.  
Participants arrived, provided fasting blood and ingested the treatment, followed by a 
2.5 h wait and a second blood draw.  After the blood draw, participants completed a 
graded exercise test on the ergometer, beginning at 20 W and increasing to severe 
intensity.   
Plasma NO3 was significantly higher in the NO3 groups, with the 16.8 mmol 
group being significantly higher than 4.2 and 8.4 and no difference between 4.2 and 
8.4.  The 4.2 group evidenced an approximately four-fold increase in plasma nitrate, 8.4 
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was eight-fold, and 16.8 was twenty-fold.  In addition, SBP and DBP decreased relative 
to the dose, with 16.8 showing a significant decrease at all time points, 8.4 showing an 
initial significant decrease and returning closer to baseline, and 4.2 showing no 
difference.  MAP was significantly decreased in the 8.4 and 16.8 mmol groups but was 
unchanged in the 4.2 mmol group. 
Regarding performance, the 16.8 mmol group significantly decreased end-
exercise VO2 during moderate-intensity exercise by 3%, 8.4 mmol decreased by 2% 
which was not significant but did evidence a trend, and 4.2 was not significant.  No 
significant differences were noted in response to severe-intensity exercise; however, 
the time to exhaustion in the final test was significantly greater in the 8.4 and 16.8 
mmol groups with no difference in the 4.2 mmol group. 
 Based on the studies reviewed, nitrates appear to be effective in doses as low as 
5 mmol (310 mg) [35, 110, 124, 133].  The pattern noted within the studies reviewed 
illustrates a decrease in VO2 at low- and moderate exercise intensities compared to 
placebo, increased plasma nitrite and nitrate compared to placebo, increased time to 
exhaustion compared to placebo, and some benefit to cognition.  The current work 
utilized a dose of 5.7 mmol (353 mg) of inorganic nitrate; given the literature reviewed, 
a significant ergogenic effect in RtF should occur but the literature appears to be 
inconclusive regarding the severe-intensity 4 km time trial at the present dose. 
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2.3.3. L-Arginine 
 As noted previously, L-arginine enhances nitric oxide via enzymatic conversion 
using nitric oxide synthase (NOS), oxygen, and L-citrulline.  Nitric oxide is accepted to 
promote vasodilation and thus believed to increase nutrient delivery and metabolite 
removal to and from working tissue [134, 135] which has been associated with recovery 
following stress [136].  L-arginine is created in the liver as part of the urea cycle and is a 
conditionally essential amino acid.  Following injury and during periods of growth, L-
arginine requirements may increase to aid in repair [135, 137].  A review by Bescos, et 
al. [138] provided an overview of nitric-oxide enhancing supplements in relation to 
human performance.  L-arginine is typically taken in daily doses of 4 to 5 g and can be 
found in high amounts in seafood, watermelons, and rice or soy protein.  The action of 
L-arginine in endothelial vasodilation appears to be dependent on the presence of 
oxygen as well as NADP.  Bescos, et al. [139] also reports infusion of L-arginine can have 
a beneficial effect to growth hormone.  A summary of the studies reviewed may be 
found in TABLE 2.3. 
Evans, et al. [140] sought to further elucidate the biochemical response(s) of 
arginine in healthy humans.  Twelve healthy untrained individuals (Males n=5, Females 
n=7, demographics were not clearly defined) were recruited for this dose response 
study to analyze the biochemical changes in response to 1 g (3 g/d), 3 g (9 g/d), 7 g (21 
g/d), and 10 g (30 g/d) of L-arginine taken as a powder mixed with juice three times 
daily.  Doses increased weekly from 1 g during the first week to 10 g for the fourth 
 50 
 
week.  At the end of each week, participants returned to the lab for analysis and to 
receive more supplement.  Urinalysis, blood chemistry analysis, and blood pressure 
were analyzed weekly.   
At baseline, L-arginine concentration was between 80 and 125 mmol/L, within 
normal limits.  Side effects were reported in the 21 g/d (n = 4) and 30 g/d groups (n = 
10).  There were no significant differences reported in blood pressure for any dose.  
There was significance with regards to plasma concentration of L-arginine, glycine, and 
L-ornithine.  Glycine was found to be significantly lower after 3 weeks (p = 0.010) 
whereas L-ornithine increased by the third week (p = 0.001).  The increase in L-arginine 
plateaued at 9 g/d, indicating a physiological ceiling effect for L-arginine concentration.  
Finally, at 3 g/d, insulin increased from 137 ± 33 mmol/L at baseline to 176 ± 44 mmol/L 
and then dropped to 127 ± 32 mmol/L for the remaining weeks.  This change, while not 
significant, showed a trend (p = 0.09); there was no change in blood glucose.  Of note, 
demographics of the participants were not defined in this study, only that they were 
healthy; therefore, these data can only be used to give a general idea of dosing and 
biochemical/hormonal response. 
Forbes & Bell [141] analyzed fourteen recreationally active males (25 ± 5 y, 78.0 
± 8.5 kg, 179.5 ± 4.7 cm) for the response of nitrate/nitrite, growth hormone (GH), 
insulin-like growth factor 1 (IGF-1), and insulin.  Prior to the first testing session, 
participants provided a 1 d food recall to adjust for macronutrient intake; total calories 
and diets were altered to maintain protein at 0.8 g/kg/d.  Participants were assigned to 
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either a flour placebo group, 0.075 g/kg L-arginine (µ = 5.85 g) , or 0.15 g/kg L-arginine 
(µ = 11.7 g)  in a randomized, double-blind manner.  For each of the three study days, 
randomly assigned in a crossover fashion, participants ingested the supplement and 
rested for a period of 2 h with blood draws at regular intervals.  For each testing 
session, blood was collected at baseline and in 30 min increments following ingestion. 
The 10 g dose was accompanied by complaints of gastrointestinal distress (n = 
2).  There was not a difference in plasma L-arginine between the low- and high dose 
although both treatments yielded greater concentrations of L-arginine compared to 
placebo (p < 0.05).  While there were no differences reported in the GH or IGF-1 
markers, the authors did note a difference in insulin concentration between 30, 90, and 
180 min (p < 0.05) as well as an increase in nitric oxide that was significantly higher 
than placebo (p < 0.05) with no difference between low- and high-dose at 1 h with no 
significant differences after 1 h.  The implications of this study evidenced no difference 
between an average dose of 5.85 and 11.7 g of L-arginine in terms of biochemistry; 
however, complaints of side effects were not present at the lower dose [140]. 
Forbes, et al. [142] found similar results in so far as L-arginine at a dose of 5.8 g 
yielded higher plasma L-arginine compared to placebo with no change in GH, lactate, 
glucose, VO2, VCO2, RER, or nitrate/nitrite concentrations.  This study involved fifteen 
aerobically trained men (28 ± 5 y, 77.4 ± 9.5 kg, 180.9 ± 7.9 cm) with an average VO2max 
of 59.6 ± 5.9 mL/kg/min.  In addition to blood chemistry and physiological measures of 
health, this study also utilized submaximal exercise at 80% of the power output 
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associated with individual ventilatory threshold for a duration of 60 min.  There were 
no differences seen in performance. 
 Forbes, et al. [143] analyzed fourteen strength trained males (25 ± 4 y, 81.4 ± 
9.0 kg, 179.4 ± 6.9 cm) with an average training experience of 6.3 ± 3.4 y.  Following 
baseline testing, participants were randomly assigned to either a dose of 0.075 g/kg (µ 
= 6.105 g) or flour placebo packaged in a gel capsule.  This double-blind, randomized, 
crossover study utilized 1-RM protocols on bench press and leg press as well as multiple 
repetition maximum on pulldowns, leg extension/flexion, shoulder press, elbow 
extension/flexion, and calf raises.  In addition to strength testing, blood was collected 
to analyze for L-arginine concentration, GH, ghrelin, and IGF-1. Finally, HR and RPE were 
assessed before and after testing. 
Concentrations of L-arginine were elevated in the arginine group by 120% 
compared to placebo (p < 0.05).  There were significant differences in GH, growth 
hormone releasing hormone (GHRH), ghrelin, and IGF-1.  Immediately following 
exercise, GH was enhanced in the placebo group immediately following exercise and 
significance was maintained for 30 min post exercise.  GHRH was also elevated in the 
placebo group immediately following exercise and followed the same trend of 
maintaining significance for 30 min post-exercise.  Ghrelin and IGF-1 were significantly 
higher in the placebo group at the onset of exercise.  Despite the decreased GH and 
GHRH in the L-arginine group, growth hormone inhibiting protein (GHIH) remained the 
same between groups.  There were no differences related to strength, HR, or RPE at 
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any time point.  These data are in opposition to prior claims of a beneficial effect of L-
arginine to anabolic signaling via GH and IGF-1. 
In a study by Alvares, et al., [144] fifteen trained runners (Males n=11, Females 
n=4) were divided into an arginine (36.8 ± 7.1 y, 66.7 ± 14.4 kg, 172.3 ± 10.6 cm) and 
placebo group (30.6 ± 9.5 y, 68.1 ± 10.6 kg, 175.0 ± 7.5 cm).  Following familiarization, 
participants presented for baseline testing followed by 4 weeks of L-arginine (6 g/d) or 
cornstarch placebo supplementation and follow-up testing.  During testing sessions, 
thirty minutes post-ingestion, participants underwent two 5 km time trials separated by 
a 10 min rest.  Blood was collected prior to, between, and after the time trials.  Blood 
was analyzed for nitrate/nitrite, L-arginine, L-citrulline, L-ornithine, and hormonal 
response. Finally, participants were instructed to avoid foods high in nitrate and nitrite 
on the day prior to the testing session.  As expected, plasma L-arginine concentration 
increased significantly and remained significantly elevated even at 20 min post 
exercise.  No differences were noted regarding nitrate/nitrite, L-citrulline, L-ornithine, 
GH, lactate, or cortisol.  In regard to ergogenic potential, there were no differences in 
time trial performance between groups.  Further work from this lab evidenced L-
arginine at 6 g/d to have a beneficial effect on muscle blood volume measured by near-
infrared spectroscopy; however, there were no increases in performance compared to 
placebo [145]. 
Da Silva et al. [146] developed a study targeting insulin and GH as primary 
outcomes.  The study involved fifteen aerobically trained individuals (Males n=11, 
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Females n=4) whom were randomly assigned to either an L-arginine (6 g, 36.8 ± 7.1 y, 
66.7 ± 14.4 kg, 172.3 ± 10.6 cm) or cornstarch placebo group (30.6 ± 9.5 y, 68.1 ± 10.6 
kg, 175.0 ± 7.5 cm).  Following baseline fasting blood draws, participants ingested their 
assigned treatment, waited for 30 min and then underwent two 5 km time trials.  Blood 
samples were analyzed for insulin, GH, IGF-1, and cortisol.  Despite the typical increase 
in GH and IGF-1 associated with exercise, there were no significant differences in 
hormonal profiles between groups.  In addition, there was no significant difference in 
time trial performance between-groups. 
 Chen, et al. [147] investigated a population of Tae-Kwon-Do athletes using a 
cycle ergometer analog to simulate the intensity of a normal Tae-Kwon-Do match.  
Twelve male athletes (20 ± 0.8 y, 66.9 ± 5.0 kg, 177 ± 4 cm) were recruited to partake in 
this study.  After baseline measures, participants were randomly assigned to a 
treatment group containing BCAAs, L-arginine (0.05 g/kg, µarg=3.35 g), and L-citrulline 
(0.05 g/kg) or a starch placebo pre-packaged in gel capsules.  Treatments were 
separated by a 7 d washout period.  Following treatment randomization, participants 
underwent three “matches” on a cycle ergometer.  Each match consisted of 5 sec all-
out sprints with 25 sec normal pedaling.  Each match consisted of performing this 
protocol for two minutes for two bouts.  Between the first and second match was a 1 h 
rest period and the rest period between matches 2 & 3 was 2 h, with the treatment 
being administered at 1 h.  Following the matches and supplementation, the athletes 
were introduced to a reaction test battery wherein they held a button in one hand and 
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were instructed to press it upon visual cue from a light.  In addition, blood was 
collected prior to breakfast, after each match, and immediately before the third match 
(p = 0.002).  There were no differences in RPE between groups.   
Further investigating performance, Wax, et al. [148] tested acute and short-
term treatment of L-arginine α-ketoglutarate on performance in resistance training.  
Sixteen males, eight trained (19.8 ± 1.9 y, 78.1 ± 7.5 kg, 176 ± 9 cm) and eight untrained 
(21.8 ± 2.4 y, 88.6 ± 22.4 kg, 179 ± 4 cm), were recruited to partake in this study.  After 
a familiarization session where baseline 1-RM was determined for both bench press 
and leg press, participants were randomized to either the treatment group (3 g/d 
arginine α-ketoglutarate) or placebo.  Participants took the treatment daily for a week 
and returned to the lab for follow-up testing.  During the first testing session, 
participants ingested the assigned treatment, waited 45 min, and 1-RM was 
determined on bench press and leg press followed by RtF at 60% 1-RM.  Total load was 
determined by multiplying the weight lifted (60% 1-RM) by RtF for each exercise.  After 
follow-up testing, participants waited 1 week to allow for washout followed by 
undergoing the same protocol on the alternate treatment/placebo.  There was no 
treatment effect on 1-RM, RtF, total volume, or HR between groups for trained and 
untrained individuals (p > 0.05). 
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Table 2.3. L-Arginine 
Author (year) Study 
Design 
Sample Dosing Protocol Assessment 
Protocol 
Significant Findings 
Evans, et al. (2004) 
[140]  
P, R, DB, 
CO 
n = 12 (5 M, 7 F) 
healthy untrained 
individuals 
3 g/d at week 1, 9 g/d at 
week 2, 21 g/d at week 3, 
30 g/d L-arginine at week 
4 
Blood chemistry, 
hemodynamics, side 
effects 
Gastric distress reported in 21 and 30 
g/d groups, plasma L-arginine 
plateaued at 9 g/d  
Forbes & Bell 
(2011) [141] 
P, R, DB, 
CO 
n = 14 recreationally-
active males (25 ± 5 
y) 
0.075 g/kg L-arginine or 
0.15 g/kg L-arginine acute 
dose, 7 d w/o 
Blood draws every 
30 min following 
ingestion for 2 h 
Gastrointestinal distress reported in 
high dose (~10 g), no difference in GH 
or IGF-1, increase NO at 1 h only 
Forbes, et al. 
(2013) [142]  
P, R, DB, 
CO 
n = 15 aerobically-
trained men (28 ± 5 
y) 
5.8 g L-arginine 1 h prior 
to exercise, 7 d w/o 
Submax exercise at 
80% ventilator 
threshold 
No difference in performance, VO2, 
RER, GH 
Forbes, et al. 
(2014) [143] 
P, R, DB n = 14 resistance-
trained males (25 ± 4 
y) 
0.075 g/kg 1 h prior to 
exercise 
1-RM and RtF on BP 
and LP 
GH, ghrelin, and IGF-1 enhanced in 
placebo group and no differences in 
performance 
Alvares, et al. 
(2012) [145] 
P, R, DB, 
CO 
n = 15 aerobically-
trained participants 
(36.8 ± 7.1 y) 
6 g/d L-arginine for 4 
weeks.  Exercise testing 
30 min post-ingestion, 7 
d w/o 
Two 5 km TT with 10 
min rest between 
Increase in muscle blood volume in L-
arginine group with no difference in 
performance 
Vanhatalo, et al. 
(2013) [149] 
P, R, DB, 
CO 
n = 18 recreationally-
active males (22 ± 3 
y) 
6 g L-arginine 65 min pre-
exercise, 7 d w/o 
Incremental test on 
TM 
No difference in performance, 
decreased DBP and MAP in L-arginine 
(within normal limits) 
Yavuz, et al. (2014) 
[150] 
P, R, DB, 
CO 
n = 9 professional 
wrestlers (24.7 ± 3.8 
y) 
0.15 g/kg L-arginine, 7 d 
w/o 
Incremental test on 
CE 
Increased TTE in L-arginine group with 
no difference in lactate  
Chang, et al. (2015) P, R, DB, 
CO 
n = 15 male (21.1 ± 
1.0 y) and 7 female 
handball players 
(20.3 ± 0.5 y) 
Average dose of 3.13 g L-
arginine for males and 
2.16 g for females 30 min 
pre-exercise. 24 h w/o 
Simulated handball 
matches using two 
30 min blocks of 
activity and 20 m 
sprints 
L-arginine improved spring 
performance 
P = Placebo controlled, R = Randomized, DB = Double-blind, CO = Crossover, w/o = washout, GH = growth hormones, IGF-1 = insulin-like growth factor 1, NO = nitric oxide, VO2 = volume 
of oxygen consumption, RER = respiratory exchange ratio, 1-RM = one repetition maximum, RtF = repetitions to failure, BP = bench press, LP = leg press, TT = time trial, TTE = time to 
exhaustion, TM = treadmill 
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In a study by Bailey et al. [151], eight recreationally-active healthy males (22 ± 2 
y, 79 ± 12 kg, 183 ± 9 cm) were recruited and required to report to the lab for eight 
testing sessions over the course of 7 to 9 weeks.  At familiarization, a ramp incremental 
exercise test was conducted to determine VO2peak followed by random assignment to a 
watermelon juice or apple juice placebo.  The watermelon juice, which contained 1.39 
g/L L-arginine and 11.4 g/L L-citrulline, was consumed at 150 mL/d.  During each visit, 
pulmonary and muscular oxygen kinetics as well as exercise performance were 
assessed in addition to 5 d dietary recalls.  Testing days included analyses of 
performance on an incremental cycle ergometer test as well as moderate- or severe-
intensity step testing, pulmonary gas exchange, muscle oxygenation, and blood 
chemistry. 
Even at the low dose of L-arginine, reports of gastrointestinal discomfort were 
common.  L-arginine and plasma nitrate/nitrite were both higher in the watermelon 
juice (p < 0.001).  The watermelon group yielded significant increases in HR, SBP, and 
MAP (p < 0.05) but DBP was unchanged.  There were no differences between groups in 
measures of VO2 kinetics, blood glucose or lactate, or exercise performance. 
The review by Bescos, et al. [138] found seven studies analyzing L-arginine 
supplementation with no extra compounds.  Of these, two studies involved healthy 
untrained males and one involved healthy post-menopausal women.  In the study 
investigating post-menopausal women (n = 30, Treatment: 54.4 ± 4.1 y, 67.5 ± 13.7 kg, 
165.9 ± 7.1 cm; Placebo: 55.3 ± 4.4 y, 61.3 ± 6.9 kg, 165.4 ± 5.4 cm), Fricke, et al. [152] 
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investigated the effects of L-arginine supplementation on muscle force and power.  Of 
the recruited women, four treatment and three placebo participants were unable to 
complete mechanographic analyses due to perceived back and knee pain.  The 
treatment group consumed 18 g/d arginine HCl (14.2 g L-arginine, 3.8 g hydrochloride) 
for 6 months compared to 18 g dextrose placebo.  The tests included mechanographic 
and force analysis of two-leg countermovement jumping, isometric grip to assess MVC, 
and standard anthropometrics.  Over the 6 month study, no differences arose related 
to anthropometry.  Those in the treatment group exhibited a significant increase in 
peak jump force when adjusted for weight (p = 0.04) and a trend towards significance 
without adjusting for weight (p = 0.09).  No significance was found in any other metric 
including MVC.  There was an ergogenic effect of a high-dose of L-arginine in post-
menopausal women in lower body force production. 
In contrast to the findings by Evans, et al. and Forbes & Bell, Campbell, et al. 
[153] found higher dosing of L-arginine did not cause side effects.  In this study, 35 
resistance-trained men were enrolled in a randomized, double-blind design.  The study 
consisted of four standardized resistance workouts per week for eight weeks and data 
collection at weeks 0, 4, and 8.  During this time, participants consumed a total of 12 g 
L-arginine α-ketoglutarate daily split over three doses of 4 g.  Eight hour fasting blood 
sample were collected at the onset of each testing session, followed by measurements 
of 1-RM on bench press, muscular endurance in the quadriceps, Wingate power testing, 
and aerobic capacity.  At 12 g/day, there were no side effects reported.  In addition, 
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significant increases were noted in 1-RM on bench press, peak power on the Wingate, 
blood glucose, and plasma arginine concentration. 
Koppo, et al. [154] analyzed oxygen kinetics in response to L-arginine treatment.  
Physically active males (n = 7, 21.1 ± 0.6 y, 70.7 ± 5.5 kg, 184 ± 5 cm) were recruited to 
this double-blind, placebo-controlled, crossover study.  Following familiarization and 
baseline data collection on an incremental exercise test to assess ventilatory threshold 
and VO2peak, participants were assigned to either an L-arginine (6 g/d) or lactose 
placebo to be supplemented for a period of 14 d with a 7 d washout separating 
treatments.  In addition, capillary blood samples were obtained to analyze lactate and 
venous blood was collected to assess L-arginine and other amino acids.  
Also, blood pressure and urinary nitrate/creatinine content were assessed.  No 
difference between groups was reported for blood pressure or heart rate prior to and 
after exercise.  There were also no differences in creatinine, lactate, or nitrate.  There 
was, however, a significant difference in the speed of VO2 response to achieving steady 
state during the exercise test (p = 0.014).  Despite the increased speed of oxygen 
kinetics, O2 deficit was similar between the two groups and there were no effects on 
performance. 
Further evidencing a lack of ergogenic benefit, Vanhatalo, et al. [149] 
investigated the effects of acute L-arginine ingestion on exercise tolerance measured by 
VO2 uptake.  Eighteen recreationally active males (22 ± 3 y, 75 ± 9 kg, 176 ± 6 cm) were 
recruited for this study and randomly assigned to either a L-arginine group (6 g L-
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arginine) or flavor- and color-matched placebo separated by a 1 week washout.  The 
performance evaluation in this study was a ramp incremental running test on a 
treadmill at 1% incline.  The test began at 4 km/h and was increased 1 km/h each 
minute to volitional fatigue.  Sixty-five minutes post-ingestion, a second test was 
employed consisting of two 6 min bouts, one at moderate intensity and the other 
severe.  Pulmonary gas exchange and blood chemistry were monitored and recorded.  
In this study, SBP was found to be lower in the L-arginine group although it was still 
within normal limits (124 ± 7 mmHg compared to 128 ± 7 mmHg for placebo).  DBP and 
MAP were also decreased in the L-arginine group yet these were still within normal 
limits (DBP: 67 ± 5 mmHg compared to 69 ± 5 mmHg for placebo; MAP: 86 ± 5 mmHg 
compared to 89 ± 5 mmHg for placebo).  No differences were noted related to VO2 
kinetics or exercise tolerance/performance.  
 Yavuz, et al [150] demonstrated acute L-arginine supplementation to have a 
beneficial effect on time to exhaustion.  Nine nationally and internationally competitive 
wrestlers were recruited (24.7 ± 3.8 y, 80.4 ± 4.1 kg, 174.2 ± 5.2 cm).  Athletes were 
randomly assigned to either an L-arginine group (1.5 g per 10 kg, µarg=12.1 g) or placebo 
as gel capsules separated by a 7 d washout.  The testing session consisted of ingestion 
of the assigned treatment followed by incremental bicycle ergometer test to 
exhaustion beginning at 60 rpm for a warm-up.  Following the warm-up, a resistance of 
90 W was applied which increased by 30 W every 3 min.  Gas exchange was measured 
continuously and blood was collected at the end of each stage.  Heart rate was also 
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measured continuously and remained under recording until lactic acid concentration 
had decreased by 50%.  Lactate, heart rate, and VO2 were similar between groups.  
Despite no changes in the physiological indices, the authors did report a 5.8% increase 
in time to exhaustion for the L-arginine group (p < 0.001).  Interestingly, although the L-
arginine group took significantly longer to achieve fatigue, blood lactate levels were 
similar between groups. 
Chang, et al. [155] investigated the combination of branched-chain amino acids 
and L-arginine on handball performance.  Handball players (Males n = 15, 21.1 ± 1.0 y, 
78.3 ± 11.7 kg, 180 ± 7 cm; Females n = 7, 20.3 ± 0.5 y, 53.9 ± 5.0 kg, 161 ± 4 cm) were 
recruited to this study and randomly assigned to a treatment group (0.17 g/kg BCAA 
and 0.04 g/kg L-arginine, µarg = 3.13 g for males and 2.16 g for females) or placebo with 
a 24 h washout between treatments. 
The exercise tests included 60 min simulated handball games on two 
consecutive days featuring a crossover model between days.  The simulation was 
achieved using thirty 2 min blocks of activity with a 20 m sprint at the end of each 
block.  Sprint time and RPE were recorded and assessed and blood samples were 
collected to assess ammonia, glycerol, and lactate.  The L-arginine group yielded 
significantly better sprint performance on Day 2 compared to placebo (p = 0.001).  RPE 
was also decreased in the L-arginine group (p = 0.005) and no difference in HR was 
reported.  The authors propose the combination of L-arginine and BCAA was ergogenic 
due to attenuation of central fatigue as defined by Blomstrand, et al. [156]. 
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Ergogenic benefits were seen sporadically in the articles reviewed independent 
of dose, with Chen, et al. [147] demonstrating increased performance in Tae-Kwon-Do 
athletes at 3 g/d and Fricke, et al. [152] evidencing increased force production in post-
menopausal women at 14 g/d.  The lowest reported dose of 1.39 g/d, which is higher 
than the current dose of 0.95 g, did not demonstrate any significant effects on 
performance [151].  Given the inconsistencies and findings and the low dose of L-
arginine in the current RTD, it is unlikely L-arginine would add to the proposed 
ergogenic effect of the RTD. 
 
2.3.4. Arginine Nitrate 
Arginine and nitrates have both been associated with endothelium-independent 
vasodilation via increasing the concentration of nitric oxide (NO) [138, 157, 158].  
Physiologically, shear stress and stretch applied to vasculature elicits the endothelium-
dependent release of endothelial nitric oxide synthase (eNOS) which translates to the 
formation of NO.  NO then acts upon the smooth muscle to cause relaxation and the 
resultant effect is vasodilation.  It should be noted the half-life of NO is short, ranging 
from a few seconds to 5 min [96, 159]. 
L-arginine converts to NO via a catabolic pathway and enzymatic conversion to 
NO [160, 161] whereas nitrates (NO3) convert to NO via reduction to nitrites (NO2) and 
further reduction to NO [96].  The rationale behind formulating L-arginine and nitrates 
into a single arginine nitrate compound holds that the dual vasodilatory effect 
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synergistically enhances the effect and provides a more noticeable ergogenic outcome.  
It was also hypothesized that the combination would result in increased bioavailability 
of L-arginine [162, 163] as well as decreasing ATP cost by increasing the removal of 
metabolites, increasing mitochondrial respiration [108], and maximizing perfusion[138, 
164, 165]. 
Sandbakk, et al. [157] analyzed the combined treatment of L-arginine and 
nitrate on endurance and sprint performance.  Nine college-aged competitive cross-
country skiers (18 ± 0 y, 74.2 ± 8.6 kg, 181.0 ± 8.5 cm) were recruited and VO2max was 
determined by an incremental running test to exhaustion to be 69.3 ± 5.8 mL/ kg/min.  
Incline began at 10.5% and speed increased 0.5- to 1.0 km/h when VO2 stabilized for 30 
sec.  Following ingestion of the assigned treatment participants endured three trials 
with a one week washout separating each trial and either L-arginine + nitrate (600 mg 
and 614 mg or 9.9 mmol), nitrate + placebo, or L-arginine + placebo.  Each trial had two 
5 min submaximal running tests on a treadmill and both a 180 m and 5 km time trial on 
an indoor track.  Heart rate and blood pressure were monitored at regular intervals 
while blood was drawn at the beginning of each trial and between each test. 
There were no differences in the two submaximal tests or the 5 km time trial 
between any of the three groups.  In the 180 m time trial, the L-arginine + nitrate group 
(24.4 ± 0.8 sec) and L-arginine + placebo group (24.3 ± 0.7 sec) were no different from 
placebo; however, the nitrate + placebo group completed the 180 m time trial in a 
faster time (24.1 ± 0.9 sec, p = 0.04).  L-arginine + nitrate showed a trend toward lower 
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baseline plasma nitrate concentrations (23 ± 6 mmol/L or 1.426 ± 0.372 mg/dL) than 
nitrate + placebo (32 ± 10 mmol/L or 1.984 ± 0.62 mg/dL, p = 0.07) or L-arginine + 
placebo (35 ± 19 mmol/L or 2.17 ± 0.992 mg/dL, p = 0.06).  Following treatment, the L-
arginine + nitrate (296 ± 77 mmol/L or 18.35 ± 4.77 mg/dL) and nitrate + placebo 
groups were not significantly different (296 ± 77 mmol/L or 20.77 ± 4.03 mg/dL); 
however, both treatments yielded significantly higher nitrate concentration compared 
to L-arginine + placebo (26 ± 16 mmol/L or 1.612 ± 0.992, p < 0.001).  The elevation of 
the two groups was maintained throughout the entirety of the trial (p < 0.001).  The 
results showed an increase in nitrate concentration resultant on combination with L-
arginine; however, nitrates alone still yielded a significant increase in nitrates.  Even so, 
the increased concentrations did not yield consistent ergogenic outcomes outside of 
the 180 m time trial. 
 Given the putative vasodilation associated with L-arginine and nitrate use, there 
is some concern of safety, particularly in regards to alterations in cardiovascular 
response [166-169].  Vasodilation decreases systemic vascular resistance, leading to a 
decrease in venous return and subsequent decrease in diastolic blood pressure and 
stroke volume.  The decrease in stroke volume facilitates a decrease in cardiac output 
which must be compensated for by an increase in heart rate.  In those with 
cardiovascular abnormalities or diseases, this compensation may be inhibited or 
blunted and could lead to orthostatic hypotension; as such, only literature pertaining to 
 65 
 
safety as well as performance benefits of nitric oxide enhancing supplements were 
considered. 
 Bondonno, et al. [96] summarized the effects of dietary nitrate and nitric oxide 
on cardiovascular health.  Cardiovascular disease (CVD) is the leading cause of death 
world-wide [170].  CVD can be attributed to loss of vascular compliance leading to 
decreased oxygen (ischemia), ‘hardening’ of vasculature (atherosclerosis), and 
increased systemic vascular resistance from a combination of the factors or buildup of 
plaque.  The endothelial aspect was the primary focus as it is most affected by the 
ingredients within the supplement.  CVD can be influenced by a variety of factors 
ranging from obesity and dyslipidemia to aging and gender; any perturbation to 
endothelial response can influence how well the heart can compensate and maintain 
cardiac output. 
 In compromised endothelium, eNOS may not function optimally or at all, 
reducing the ability to locally vasodilate.  As such, pharmacological treatments were 
developed but more recently dietary interventions have been seen to have similar 
efficacy in blood pressure control via alteration of endothelial function, to wit, fruits 
and green leafy vegetables are promoted to patients with CVD [169, 171, 172].  Green 
leafy vegetables have been found to be in high in nitrates, leading to more research in 
the area, specifically with regards to vegetables high in nitrates such as beet roots.  The 
findings by Bondonno, et al. dispute the claims of risk to safety by showing the research 
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thus far has been inconsistent and potentially misleading relative to drops in SBP and 
DBP. 
 Lovegrove, et al., [173] sought to further elucidate the role of dietary nitrates in 
CVD.  This review further investigates the current literature regarding nitrates and 
provides further evidence of nitrates being beneficial to vascular compliance.  L-
arginine requires sufficient oxygen catalyze with eNOS to form NO whereas the 
reduction of nitrates to nitrates and further reduction to NO is oxygen independent, 
releasing oxygen in the reduction.  Since the seminal paper by Larsen, et al. in 2006 of 
nitrates lowering blood pressure in healthy individuals [169, 174], the mechanisms and 
actions have been further investigated and extrapolated to more populations and have 
shown nitrates to be very effective in the treatment of hypertension and other aspects 
of CVD.  Furthermore, increasing nitrate consumption has been evidenced to decrease 
the symptoms of metabolic syndrome [169, 175] and up-regulate GLUT4 to better 
utilize glucose [97].   
An overview of the studies reviewed regarding nitrates and L-arginine in relation 
to exercise performance can be found in TABLE 2.2 and TABLE 2.3, respectively.  The 
studies reviewed no significant risk in regards to cardiovascular health; although, 
multiple studies reported complaints of gastrointestinal discomfort [140, 151, 176].  
The review article by Bescos, et al. [138] asserts an average intake of 4 to 5 g/d of L-
arginine from normal diet.  The studies reviewed ranged from 3 g [147, 155] to over 10 
g of L-arginine [150, 152] with most of the studies involving 6 g of L-arginine [145, 146, 
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154, 176].  Based on the study by Evans, et al., doses greater than 9 g/d appear to 
increase the likelihood of gastrointestinal discomfort [140] which is further supported 
by Fricke, et al. and Forbes & Bell [152, 176]. 
 
2.3.5. β-Alanine 
 Beta-alanine (β-alanine) is an endogenous amino acid with roles in skeletal 
muscle function.  β-alanine acts by regulating carnosine synthesis which then serves a 
buffering effect within the skeletal muscle, blunting the drop in pH associated with 
high-intensity exercise [177, 178].  During exercise, pH drops from 7.2 to as low as 6.6 
which results in perturbations in oxygen kinetics, fat oxidation, glycolysis, and EC-
coupling.  These perturbations can and do have detrimental effects on exercise; if 
supplementation results in increased buffering capacity, pH can be maintained closer to 
7.2 resulting in longer time to exhaustion during strenuous exercise. 
Early examination of carnosine was conducted in horses and found that horses 
with increased carnosine content in the gluteus medius was associated with greater 
performance [179, 180].  Carnosine is also found to be higher in Type II muscle fibers 
[181].  Carnosine in human skeletal muscle ranges between 10 and 40 mmol/ kg (dry 
weight) with resistance trained athletes boasting higher concentrations [182] and 
supplementation of β-alanine yielding anywhere from 20 to 80% increases in muscle 
carnosine [177].  It makes sense that carnosine is elevated in Type II muscle fibers and, 
taking the increased carnosine of resistance trained athletes into account, the 
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mechanism of pH buffering fits well with current physiological understanding.  β-
alanine has been found to increase muscle carnosine in both Type I and Type II fibers, 
leading to further buffering capacity [183].   
 In contrast to the findings by Tallon, et al. on resistance trained athletes [182], 
other studies have investigated the effects of training on carnosine content.  Harris, et 
al. [178] reported no training effect after 8-weeks of supplementation were found [184, 
185]; however, supplementation of β-alanine over similar durations using similar 
training protocols yielded increased muscle carnosine [185, 186].  Additionally, females 
have lower muscle carnosine content than males [187] and age has a detrimental effect 
on muscle carnosine [181, 188]. 
 The International Society of Sports Medicine (ISSN) issued a position stand in 
2015 recommending chronic daily doses of 4 to 6 g/d to increase muscular carnosine 
content by 20 to 30% [14].  The overview of ergogenic potential provided in this 
position stand presents claims of enhanced high-intensity exercise performance [177] 
and increased performance in tasks lasting 60 to 240 sec but no effect to exercise 
lasting less than 60 sec [189].  β-alanine also has a beneficial effect on aerobic activity 
lasting more than 4 min [189].  Additionally, there is evidence for claims of decreasing 
neuromuscular fatigue and inconclusive evidence related to enhancing strength [14].  
These claims are supported in other review articles [177, 189]. 
 Carpentier, et al. [190] assessed the effects of chronic β-alanine usage at 4.0 to 
5.6 g/d on high intensity performance.  Twenty seven physically active college-aged 
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individuals were randomly assigned to either β-alanine (BA, Males n=6, Females n=8, 
22.1 ± 2.1 y, 63.6 ± 10.0 kg, 168.8 ± 9.4 cm) or placebo (PL, Males n=6, Females n=7, 
21.4 ± 2.1 y, 63.7 ± 8.5 kg, 174.7 ± 11.6 cm) for daily supplementation over 8-weeks.  
Prior to the first treatment, baseline data was gathered using vertical jump tests, five 
maximal effort jumps and five countermovement jumps.  Following those, participants 
performed a fatigue test of 45 consecutive countermovement jumps.  Blood lactate 
was assessed prior to the fatigue test and every 5 min post-test.  Analysis revealed a 
significant effect of BA treatment on jump height in both the standing and 
countermovement conditions (p < 0.01 and < 0.001, respectively).  The mean height of 
the fatigue test was also greater in the BA group (p < 0.01), indicating preservation of 
force production.  No difference was noted in blood lactate.  
 Another study investigating the effect of BA on less oxidative exercise was 
conducted by Glenn, et al. [191] with Wingate performance as the primary outcome.  In 
contrast to many exercise studies, this study recruited only females whom were 
competitive cyclists (n = 12, 26.6 ± 1.3 y, 58.67 ± 1.74 kg, 161.08 ± 1.78 cm).  
Participants were randomly assigned to either a BA group (1.6 g β-alanine) or dextrose 
placebo as an acute dose.  BA in doses of less than 4 g/d have not been evidenced to 
have ergogenic effect.  During familiarization, anthropometrics were recorded and 
participants completed one bout on the Wingate stress test.  The Wingate protocol was 
completed 30 min following ingestion of the assigned treatment.  Time to completion, 
power, RPE, lactate, and heart rate were recorded prior to, immediately after, and 2 
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min post-Wingate.  The BA group had lower RPE values (p < 0.001) with no difference in 
performance between groups. 
Glenn, et al. [192] utilized a female-only population; however, this study investigated a 
larger dose of 3.2 g β-alanine compared to the previous study’s dose of 1.6 g β-alanine 
[191].  In addition to the increased dose, this study investigated an older population of 
competitive cyclists.  At familiarization, anthropometrics were recorded and VO2peak 
was determined.  During the second day, baseline time to exhaustion data were 
gathered on a cycle ergometer cycling at 120% VO2peak.  Participants were then 
randomly assigned to either the BA group (800mg β-alanine, four times daily) or 
dextrose placebo (PL) for a supplementation period of 28 d (BA n = 11, 54 ± 2 y, 64.01 ± 
2.82 kg, 163.00 ± 2.08 cm; PL  n = 11, 53 ± 1 y, 68.7 ± 5.64 kg, 162.33 ± 2.5 cm).  The 
time to exhaustion protocol was completed weekly followed by final analysis of 
anthropometrics and VO2peak.  The BA group showed a significant increase in time to 
exhaustion of 23% compared to 1% for placebo (p = 0.03) as well as an increase in total 
work of 21% compared to 2% for PL (p = 0.03).  Lactate was not significantly different 
between groups however there did exist a trend in favor of BA (p = 0.056).   The data 
indicate an ergogenic effect on time to exhaustion after 4 weeks of daily 
supplementation of β-alanine at 3.2 g/d.  Of note, the authors did speculate a potential 
influence of gender on β-alanine efficacy, specifically that females may be more 
sensitive.   
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Table 2.4. β-Alanine 
Author (year) Study 
Design 
Sample Dosing 
Protocol 
Assessment 
Protocol 
Significant Findings 
Carpentier, et al. 
(2015) [190] 
P, R, DB n = 27 
recreationally 
active (6 M, 8 F, 
22.1 ± 2.1 y) 
4 to 5.6 g/d 
for 8 weeks 
Jump fatigue 
test 
Increased peak and average jump 
height for BA group and no 
difference in blood lactate 
Glenn, et al. (2015) 
[191] 
P, R, DB n = 12 trained 
female cyclists 
(26.6 ± 1.3 y) 
1.6 g/d BA 
for 28 d 
Wingate Lower RPE in BA with no difference 
in performance 
Glenn, et al. (2015) 
[192] 
P, R, DB n = 22 trained 
female cyclists 
(54 ± 2 y) 
3.2 g/d BA 
for 28 d 
TTE on CE at 
120% VO2peak 
Increased TTE in BA 
Glenn, et al. (2016) 
[15] 
P, R, DB N = 22 trained 
female cyclist 
(54 ± 2 y) 
3.2 g/d BA 
for 28 d 
Handgrip and 
leg MVC 
Increased lower body MVC in BA 
with no change in handgrip or 
anthropometrics 
Hoffman, et al. (2015) 
[193] 
P, R, DB, 
CO 
n = 18 elite male 
soldiers (19.9 ± 
0.8 y) 
6 g/d BA 2.5 km run, 1 
min sprint, 50 
m ‘casualty 
carry’ 
Faster time in 50 m casualty carry 
in BA with no difference in any 
other performance aspect; 
improved cognitive function in BA 
P = Placebo, R = Randomized, DB = Double-blind, CO = Crossover, BA = β-alanine, TTE = time to exhaustion, CE = cycle ergometer 
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This hypothesis as not yet been directly tested yet the ergogenic effect from the lower 
dose in this study does strengthen the claim; however, the effect may have been 
resultant of an older population as well. 
In a study by Glenn, et al. [15], Master’s-level competitive female cyclists were 
recruited to analyze the effect of chronic β-alanine supplementation on isokinetic 
strength.  Participants were randomly assigned to either BA (n = 11, 54 ± 2 y, 64.01 ± 
2.82 kg, 163.00 ± 2.08 cm) or PL (n = 11, 53±1 y, 68.7 ± 5.64 kg, 162.33 ± 2.5 cm) for the 
28 d supplementation period.  Dosing remained the same as the previous study at 3.2 
g/d spread over four doses.  Participants were assessed for isometric handgrip strength 
and dominant leg isometric contraction at baseline, each week of the supplementation 
period, and following supplementation.  The BA group had greater peak torque during 
the lower body isokinetic test (p = 0.012) as well as total work (p = 0.008).  Handgrip 
strength and anthropometrics were unchanged by treatment.  The results evidence an 
ergogenic effect daily supplementation of β-alanine supplementation at 3.2 g/d on 
lower body strength. 
 Hoffman, et al. [13] reviewed the effects of β-alanine supplementation in 
military personnel.  Previous reports have presented evidence of cognitive and physical 
detriments associated with the intense training in tactical athletes [194, 195] and one 
report stated an estimated 53% of military personnel use some form of ergogenic aid 
[196].  Given the stress of military training, the authors speculate a potential increase in 
performance and combat ability with chronic use of β-alanine, thus, enhancing 
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survivability [13].  In addition, the authors hypothesized the increased carnosine found 
in the brain following β-alanine supplementation may enhance brain-derived 
neurotropic factor (BDNF) and suggest a potential neuroprotective effect as well as a 
possible avenue of research in the treatment of post-traumatic stress disorder (PTSD).  
One particular study in the review yielded evidence of β-alanine enhancing peak jump 
power, speed of target acquisition, and shooting accuracy [193].   
Hoffman, et al. [193] investigated eighteen soldiers from an elite combat unit 
(19.9 ± 0.8 y, 74.2 ± 5.7 kg) for brain and muscle carnosine concentration and a battery 
of combat-related exercise tests.  Magnetic resonance spectroscopy (MRS) was used to 
evaluate carnitine concentration and exercises tests conducted included 2.5 km run, a 1 
min sprint, a 50 m ‘casualty carry’ of a 60 kg mannequin, and repeated sprints 
interspersed with shooting performance evaluation.  Cognitive function was also 
evaluated using the Serial Sevens Test following the shooting evaluation.  Participants 
were assigned to either a BA group (6 g/d) or rice powder placebo and 
supplementation lasted for a period of 30 d.  The BA group demonstrated a significant 
increase in muscle carnosine (p = 0.048) compared to placebo but no change in brain 
carnosine.  No differences were seen in the 2.5 km run or 1 min sprint.  The BA group 
performed a significantly faster time in the 50 m casualty carry (p = 0.044).  
Interestingly, there was no difference in the shooting drill; however, despite no change 
in brain carnosine, the BA group yielded significantly greater results on the cognitive 
function test (p = 0.022).  Referring back to the Hobson [189] meta-analysis, β-alanine 
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appears to exert the most noticeable effect in exercise lasting 60  to 240 sec.  The 2.5 
km run yielded an average time of approximately 620 sec and the 1 min run only 
reached the lower limit of the ergogenic zone.  Also of note, the lack of increase in 
brain carnosine is consistent with other research; however, work by Solis, et al. [197] 
found no increase in cognition which is in contrast to the increased cognitive 
performance reported by Hoffman, et al. 
 Aside from paresthesia, no side effects were reported with chronic or acute use 
of β-alanine.  The studies reviewed yielded a range of 1.6 g/d [191] to 6 g/d [193, 197] 
with varying results dependent on the methodology.  In the two studies by Glenn, et al. 
[15, 192] involving Masters-level competitive female cyclists, chronic daily intake of 3.2 
g for 28 d yielded increased time to exhaustion and increased lower body strength.  
Carpentier, et al. [190] used a dose of 4 g/d and found a significant increase in mean 
jump height for a jump test to exhaustion and no change in single maximal effort 
jumps.  Hoffman, et al. [193] provided evidence of 6 g/d enhancing performance in a 
casualty carry test as well as cognition in elite military personnel.  The cognitive effect 
appears to be reliant on training as Solis, et al. [197] found no change in cognition with 
β-alanine supplementation (6 g/d) alone. 
These findings are in line with the ISSN position stand; chronic daily intake of 4 
to 6 g β-alanine has an equivocal ergogenic effect on exercise lasting between 60 and 
240 sec [14].  The present study investigated a RTD containing 2.1 g of β-alanine.  Given 
the short (<10 d) supplementation period and the low dose, it is unlikely the β-alanine 
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within this RTD was responsible for any ergogenic benefit in the tests performed.  An 
overview of the studies reviewed can be found in TABLE 2.4. 
 
2.4 Relevant Work from Exercise and Sports Nutrition Laboratory 
The Exercise and Sports Nutrition Laboratory (ESNL) has served an independent 
investigation role for a variety of ergogenic aids, both as independent compounds and 
as combinations of various nutrients.  A study by Campbell, et al. [153] was covered 
previously regarding L-arginine α-ketoglutarate, finding a dose of 12 g of L-arginine α-
ketoglutarate to show improvements in 1-RM on bench press, peak power on the 
Wingate, blood glucose, and plasma arginine concentration with no side effects. 
Roberts, et al [198] investigated the effects of ingestion of a popular coffee-
flavored energy drink in a randomized, crossover design study.  Ten healthy, 
recreationally-active males (n = 5, 27.6 ± 4.2 y, 93.2 ± 11.7 kg, 181.6 ± 6.9 cm) and 
females (n = 5, 29.0 ± 4.6 y, 61.5 ± 9.2 kg, 167.6 ± 6.9 cm) whom were habitual coffee 
drinkers with a self-reported intake of 223.9 ± 62.7 mg/d of caffeine were recruited.  
Baseline testing began with assessment of resting hemodynamics followed by a graded 
exercise test using normal Bruce protocol procedures.  Oxygen kinetics were assessed 
every 3 min during the test and at 3 and 10 min post-test.  After a 20 min rest, 
participants underwent a standard Wingate protocol.  After 1 week, participants were 
given either the supplement (450 mg caffeine, 1200 mg garcinia cambogia, 360 mg 
citrus aurantium extract, 225 mcg chromium polynicotinate) or a decaffeinated form of 
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the supplement, waited 15 min, and performed the same baseline tests.  After a 1 week 
washout, participants returned to the lab to complete the same tests on the alternative 
treatment. 
 Exercise post-oxygen consumption (EPOC) was significantly increased in the 
caffeinated group following the Bruce protocol compared to both baseline (p = 0.02) 
and the decaffeinated group (p = 0.03).  Heart rate was also significantly elevated in the 
caffeinated group (115 ± 6 bpm) compared to decaffeinated (107 ± 7 bpm, p = 0.03) 
during the graded exercise test; however, post hoc analysis showed the significant 
difference in HR elevation to be at the point of volitional fatigue.  There were no 
significant differences between groups on the Wingate test. 
Kresta, et al. [199] investigated the effects of chronic daily use of β-alanine, with 
and without co-administration of creatine monohydrate, on exercise performance.  This 
study involved 32 recreationally-active, college-aged females (21.5 ± 2.8 y, 60.5 ± 6.1 
kg, 40.2 ± 3.8 FFM, 26.7 ± 5.8% body fat) and used a randomized double-blind, placebo-
controlled study to assess the effects.  Participants were randomly assigned to either a 
β-alanine only group (BA, 0.1 g/kg/d), creatine monohydrate (CRE, 0.1 g/kg/d), 
combined BA and CRE (BAC), or maltodextrin placebo.  Supplements were ingested four 
times each day. 
Biopsies were obtained from the vastus lateralis on Days 6 and 27 and exercise 
testing was conducted on Days 0, 7, and 28 of each treatment.  At each testing session, 
anthropomorphic data were collected as well as body composition followed by a 
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graded exercise test on a cycle ergometer beginning at 50 W at 70 rpm and increasing 
25 W every 3 min until participants were unable to maintain 70 rpm.  Blood was 
collected via finger stick during the final minute of each stage and at 5 min post-
exercise to determine lactate threshold. 
BA, CRE, and BAC boasted significantly higher muscle carnosine concentration 
compared to PLA with no significance between groups.  Peak blood lactate 
concentration was significantly reduced in the BA group as well as a decreased delta in 
blood lactate concentration during exercise.  There were no significant differences 
between groups relative to body composition and only statistical trends were noted in 
regards to the exercise testing in VO2peak and METS.  Relative peak power was 
significantly increased in BA, CRE, and BAC on the Wingate while only BA and BAC 
demonstrated a reduced rate of fatigue. 
Galvan, et al. [100] tested a novel combination of creatine monohydrate with 
nitrate, creatine nitrate, relative to acute and chronic effects on exercise performance.  
In Study Arm 1, the acute effect was analyzed in randomized, crossover design.  
Thirteen recreationally active, college-aged men (22 ± 5 y, 84.1 ± 18.9 kg, 177.8 ± 7.4 
cm) were recruited for this study.  Following baseline testing, participants were 
randomly assigned to a placebo group (PLA, 6.5 g dextrose), creatine monohydrate 
(CrM, 5 g CrM and 1.5 g dextrose), low-dose creatine nitrate (CrN-Low, 1.5 g CrN and 5 
g dextrose), or CrN-High (CrN 3 g CrN, 3.5 g dextrose).  All treatments were separated 
by a 1 week washout.  Following ingestion of the assigned treatment, participants 
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waited 30 minutes wherein HR, SBP, DBP, and blood draws were conducted at 0, 30, 
and 60 min and every 60 min for hours 1-5.   
For Study Arm 2, chronic use was assessed.  A total of 48 recreationally active, 
college-aged males were recruited (21 ± 3 y, 77.4 ± 20.9 kg, 176.8 ± 5.8 cm).  The 
groups were slightly altered from Study Arm 1: PLA (5 g dextrose), CrM (3 g CrM, 2 g 
dextrose), CrN-Low (1.5 CrN, 3.5 g dextrose), and CrN High (3 g CrN, 2 g dextrose).  
Following a 2 week standardized exercise program after familiarization, testing was 
conducted at baseline and following 28 d of daily supplementation and biopsies were 
collected the day before baseline, and at Days 7 and 27.  At baseline, 1-RM was 
assessed on bench press followed by a single bout of the Wingate stress test.  The 1-RM 
protocol, similar to that of the present study, involved assessment of 1-RM followed by 
two sets of ten repetitions and a third set to volitional fatigue at 70% 1-RM.  The 
Wingate test was modified.  Normally, the Wingate protocol involves a single maximum 
effort of 30 sec against a resistance of 7.5 J/kg/rev; in this study a total of six bouts of 6 
sec against a resistance of 7.5 J/kg/rev were performed with a 3 min rest between each 
bout. 
In Study Arm 1, plasma creatine was significantly higher in CrM than PLA (p = 
0.001), CrN-Low (p = 0.004), and CrN-High (p = 0.007) with no differences between PLA, 
CrN-Low, or CrN-High.  Conversely, plasma NO3 was significantly higher in CrN-High 
than CrM (p = 0.001) and PLA (p = 0.001) but not different from CrN-Low.  Relative to 
the full blood panel, significant overall interaction effects were only seen in creatinine 
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(p = 0.001) with CrN-Low/High being significantly greater than PLA from 1 to 5 h post-
ingestion.  Finally, no significant group or time x group interaction effects were noted in 
regards to hemodynamics. 
In Study Arm 2, there were no statistical differences noted in anthropometrics 
following 28 d of chronic use.  There were overall interaction effects in plasma NO3 (p = 
0.001) and creatine (p = 0.01) that followed a similar pattern to that of Study Arm 1.  
There were no overall group or time x group interaction effects for any of the 
performance variables; however, analysis of 95% confidence intervals revealed 
significant improvement on average power on the bench press in CrN-High only.  CrN 
improved significantly more than PLA and CrN-Low and was not different from CrM 
relative to average power.  While there were no significant improvements on total 
volume for bench press, CrN-High improved significantly more than PLA but was not 
different from CrM or CrN-Low. 
In the first experimental arm of Jung, et al. [99] a randomized, double blind, 
crossover study involving 25 individuals (n = 20 M, 5 F, 21.7 ± 3.0 y, 78.2 ± 13.0 kg, 
176.1 ± 8.2 cm) was conducted to assess the effects of a pre-workout supplement 
containing β-alanine (3 g), CrN (2 g), L-arginine α-ketoglutarate (2 g), N-Acetyl-L-
Tyrosine (300 mg), caffeine (284 mg), Mucuna pruiriens extract (15 mg) and vitamins.  
This PWS came as stated or with the inclusion of Citrus aurantium (p-synephrine, PWS + 
S).  Placebo (PLA) contained 12 g of flavored maltodextrin.  The treatments were 
blinded and provided as a powder to be mixed with 235 mL of water. 
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At each testing session, following ingestion, supine HR, SBP, DBP, and ECG were 
recorded at 10 min intervals during a 30 min REE.  At 1 h post-ingestion, blood was 
collected and participants completed a Stroop Color-Word test.  Participants completed 
a warm-up and proceeded to perform a 1-RM on bench press and leg press followed by 
completion 2 sets of 10 repetitions and 1 set to volitional fatigue at 70% 1-RM with 2 
min rest breaks.  After a 5 min rest, participants completed a standard Wingate stress 
test followed by the Stroop test and one more blood sample.  Each testing session for 
each of the 3 treatments were separated by a 7 d washout. 
No significant differences were noted relative to hemodynamics or ECG.  There 
was an overall interaction effect on REE (p < 0.001) with PWS and PWS + S showing an 
increased VCO2 compared to PLA.  Significant interaction effects were also noted on the 
readiness to perform questionnaire (p = 0.004) and Stroop Color-Word test (p < 0.001); 
in both cases, PWS and PWS + S were not significantly different from each other but 
were both significantly higher than PLA.  No significant differences were noted in any of 
the performance variables. 
In the second arm, Jung, et al. [98] investigated the same supplements and the 
effects of 8 week chronic daily use on training adaptations.  Following familiarization, 
eighty resistance-trained males were randomly assigned to either PLA (n = 27, 22.3 ± 
3.9 y, 81.1 ± 13.3 kg, 178.4 ± 6.9 cm), PWS (n = 27, 20.9 ± 3.9 y, 81.5 ± 13.0 kg, 177.0 ± 
4.6 cm), or PWS + S (n = 26, 22.0 ± 2.6 y, 80.2 ± 15.8 kg, 177.8 ± 5.6 cm).  Participants 
completed baseline testing followed by an 8 week standardized training program and 
 81 
 
follow-up testing at 4 and 8 weeks.  Participants were instructed to consume the 
assigned treatment 15 to 30 minutes prior to exercise or with breakfast on non-training 
days.  
 No differences were observed in any measurement of performance; however, 
analysis of 95% confidence intervals showed significant changes from baseline.  On 
bench press, PWS and PWS + S significantly improved at Week 4 while all three groups 
significantly improved at Week 8 with no between-groups differences.  Leg press 
yielded a similar pattern; however, PWS improved significantly more than PWS + S and 
PLA and PWS + S improved significantly more than PLA.  95% confidence interval 
analysis showed significant improvements in the Stroop Color-Word test.  PWS and 
PWS + S improved at Week 4 and 8 while PLA only improved at Week 8 on the Word 
portion; there were no significant differences between groups.  All three groups 
significantly improved the Color portion at both Week 4 and Week 8.  There were no 
significant differences between groups at Week 4; however, at Week 8 PWS improved 
significantly more than PWS + S which improved significantly more than PLA.  Only PWS 
and PWS + S improved on the Color-Word portion at Week 4 with PWS + S improving 
significantly more than PWS; at Week 8 all three groups significantly improved and 
there was no difference. 
 Koozehchian, et al. performed a double-blind, randomized, placebo-controlled, 
crossover study wherein 19 resistance-trained participants (21 ± 2 y, 83.9 ± 18.1 kg, 175 
± 9 cm) were recruited.  Following baseline testing, participants were assigned to either 
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a PLA group (12 g glucose), pre-workout supplement (PWS) group  [β-alanine (3.2 g), 
arginine α-ketoglutarate (2.0 g), creatine nitrate (2.0 g), N-acetyl tyrosine (300 mg), 
caffeine (300 mg), Mucuna pruriens extract standardized for 15% L-Dopa (1.0 g), and B-
vitamins], or a PWS150 group containing the ingredients from PWS at 150% the dose.  
All treatments included baseline and short-term (7 d) supplementation period testing 
and were separated by a 7 d washout.  Participants underwent an REE protocol for 30 
min, ingested the supplement, and underwent a second REE protocol for 30 min, 
followed by cognitive testing and performance testing.  Participants were assessed by 
performance by establishing 1-RM followed by repetitions to failure at 70% 1-RM and 
Wingate stress test.  PWS and PWS150 exhibited significant improvements in cognitive 
testing and no ergogenic effects were noted in exercise performance or resting energy 
expenditure. 
 
2.5. Summary of Literature Regarding Ergogenic Potential 
 Literature related to ergogenic effects to performance from caffeine, nitrates, L-
arginine, and β-alanine was examined in detail in this review.  To review, caffeine is 
claimed to enhance strength, endurance, cognition, and enhance fat oxidation to 
potentially increase glucose sparing [22].  Nitrates have been reported to decrease VO2 
requirement at various exercise intensities through multiple proposed mechanisms [35] 
including enhancements in PCr synthesis [103].  Similar to nitrate, L-arginine is reported 
to increase nitric oxide and thus improve nutrient delivery[134].  In addition, it has 
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been claimed to enhance growth hormone and reduce recovery time [200].  β-alanine 
is claimed to enhance performance by buffering pH during exercise, thus potentially 
prolonging the duration of high-intensity exercise [14]. 
 With regards to the claims presented, caffeine is evidenced to be ergogenic, 
consistently being found to enhance performance in doses of 3 to 9 mg/kg.  Nitrates 
also appear to be ergogenic in doses of 5 mmol/d or more when analyzing VO2 
response to exercise and power production in high-intensity exercises lasting 60 to 240 
sec.  L-arginine was consistently found to have no effect on hormonal balance, 
specifically with regard to growth hormone with one study actually showing a decrease 
[143].  Additionally, L-arginine at any dose consistently yielded no effect on 
performance unless combined with L-citrulline.  Finally, chronic use β-alanine at 3.2 to 
6 g or greater was consistently found to increase time to exhaustion as well as 
maintenance of power output during the later stages of exhaustive exercise. 
Martinez, et al. [201] investigated a RTD (Assault ™)containing 2 g of β-alanine, 
an undisclosed amount of nitrates as arginine nitrate, BCAA nitrate, and beetroot 
extract, as well as 400 mg caffeine (4.79 mg/kg).  Supplementation yielded enhanced 
peak and mean power on the Wingate stress test.  Spradley, et al. [202] investigated 
the same RTD as Martinez, et al. and found a significant increase in repetitions to 
fatigue on leg press as well as increased cognitive function and perceived energy.  
Ormsbee, et al. [203] analyzed a different RTD (NO-Shotgun ™) which contained 190 ± 
10 mg of caffeine anhydrous (2.27 mg/kg) in addition to BCAAs, creatine, and β-alanine.  
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No performance improvement was noted; however, the RTD group exhibited 
significantly greater increases in fat-free mass compared to placebo.  Of note, only 
caffeine existed in these RTD within the ergogenic range of 3 to 9 mg/kg. 
 We previously reported the effects of an RTD containing β-alanine (3 g), 
creatine nitrate (2 g), arginine α-ketoglutarate (2 g), caffeine anhydrous (284 mg, 3.63 
mg/kg), and B-vitamins [99].   This study used the same protocol as the present study to 
assess maximal strength and repetitions to failure on bench press and leg press as well 
as resting energy expenditure (REE) and Wingate anaerobic performance.  The RTD 
yielded evidence of increased cognition and greater changes in REE; however, despite 
the ergogenic level of caffeine, there were no differences in the performance 
measures. 
 The primary outcome of the current study was the effect of RTD on exercise 
performance assessed by total lifting volume, maximal strength, muscular endurance, 
and 4 km time trial performance.  Based on the reviewed studies, there was a logical 
assumption that there would be a significant difference favoring the RTD group, most 
likely as a function of increased repetitions to failure.   
The secondary outcomes in the current study were related to safety.  A review 
of energy drink-related research from 1970 to 2010 was performed by Higgins, et al. 
[204].  In this review, the authors conclude that, despite the increase in heart rate and 
blood pressure, caffeine-containing energy drinks are safe in healthy population; 
however, they assert consumption of energy drinks should be avoided prior to training.  
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In a separate review by Eudy, et al. [205], the authors make mention of the potential 
dangers of proprietary blends, asserting a need for further research in new supplement 
formulations to assess for safety and efficacy.  In both reviews, side effects included 
gastrointestinal distress, cardiovascular perturbations, and alterations to blood lipids 
and glucose homeostasis.  These findings and conclusions are in agreement with the 
International Society of Sports Nutrition [21]. 
In the present work, safety was assessed by measuring hemodynamic response 
to a postural challenge, serum and whole blood chemistry, and self-reported side 
effects.  Based on the literature, a significant increase in plasma nitrate was expected 
with the nitrate dose of 5.7 mmol as all studies involving nitrates evidenced a 
significant increase in plasma nitrate but no other differences were expected in regard 
to blood chemistry.  The safety concerns of nitrate use were addressed within this 
review and, fortunately, the concerns appear to be unfounded.  Granted, there were a 
studies where MAP or blood pressure were significantly lower compared to placebo; 
however, these were still well within normal limits and not cause for concern [109, 
110].  Finally, aside from paresthesia common to β-alanine use, no evidence in the 
literature suggests a significant difference between groups in regard to side effects as 
the 1 g dose of L-arginine was well below the 9 g threshold found by Evans, et al. [140]. 
 
*Reprinted with permission from “Short-Term Effects of a Ready-to-Drink Pre-Workout 
Beverage on Exercise Performance and Recovery” by Collins, et al., Nutrients, 2017, 
1;9(8), Copyright 2017 by Patrick Blaise Collins 
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CHAPTER III 
METHODS* 
 
3.1. Study Overview 
Prior to starting the study, approval was obtained from the Texas A&M 
University Institutional Review Board (#2016-754F).  Although not required, the study 
was registered with clinicatrials.gov (#NCT03032549).  Additionally, the study has been 
previously published [206]. 
Recreationally active men and women between the ages 18–40 years were 
recruited to participate in this study through the campus email system as well as 
posting flyers throughout the university. Participants responding to recruitment 
advertisements were initially screened by phone to determine general eligibility. 
Inclusion criteria required that each participant have at least six months of resistance 
training experience immediately prior to entering the study, inclusive of bench press 
and leg press or squat training. Participants were excluded from participation if they 
had a history of treatment for metabolic disease (i.e., diabetes), hypertension, 
hypotension, thyroid disease, arrhythmias, and/or cardiovascular disease; if they were 
currently using any prescription medication with the exception of birth control; if they 
were pregnant, lactating, or planned to become pregnant within the next month; if 
they had a history of smoking; if they drank excessively (>12 drinks per week); or, if 
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they had a recent history of consuming dietary supplements or energy drinks 
containing β-alanine or high amounts of caffeine within eight weeks of the start of 
supplementation. 
 
Table 3.1 presents the general study design. Participants meeting initial phone 
screening conditions were invited to attend a familiarization session. During the 
Table 3.1. Protocol Overview 
 Baseline  Follow-up 
FAM Day 1 Day 2 Days 3-5 Day 6 Day 7 
Physical exam 
8 h fasting 
blood sample 
8 h fasting 
blood sample 
Daily 
supplementation 
8 h fasting 
blood sample 
8 h fasting 
blood sample 
DXA Body 
Composition 
Side effects 
questionnaire 
Side effects 
questionnaire 
Side effects 
questionnaire 
Side effects 
questionnaire 
Bench Press 
& Leg Press 1-
RM and 70% 
1-RM test 
Pre-ingestion 
Hemodynamic 
Challenge Test 
Ingest 
supplement 
Pre-ingestion 
Hemodynamic 
Challenge Test 
Ingest 
supplement 
Practice 4 km 
cycling Time 
Trial 
Initial Strength 
Testing 
Wait 30 min 
Initial Strength 
Testing 
Wait 30 min 
Schedule 
Testing 
Ingest 
Supplement 
4 km Time 
Trial 
Ingest 
Supplement 
4 km Time 
Trial 
Randomize to 
treatment 
Wait 15 min 
Side effects 
questionnaire 
Wait 15 min 
Side effects 
questionnaire 
 
Post-ingestion 
Hemodynamic 
Challenge Test 
 
Post-ingestion 
Hemodynamic 
Challenge Test 
 
 
Recovery 
Strength 
Testing 
 
Recovery 
Strength 
Testing 
 
 
Side effects 
questionnaire 
 
Side effects 
questionnaire 
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familiarization session, participants signed informed consent statements and had a 
physical exam inclusive of providing their medical history, determination of resting 
heart rate and blood pressure, and assessment of body composition via dual-energy X-
ray absorptiometry (DXA). Once cleared to participate, participants had bench one-
repetition maximum (1-RM) determined, performed 3 sets of 10 repetitions on the 
bench press at 70% of 1-RM, with the last set completed to failure. Participants 
followed a similar familiarization on the leg press and then rested for 15 min prior to 
performing a warm-up and a 4 km TT on an electronically-braked cycle ergometer. 
Participants were then randomized to initiate the study with their respective 
treatments. 
Baseline testing took place on two days. Day 1 included fasting blood, 
hemodynamic assessment, and strength testing while Day 2 included the 4 km TT. All 
fasting blood samples were obtained following an 8 h fast primarily between the hours 
of 0600–0900. Participants performed a pre-supplementation hemodynamic postural 
challenge test using a tilt table, performed 1-RM and a muscular endurance test (3 sets 
of 10 repetitions with the last set to failure) on the bench press and leg press. 
Participants then ingested their assigned RTD, waited 15 min and were placed in the 
supine position on the tilt table for 15 min prior to performing the postural 
hemodynamic challenge test. Participants then repeated the 1-RM test and one-set to 
failure at 70% of 1-RM on the bench press and leg press to assess recovery Table 3.2. 
The rationale for this approach was to determine whether ingestion of the RTD would 
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influence exercise capacity after exhaustive exercise and toward the end of a training 
session. On Day 2, participants ingested the assigned treatment, waited 30 min, 
performed a standard warm-up, and performed a 4 km cycling TT Table 3.3.  
Participants continued the supplementation protocol for Days 3 to 5 with follow-up 
testing on Day 6 and Day 7 to repeat experiments as described Figure 3.1.  
 
Table 3.2 Detailed Protocol for Days 1 and 6 
Participant arrival 
8 h fasting blood sample, anthropomotry, & pre-ingestion side effects questionnaire  
 
Pre-Ingestion Hemodynamic Challenge Test 
15 min in supine position 
2 min in standing position 
Heart rate and blood pressure assessment during final 30 sec of each position 
 
Initial Strength and Endurance 
Warmup: 10 x 50%, 5 x 75%, 3 x 90% 
1RM attempts interspersed with 2 min rest 
Two sets of 10 repetitions at 70% 1RMFAM (2 min rests) 
One set to volitional fatigue at 70% 1RMFAM 
 
Ingest treatment and wait 15 minutes 
 
Post-Ingestion Hemodynamic Challenge Test 
Same as initial 
 
Recovery Strength and Endurance 
Warmup: 10 x 50%, 5 x 75%, 3 x 90% 
1-RM attempts interspersed with 2 min rest 
One set to volitional fatigue at 70% 1RMFAM 
Figure 3.1. Overview of Crossover Design 
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3.2 Supplementation Protocol 
Participants were instructed to maintain normal training, diet, and caffeine 
intake habits throughout the study. Participants were assigned in a randomized, 
double-blind, cross-over manner to a placebo (PLA) beverage containing 6.0 g dextrose 
and non-caloric sweetener or a beverage (RTD) containing caffeine anhydrous (200 
mg), _-alanine (2.1 g), niacin (65 mg), folic acid (325 mcg), Vitamin B12 (45 mcg), 
arginine nitrate (1.3 g providing about 350 mg of nitrates and 950 mg of arginine). A 7 
to 10 days washout period was observed between treatment experiments consistent 
with prior research on caffeine and nitrates using crossover designs. The beverages 
were prepared by a third party (South East Bottling and Beverage, Dade City, FL, USA) in 
10 oz. of purified water matched for color and flavor in indistinguishable bottles. The 
nutrient contents of the RTD’s were analyzed for contaminants and nutrient content by 
Century Foods International (Sparta, WI, USA). The pre-packaged bottles were received 
in boxes containing sealed bottles generically labeled as “Treatment A” and “Treatment 
B” for double-blind administration. The supplement code was maintained in a sealed 
envelope and was not disclosed to the researchers until the completion of the study for 
statistical analysis.  
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3.3. Test Methodology 
3.3.1. Anthropometry & Body Composition 
Standardized anthropological testing included assessments for body mass and 
height on a Healthometer Professional 500KL (Pelstar LLC, Alsip, IL, USA) self-calibrating 
digital scale with an accuracy of ±0.02 kg.  Whole body bone density and body 
composition measures (excluding cranium) were determined with a Hologic Discovery 
W Dual-Energy X-ray Absorptiometer (Hologic Inc., Waltham, MA, USA) equipped with 
APEX Software (APEX Corporation Software, Pittsburg, PA, USA) by using standardized 
procedures [207, 208].  Mean test-retest reliability studies performed on male athletes 
in our lab over repeated standardized assessment procedures have demonstrated 
coefficients of variation for total bone mineral content and total fat free/soft tissue 
mass of 0.31–0.45% with a mean intraclass correlation of 0.985 [208].  On the day of 
each test, the equipment was calibrated following the manufacturer’s guidelines. 
 
3.3.2. Blood Collection Procedures 
Participants provided an 8 h fasted blood sample via venipuncture of an 
antecubital vein in the forearm in accordance with standard phlebotomy procedures. 
Approximately 10 mL of whole blood was collected at the beginning of each testing 
day, in one 7.5 mL BD Vacutainer® serum separation tube (Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA) and in one 3.5 mL BD Vacutainer® K2 EDTA tube 
(Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Both tubes sat at room 
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temperature for 15 min, then the 7.5 mL serum separation tube was centrifuged at 
3500-rpm for 10 min using a 4 oC refrigerated bench top ThermoScientific Heraeus 
MegaFuge 40R Centrifuge (Thermo Electron North America LLC, West Palm Beach, FL, 
USA). Both tubes were stored at 4 oC for 3 to 4 h prior to analysis or storage. Serum was 
stored at -80 oC in polypropylene microcentrifuge tubes for later analysis. 
 
3.3.3. Blood Chemistry 
Blood serum samples were analyzed for the following: alkaline phosphatase 
(ALP), aspartate transaminase (AST), alanine transaminase (ALT), creatinine, blood urea 
nitrogen (BUN), creatine kinase (CK), lactate dehydrogenase (LDH), glucose, total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and 
triglycerides (TG) using a Cobas® c111 (Roche Diagnostics, Basel, Switzerland) 
automated clinical chemistry analyzer. The Cobas® c111 automated clinical chemistry 
analyzer was calibrated daily per manufacturer guidelines. This analyzer has been 
known to be valid and reliable in previously published reports [209].  The internal 
quality control for the Cobas® c111 is performed using two levels of control fluids 
purchased from the manufacturer to calibrate acceptable standard deviation (SD) and 
coefficient of variation (CV) values for all assays. Samples were re-run if the values 
observed were outside control values and/or clinical norms according to standard 
procedures. Prior analysis in our lab has yielded test-to-test reliability of a range of CV 
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from 0.4 to 2.4% for low control samples and 0.6–1.9% on high controls. Precision has 
been found between 0.8 and 2.4% on low controls and 0.5–1.7% on high controls.  
 
3.3.4. Hemodynamic Challenge Test 
During the strength testing days (Days 1 and 6) participants had hemodynamic 
response assessed at two time points, prior to initial strength testing measures and 
following supplementation. Participants were placed on a standard tilt table in a supine 
position (Gravity 4000 Inversion Table; City of Industry, CA, USA). After 15 min, blood 
pressure and heart rate were assessed and recorded. Next, the tilt table was adjusted 
to vertical where the participant rested for 2 min and the metrics were re-assessed. 
Participants then performed pre-supplementation muscular strength and endurance 
tests, ingested the assigned treatment, and rested for 15 min prior to be placing on the 
tilt table in the supine position for 15 min. Heart rate and blood pressure 
measurements were then taken prior to and after 2 min of being moved to a vertical 
position. Mean arterial pressure was calculated as ((2 x DBP) + SBP)/3 as an indicator of 
venous return. Rate pressure product (RPP) was calculated as the product of heart rate 
and systolic blood pressure to represent an indirect assessment of myocardial oxygen 
demand. The latter two tests were chosen as they represent a more robust response to 
a cardiovascular challenge compared to heart rate or blood pressure alone. 
Hemodynamic response was defined as the change in systolic blood pressure, diastolic 
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blood pressure, heart rate, mean arterial pressure and rate pressure product from the 
supine to upright position. 
 
3.3.5. Self-Reported Side Effects 
The side effect questionnaires were completed before and after each testing 
session to access perceived side effects and monitor compliance with the 
supplementation protocol. The questionnaires were completed a total of 16 times by 
each participant over the duration of the study: two times each testing day for four 
testing days per supplement for two different supplements. Participants were asked to 
rank the frequency and severity of their symptoms—dizziness, headache, tachycardia, 
heart skipping or palpitations, shortness of breath, nervousness, blurred vision, and 
unusual or adverse effects. Participants were asked to rank their perception of 
symptoms using the following scale: 0 (none), 1 (minimal: 1–2/week), 2 (slight: 3–
4/week), 3 (occasional: 5–6/week), 4 (frequent: 7–8/week), or 5 (severe: 9 or 
more/week).  
 
3.3.6. Strength Testing 
Participants performed three warm up sets prior to performing 1-RM attempts 
(i.e., one set of 10 at 50%, one set of 5 at 70%, and one set of 3 at 90% of anticipated 1-
RM). Following the warm-up, participants gradually increased weight between 1-RM 
attempts until they could not lift the load under their own volition. Following 
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determination of 1-RM, participants performed two sets of 10 repetitions with 2 min 
rest recovery between sets at the closest bar/leg press weight corresponding to 70% of 
familiarization session 1-RM. Participants then rested 2 min and performed a third set 
to failure. After 2 min of rest, participants followed the same procedure to determine 
leg press 1-RM and leg press muscular endurance. Hand placement on the bench press 
bar and seat and foot positioning on the leg press were placed in the same position 
among attempts and testing sessions Table 3.4. 
The initial strength tests were performed to pre-fatigue the participant before 
assessing recovery performance after RTD ingestion. The recovery muscular strength 
and endurance performance assessment involved performing a 1-RM test and then one 
set to failure at 70% of the familiarization 1-RM following similar procedures as 
described above. In this way, the effects of acute RTD ingestion could be assessed on 
muscular strength and endurance recovery following a standard bout of resistance 
exercise on Day 1, the effects of 6 days of RTD ingestion could be assessed on initial 
muscular strength and performance on Day 6, and the effects of acute RTD ingestion on 
recovery of exhaustive exercise could be assessed after 6 days of supplementation on 
Day 6. The two sets of 10 repetitions were not conducted during recovery analysis as 
the initial bout of exercise fatigued the participants; it was unlikely participants could 
complete all 10 repetitions of these sets and it was unnecessary to assess recovery 
muscular endurance. Total 1-RM weight lifted in kg and the number repetitions 
performed each set using 70% of the familiarization weight (rounded to the nearest 
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2.27 kg or 5 lbs. that could be put on the bar) were recorded. Total lifting volume was 
calculated by multiplying the 70% of 1-RM weight lifted times the number of 
repetitions performed each set and summing the total volume performed for all sets. 
Total combined lifting volume was calculated by adding the bench press and leg press 
total lifting volumes. Day to day test reliability of performing this performance test in 
our lab on resistance-trained participants has yielded a CV of 0.34 and an intraclass 
correlation coefficient of 0.99 for three sets of bench press total lifting volume and an 
intraclass correlation coefficient of 0.96 for three sets of leg press total lifting volume. 
 
3.3.7. Time-Trial Performance 
Time-trial performance was examined on a magnetically braked cycle ergometer 
(Lode Sport Excalibur, Groningen, The Netherlands) over a distance of 4 km. 
Participants were allowed a one minute warm up with a gradually increasing load. At 
the completion of the warm up, a standardized resistance (4 J/kg/rev) was applied and 
the participant was instructed to complete the distance in as short a time as able. Upon 
completion, the participant was instructed to continue at a slow pace to facilitate 
recovery. Data were recorded as time to completion and average power in Watt. 
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Table 3.4. Strength and Endurance Protocol 
 Initial Rest Recovery 
Warm-up 10 reps @ 50% 
Ingest supplement 
10 reps @ 50% 
 5 reps @ 70% 5 reps @ 70% 
 3 reps @ 90% 
Seated rest (15 min) 
3 reps @ 90% 
Strength 1-RM attempts 1-RM attempts 
Endurance 10 reps @ 70% 
Hemodynamic 
Challenge Test 
 
 10 reps @ 70%  
 RtF @ 70% RtF @ 70% 
*   All percentages calculated from 1-RM at familiarization 
** All sets separated by 2 min seated rest 
 
3.4. Statistical Analysis 
Data were analyzed using IBM® SPSS® Version 24 software (IBM Corp., Armonk, 
NY, USA). The sample size was determined based on the expectation of a five percent 
improvement in exercise performance and corresponding power of 0.80. The analysis 
was initiated by inspecting data for missing values using Little’s test for data missing 
completely at random (MCAR). This analysis showed the data were MCAR (p = 1.0, 
<1.5%) and subsequently replaced using a multiple imputation algorithm. Data were 
then analyzed using univariate, multivariate and repeated measures general linear 
models (GLM) using gender and relative caffeine intake (mg/kg) as covariates using the 
following models:  
Model 1: The cohort was examined for potential gender-by-treatment effects, 
finding none. Hence, the data were pooled into one cohort instead of reporting 
gender data separately.  
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Model 2: Since menstrual cycle, birth control medications, and other gender-
related parameters were not controlled, gender was included as a covariate.  
Model 3: Given the weight difference between males and females in the study, 
the analysis was further adjusted for relative caffeine intake (mg/kg).  The 
results are presented for Model 3 with performance-related data expressed in 
absolute and relative terms to fat free mass.  
Data were also examined for a treatment order effect to confirm that randomization 
procedures were effective. Least significant difference post hoc comparisons were used 
to compare between-treatment differences when significant time _ treatment 
interaction effects were observed. Hematological variables were also examined relative 
to normal clinical limits to examine the frequency of changes in hematology outside of 
normal, clinical limits from baseline to follow-up a Chi-square and adjusted residual 
analyses. This analysIs examined the likelihood of excursions outside of clinical limits 
for each treatment as follows: (1) No change; (2) Normal at Baseline, High at Follow-up; 
(3) High at Baseline, High at Follow-up; (4) High at Baseline, Normal at Follow-up. Data 
are reported as mean (SD), mean change from baseline and 95% confidence intervals, 
and frequency of occurrence according to the chi-square analysis. Data were 
considered statistically significant when the probability of type I error was 0.05 or less 
while tendencies towards statistical significance were noted when p-levels were p > 
0.05 to p < 0.10. 
  
*Reprinted with permission from “Short-Term Effects of a Ready-to-Drink Pre-Workout 
Beverage on Exercise Performance and Recovery” by Collins, et al., Nutrients, 2017, 
1;9(8), Copyright 2017 by Patrick Blaise Collins 
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CHAPTER IV 
RESULTS* 
 
4.1. Results 
 The results presented are previously published in the Journal of Nutrients [206].  
Data, figures, and tables are presented as they are within the published manuscript. 
 
4.2. Participants 
Thirty-one participants initially signed informed consent prior to data collection; 
however, five participants dropped out prior to baseline testing due to schedule or 
personal reasons.  Twenty-six participants began the study, with one male dropping out 
after the first baseline session due to time constraints.  Data from a total of 25 
participants were included in statistical analysis.  Participant demographic data are 
presented in Table 4.1.  
These data demonstrate that the participants were recreationally active 
resistance-trained individuals and that participants differed based on gender on a 
number of variables.  No time x gender x treatment interactions were observed on 
variables evaluated or relative caffeine intake effect.  Further, the fully adjusted 
statistical model did not produce a substantial difference to the unadjusted model.  
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Nevertheless, since menstrual cycle and birth control medication were not controlled, 
results were adjusted via covariate analysis for gender and relative caffeine intake. 
 
4.3. Performance 
Table 4.2 presents muscular strength and performance results normalized to fat 
free mass (FFM).  Multivariate analysis revealed a significant overall Wilks’ Lambda 
treatment x time interaction effect (p = 0.01).  Univariate analysis revealed significant 
treatment x time interactions in bench press (p = 0.04) and leg press repetitions to 
failure (p = 0.04) while bench press lifting volume (p = 0.09) and total combined lifting 
volume (p = 0.09) evidenced a statistical trend toward significant interaction. Post-hoc 
analysis revealed that acute RTD ingestion on Day 1 significantly improved recovery 
bench press muscular endurance to a greater degree than following PLA ingestion.  
Table 4.1. Baseline Demographics 
 
Measurement 
Male (n = 12) Female (n = 13) Overall (n = 25)  
Mean  SD Mean  SD Mean  SD p-values 
Age (y) 23.3 ± 4 24.5 ± 4 23.9 ± 4 0.43 
Height (cm) 177 ± 7 166 ± 5 171 ± 8 0.00 
Weight (kg) 81.7 ± 13 65.1 ± 8 73.1 ± 13 0.00 
Body Mass Index (kg/m2) 26.0 ± 4 23.7 ± 3 24.8 ± 4 0.12 
Body Fat (%) 17.2 ± 6 28.4 ± 6 23.0 ± 8 0.00 
Fat Free Mass (kg) 67.1 ± 9 47.8 ± 8 57.1 ± 13 0.00 
Bench Press 1-RM (kg) 88.3 ± 27 37.9 ± 10 62.1 ± 32 0.00 
Bench Press 1-RM (kg/kgFFM) 1.31 ± 0.4 0.80 ± 0.2 1.05 ± 0.4 0.00 
Leg Press 1-RM (kg) 455 ± 175 284 ± 89 366 ± 160 0.01 
Leg Press 1-RM (kg/kgFFM) 6.7 ± 2.0 6.0 ± 1.6 6.3 ± 1.8 0.18 
Mean data presented as means ± SD.  One-way ANOVA p-values listed for each variable.  PLA: placebo, RTD: ready-to-drink pre-
workout supplement, 1RM: one repetition maximum, FFM: fat free mass, kg/kgFFM: weight relative to participant fat free mass 
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Table 4.2. Strength and Muscular Endurance Relative to Fat Free Mass 
 
Variable Treatment 
Day 1 Initial Day 1 Recovery Day 6 Ingestion Day 6 Recovery Treatment  
Mean  SD Mean  SD Mean  SD Mean  SD Mean  SE p-values 
BP 1-RM 
(kg/kgFFM) 
PLA 1.02 ± 0.38 0.94 ± 0.36 1.01 ± 0.36 0.97 ± 0.37 0.99 ± 0.06 Time 0.001 
RTD 1.03 ± 0.37 0.99 ± 0.35 1.04 ± 0.35 1.00 ± 0.36 1.02 ± 0.06 Trt 0.72 
Time 1.02 ± 0.37 0.97 ± 0.35* 1.03 ± 0.35 0.99 ± 0.36‡    I 0.23 
BP Repetitions to 
Failure @ 70 % 1-
RM 
PLA 9.96 ± 3.23 9.60 ± 3.65 10.13 ± 3.37 12.27 ± 3.22* 10.5 ± 0.71 Time 0.38 
RTD 10.28 ± 4.37 12.32 ± 5.28*† 10.30 ± 4.04 13.31 ± 4.86* 11.6 ± 0.71 Trt 0.27 
Time 10.1 ± 3.81 11.0 ± 4.70 10.2 ± 3.69 12.8 ± 4.12    I 0.04 
BP Lifting Volume 
(kg/kgFFM) 
PLA 7.40 ± 3.77 7.46 ± 4.57 7.46 ± 3.73 9.17 ± 4.44 7.87 ± 0.67 Time 0.36 
RTD 7.45 ± 3.75 8.89 ± 4.07 7.48 ± 3.16 9.45 ± 3.54 8.32 ± 0.67 Trt 0.64 
Time 7.43 ± 3.73 8.17 ± 4.34 7.47 ± 3.42 9.31 ± 3.98    I 0.09 
LP 1-RM 
(kg/kgFFM) 
PLA 6.70 ± 1.66 6.41 ± 1.58 6.80 ± 1.38 6.38 ± 1.35 6.57 ± 0.26 Time 0.66 
RTD 6.72 ± 1.42 6.74 ± 1.41 6.83 ± 1.29 6.67 ± 1.52 6.74 ± 0.26 Trt 0.66 
Time 6.71 ± 1.53 6.57 ± 1.49 6.81 ± 1.33 6.53 ± 1.43    I 0.04 
LP Repetitions to 
Failure @ 70% 1-
RM 
PLA 21.2 ± 10.8 18.6 ± 8.4 20.8 ± 10.7 20.9 ± 11.0 20.3 ± 1.81 Time 0.78 
RTD 22.4 ± 15.1 26.4 ± 13.0† 19.8 ± 9.31 25.1 ± 14.1 23.9 ± 1.80 Trt 0.17 
Time 21.8 ± 13.0 22.5 ± 11.6 20.3 ± 9.94 23.0 ± 12.7    I 0.11 
LP Lifting Volume 
(kg/kgFFM) 
PLA 94.3 ± 77.9 81.1 ± 44.4 88.3 ± 49.7 91.9 ± 57.9 88.9 ± 10.60 Time 0.75 
RTD 96.6 ± 66.7 116.3 ± 74.9‡ 90.7 ± 47.6 106.9 ± 55.4 102.6 ± 10.60 Trt 0.37 
Time 95.5 ± 71.8 98.7 ± 63.5 89.5 ± 48.2 99.4 ± 56.6    I  
Combined Lifting 
Volume (kg/kgFFM) 
PLA 101.7 ± 79.0 88.6 ± 46.8 95.8 ± 50.5 101.1 ± 60.2 96.8 ± 10.87 Time 0.76 
RTD 104.1 ± 66.4 125.2 ± 75.5 98.2 ± 48.8 116.4 ± 57.3 110.0 ± 10.87 Trt 0.36 
Time 102.9 ± 72.2 106.9 ± 64.9 97.0 ± 49.2 108.8 ± 58.7    I 0.09 
Values are means ± standard deviations.  Multivariate analysis revealed overall Wilks’ Lambda treatment (p = 0.792), time (p = 0.010), and treatment x time (p 
= 0.010).  Greenhouse-Geisser p-levels are reported with univariate analyses for time, treatment, and time x treatment interactions for each variable.  * 
indicates a significant difference from initial measure, † indicates a significant between-treatment difference, and ‡ indicates a statistical trend between-
treatments.  BP = bench press, LP = leg press, 1-RM = one repetition maximum, FFM = fat free mass, PLA = placebo, RTD = ready-to-drink pre-workout 
supplement, Trt = treatment, I = time x treatment interaction 
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Pair-wise differences were also observed between treatments in Day 1 recovery leg 
press endurance (p = 0.01) and tended to improve leg press lifting volume (p = 0.054). 
No significant differences were observed between groups in follow-up assessments. 
Similar findings were observed when analyzing absolute performance results. No 
significant differences were observed among treatments in cycling performance time or 
average power output expressed in absolute (W) or relative (W/kgFFM) terms (Table 
4.3). 
Figures 4.1–4.4 show mean changes from baseline with 95% CI’s for 1-RM, 
repetitions to failure (RtF), lifting volume, and time-trial performance data, 
respectively. Acute RTD ingestion tended to maintain BP 1-RM to a greater degree (PLA: 
-0.071 (-0.09, -0.05); RTD: -0.043 (-0.05, -0.01) kg/kgFFM, p = 0.086) and maintained leg 
press 1-RM performance (PLA: -0.285 (-0.49, -0.08); RTD: 0.23 (-0.50, 0.18) kg/kgFFM, p = 
0.30) compared to PLA Figure 4.1. After 6 d of supplementation, recovery LP 1-RM 
significantly decreased in the PLA but not RTD treatment (PLA: -0.412 (-0.08, -0.07); 
RTD: 0.16 (-0.50, 0.18) kg/kgFFM, p = 0.30). Recovery RtF on the BP tended to be greater 
in the RTD versus PLA treatment on Day 1 (PLA: -4.41 (-5.8, -3.0); RTD: -2.59 (-4.0, -1.19) 
repetitions, p = 0.072) while LP RtF was significantly greater than PLA (PLA: -2.60 (-6.8, 
1.6); RTD: 4.00 (-0.2, 8.2) repetitions, p = 0.031) FIGURE 4.2. On Day 6, RtF on the LP 
was significantly increased above baseline in the RTD group but not PLA (PLA: 0.12 (-
3.0, 3.2); RTD: 3.6 (0.5, 6.7) repetitions, p = 0.116). Bench press lifting volume (Figure 
4.3) was significantly increased above baseline and was significantly greater than PLA 
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(PLA: 0.001 (-0.13, 0.16); RTD: 0.03 (0.02, 0.04) kg/kgFFM, p = 0.007) while LP lifting 
volume tended to be greater (PLA: -13.18 (-36.9, 10.5); RTD: 19.6 (-4.1, 43.3) kg/kgFFM, p 
= 0.055) in the RTD treatment on Day 1. On Day 6, LP lifting volume was increased 
above baseline values in the RTD but not PLA treatment (PLA: 3.64 (-8.8, 16.1); RTD: 
16.25 (3.8, 28.7) kg/kgFFM, p = 0.157). Recovery total lifting volume was significantly 
greater for RTD compared to PLA (PLA: -13.12 (-36.9, 10.5); RTD: 21.06 (-2.7, 44.8) 
kg/kgFFM, p = 0.046) on Day 1 and was increased above baseline while remaining 
unchanged with PLA treatment on Day 6 (PLA: 5.35 (-7.4, 18.1); RTD: 18.22 (5.5, 30.9) 
kg/kgFFM, p = 0.157). Finally, cycling performance times and power output improved to 
a greater degree in the PLA trial from baseline (PLA: -11.48 (-22.3, -1.73); RTD: -5.72 (-
15.5, 4.03) s; PLA: 0.289 (0.09, 0.49); RTD: 0.122 (-0.08, 0.32) W/kgFFM) FIGURE 4.4. 
However, it should be noted that baseline and follow-up performance times were 
faster in the RTD trials than the PLA trials (see Table 4.3) so it cannot be concluded that 
the RTD promoted an ergolytic effect.  It was hypothesized the RTD would yield 
significant improvement in muscular strength and endurance compared to PLA (H1).  
Based on the findings, there is sufficient evidence to accept this hypothesis.  It was 
hypothesized the RTD would demonstrate significant improvement in time trial 
performance measured by time to completion and average power (H2).  Based on the 
collective findings, there is insufficient evidence to accept this hypothesis; the RTD does 
not improve 4km time trial performance.
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Table 4.3. Time Trial Performance 
 
Variable Treatment 
Day 2 Day 7 Treatment  
Mean  SD Mean  SD Mean  SE p-values 
Time (s) 
PLA 296 ± 105 284 ± 104 240 ± 11 Time 0.70 
RTD 282 ± 94 276 ± 95 281 ± 11 Trt 0.56 
Time 286 ± 99 280 ± 99    I 0.41 
Power 
(W) 
PLA 224 ± 82 242 ± 93 235 ± 10 Time 0.12 
RTD 238 ± 85 246 ± 95 240 ± 10 Trt 0.62 
Time 231 ± 83 244 ± 82    I 0.26 
Power 
(W/kgFFM) 
PLA 3.87 ± 0.89 4.16 ± 0.94 4.01 ± 0.17 Time 0.26 
RTD 4.17 ± 0.87 4.29 ± 0.98 4.23 ± 0.17 Trt 0.38 
Time 4.02 ± 0.89 4.22 ± 0.95    I 0.25 
Values are means ± standard deviations.  Multivariate analysis revealed overall Wilks’ Lambda treatment (p = 0.62), time (p = 
0.036), and treatment x time (p = 0.53).  Greenhouse-Geisser p-levels are reported with univariate analyses for time, treatment, 
and time x treatment interactions for each variable.  PLA = placebo, RTD = ready-to-drink pre-workout supplement, FFM = fat free 
mass, Trt = treatment, I = time x treatment interaction 
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4.4. Safety Analysis 
Table 4.4 presents hemodynamic challenge results. Although some time effects 
were observed as expected when changing postural position, no significant overall 
multivariate interaction effects (p = 0.15) or univariate interaction effects were 
observed between treatments in HR, SBP, DBP, MAP, or RPP.   
Analysis of 95% CI changes from baseline revealed that HR increased from 
baseline on Day 1 in both groups [PLA: 8.94 (5.36, 12.5); RTD: 8.35 (4.7, 12) bpm]; only 
PLA yielded a significant increase in HR from supine to standing [6.41 (2.91, 9.92) bpm] 
compared to RTD post-ingestion [2.4 (-1.2, 6) bpm].  After 6 d of supplementation, both 
treatments evidenced an increase in HR responses from pre-ingestion [PLA: 10.84 (6.91, 
14.8); RTD: 7.08 (3.06, 11.1) bpm].  Following ingestion, HR in the PLA treatment 
increased [9.35 (5.73, 13) bpm] significantly more than the RTD [3.1 (-0.5, 6.9) bpm] 
FIGURE 4.5a.  PLA increased SBP from supine to standing pre-ingestion after 6 d of 
supplementation [2.08 (0.05, 4.11) mmHg] compared to RTD [0.5 (-1.57, 2.57) mmHg] 
with no difference on Day 1 FIGURE 4.5b.  DBP significantly increased in PLA pre-
ingestion on Day 6 [2.92 (1.12, 4.72) mmHg] and no difference in RTD [0.83 (-1.01, 2.68) 
mmHg] FIGURE 4.5c.  MAP yielded a significant increase in both groups at Day 1 after 
transitioning from supine to standing [PLA: -13.7 (-17.2, -10.1); RTD: -16.7, (-20.3, -13.1) 
mmHg].  After 6 d of treatment PLA demonstrated an increase in MAP following 
ingestion [14.3 (7.35, 21.2) mmHg] and RTD was unchanged [5.25 (-1.8, 12.3) mmHg] 
FIGURE 4.6a.  There were no significant changes for either treatment related to RPP 
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FIGURE 4.6b.  Overall, blood pressure and heart rate values observed remained low and 
were well within normal values for apparently healthy younger individuals.  
Similarly, no overall multivariate or univariate effects were observed among 
serum or whole blood markers analyzed (Tables 4.5-4.7) or when analyzing the 
frequency of changes in blood parameters outside of normal clinical ranges (Table 4.8). 
Finally, as shown in Tables 4.9 and 4.10, no significant differences were observed 
between treatments in perceived side effects monitored (i.e., headache, dizziness, 
tachycardia, palpitations, dyspnea, nervousness, or blurred vision).  As the data 
provided no overall significant effect in hemodynamic response, blood chemistry, or 
frequency and severity of side effects, sufficient evidence exists to accept H3; RTD did 
not have a significant effect on indices of safety. 
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Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SE
PLA 61.5 ± 9.79 70.6 ± 12.3 65.0 ± 8.00 71.4 ± 14.1 59.0 ± 7.86 67.7 ± 10.1 68.1 ± 7.84 77.1 ± 15.2 67.9 ± 1.40 Time 0.004
RTD 60.4 ± 8.04 68.6 ± 10.9 66.6 ± 11.7 68.9 ± 12.2 60.6 ± 7.21 67.8 ± 9.50 65.9 ± 10.0 69.3 ± 12.0 66.0 ± 1.42 Trt 0.35
Time 61.0 ± 8.88 69.6 ± 11.5 65.8 ± 9.95 70.1 ± 13.2* 59.8 ± 7.51 68.8 ± 9.77 67.0 ± 9.00 73.2 ± 14.3* I 0.19
PLA 114 ± 8.06 115 ± 9.85 116 ± 7.80 115 ± 9.83 112 ± 4.62 114 ± 7.29 114 ± 5.42 113 ± 7.39 114 ± 0.76† Time <0.001
RTD 116 ± 6.47 116 ± 7.41 118 ± 7.76 118 ± 7.24 116 ± 5.56 117 ± 5.80 116 ± 8.86 116 ± 8.68 117 ± 0.77† Trt 0.019
Time 115 ± 7.29 115 ± 8.65 117 ± 7.65* 116 ± 8.69 114 ± 5.44* 115 ± 6.68 115 ± 6.61* 115 ± 8.00 I 0.84
PLA 73.0 ± 7.44 72.6 ± 9.00 73.0 ± 6.88 73.5 ± 7.90 73.0 ± 6.76 75.9 ± 7.41 74.8 ± 7.55 75.2 ± 7.85 74.0 ± 0.78 Time 0.13
RTD 74.8 ± 7.00 74.6 ± 6.05 75.6 ± 4.69 75.4 ± 5.91 72.0 ± 7.82 72.9 ± 7.66 75.2 ± 6.46 75.6 ± 6.88 74.6 ± 0.80 Trt 0.62
Time 73.9 ± 7.21 73.6 ± 7.65 74.3 ± 5.97 74.4 ± 6.97 72.5 ± 7.24 74.4 ± 7.61 75.0 ± 6.96 75.4 ± 7.31 I 0.18
PLA 86.7 ± 6.60 72.6 ± 9.00 73.0 ± 6.88 73.5 ± 7.90 73.0 ± 6.76 75.9 ± 7.41 74.8 ± 7.55 75.2 ± 7.85 75.7 ± 0.75 Time 0.44
RTD 88.4 ± 5.67 74.6 ± 6.04 75.6 ± 4.69 75.4 ± 5.91 72.0 ± 7.82 72.9 ± 7.66 75.2 ± 6.45 75.6 ± 6.88 76.3 ± 0.77 Trt 0.63
Time 87.6 ± 6.15 73.6 ± 7.65 74.3 ± 5.97 74.4 ± 6.97 72.5 ± 7.24 74.4 ± 7.61 75.0 ± 6.96 75.4 ± 7.31 I 0.18
PLA 70.2 ± 12.5 80.9 ± 14.9 75.2 ± 70.7 82.1 ± 19.3 80.9 ± 15.0 79.4 ± 12.3 82.1 ± 19.3 87.4 ± 18.5 77.6 ± 1.77 Time 0.001
RTD 69.8 ± 9.69 79.5 ± 13.3 78.6 ± 15.1 81.4 ± 16.5 79.9 ± 13.4 79.1 ± 12.0 82.3 ± 16.2 80.4 ± 16.4 77.2 ± 1.80 Trt 0.87
Time 70.0 ± 11.04 80.2 ± 14.0 76.9 ± 13.1 81.7 ± 18.0 80.4 ± 14.1* 79.2 ± 12.0 82.2 ± 17.6 83.9 ± 17.3 * I 0.23
Table 4.4.  Hemodynamic Response to Postural Challenge
Day 1 Pre-Ingestion Day 1 Pre-Ingestion
Treatment
TreatmentVariable
Values are means ± standard deviations. Multivariate analysis revealed overall Wilks’ Lambda treatment (p = 0.055), time (p < 0.001), and treatment x time (p = 0.47).  Greenhouse-Geisser 
p-levels are reported with univariate analyses for time, treatment, and time x treatment interactions for each variable.  * indicates significant change from baseline (p < 0.05). HR=Heart 
rate, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, MAP=Mean arterial pressure, RPP=Rate pressure product, Trt=Treatment, I=Time x Treatment interaction, PLA=Placebo, 
RTD=Ready-to-drink Pre-workout supplement 
HR
SBP
DBP
MAP
RPP
Supine StandingStanding Supine p -valueStanding
Day 1 Pre-Ingestion Day 1 Post-Ingestion
Supine Standing Supine
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Table 4.5. Liver, kidney, and muscle data. 
  Variable 
 
Treatment 
  
Day 1 Day 2 Day 6 Day 7 Treatment     
  Mean   SD Mean   SD Mean   SD Mean   SD Mean   SE p-value 
Li
ve
r 
AST PLA 26.4 ± 8.29 24.1 ± 5.17 25.1 ± 8.09 25.6 ± 6.56 25.4 ± 0.99 Time 0.19 
2-50 U/L 
RTD 23.5 ± 6.17 29.0 ± 21.4 26.0 ± 6.91 25.6 ± 6.27 26.3 ± 1.01 Trt 0.77 
Time 25.1 ± 7.44 26.4 ± 15.1 25.5 ± 7.49 25.6 ± 6.35       I 0.15 
ALP PLA 67.1 ± 28.7 63.5 ± 22.2 69.1 ± 18.0 65.6 ± 23.1 66.7 ± 2.22 Time 0.05 
7-60 U/L 
RTD 71.9 ± 26.3 68.2 ± 23.2 66.2 ± 28.5 68.6 ± 20.7 67.3 ± 2.26 Trt 0.71 
Time 69.3 ± 27.4 65.7 ± 22.5 67.7 ± 23.3* 67.0 ± 21.8       I 0.59 
ALT PLA 20.5 ± 8.25 18.4 ± 6.29 24.1 ± 16.6 19.7 ± 6.96 20.8 ± 0.91 Time 0.02 
44-147 U/L 
RTD 20.0 ± 6.36 20.4 ± 7.32 20.2 ± 7.18 20.7 ± 6.73 20.3 ± 0.92 Trt 0.78 
Time 20.2 ± 7.35 19.3 ± 6.79 22.3 ± 13.1* 20.2 ± 6.8*       I 0.12 
M
u
sc
le
 
CK PLA 212 ± 171 210 ± 135 208 ± 211 228 ± 225 218 ± 33.1 Time 0.19 
0-200 U/L 
RTD 163 ± 105 447 ± 837 216 ± 202 288 ± 281 278 ± 33.7 Trt 0.34 
Time 189 ± 144 321 ± 586 211 ± 205 256 ± 252       I 0.16 
LDH PLA 190 ± 55.8 171 ± 35.5 180 ± 43.6 189 ± 64.1 182 ± 4.89 Time 0.27 
140-280 
U/L 
RTD 170 ± 39.2 170 ± 39.5 195 ± 57.6 179 ± 37.6 183 ± 4.98 Trt 0.69 
Time 181 ± 49.4 171 ± 37.0 187 ± 50.7 184 ± 53.0       I 0.11 
K
id
n
ey
 
BUN PLA 5.27 ± 1.57 4.58 ± 1.26 5.60 ± 1.52 4.93 ± 1.52 5.12 ± 0.15 Time 0.68 
2.1-7.1 
mmol/L 
RTD 5.40 ± 1.65 4.76 ± 1.24 5.14 ± 1.64 5.38 ± 1.76 5.12 ± 0.15 Trt 0.87 
Time 5.33 ± 1.59 4.66 ± 1.24 5.39 ± 1.58 5.14 ± 1.64       I 0.21 
Creatinine PLA 90.0 ± 19.4 83.9 ± 19.2 89.8 ± 19.4 82.4 ± 17.2 86.9 ± 1.69 Time 0.59 
80-115 
µmol/L 
RTD 84.1 ± 14.2 84.5 ± 14.6 86.3 ± 20.1 86.3 ± 22.4 85.0 ± 1.72 Trt 0.67 
Time 87.3 ± 17.2 84.1 ± 17.0 88.2 ± 19.6 84.2 ± 19.7       I 0.24 
Values are means ± standard deviations with normal clinical values shown for each variable. Multivariate nalysis revealed overall Wilks’ Lambda treatment (p = 0.92), time (p = 0.43), and 
treatment x time (p = 0.21).  Greenhouse-Geisser p-levels are reported with univariate analyses for time, treatment, and time x treatment interactions for each variable.  * indicates 
significant difference from prior time point (p < 0.05). AST=aminoaspartate transferase, ALP=alkaline phosphatase, ALT=aminoalanine transaminase, CK=creatine kinase, LDH=lactate 
dehydrogenase, BUN=blood urea nitrogen, PLA=Placebo, RTD=ready-to-drink pre-workout supplement,  Trt=Treatment, I=Time x Treatment interaction. 
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Table 4.6. Blood lipids, macronutrients, and nitrate data. 
Variable Trt Day 1 Day 2 Day 6 Day 7 Treatment     
    Mean   SD Mean   SD Mean   SD Mean   SD Mean   SE p-value 
Glucose PLA 5.43 ± 0.90 5.25 ± 0.76 5.62 ± 1.09 5.22 ± 0.83 5.38 ± 0.12 Time 0.23 
4-6 mmol/L 
RTD 5.13 ± 0.55 5.16 ± 0.78 5.16 ± 0.91 5.30 ± 0.93 5.19 ± 0.11 Trt 0.24 
Time 5.29 ± 0.76 5.21 ± 0.76 5.41 ± 1.03 5.26 ± 0.87       I 0.33 
Triglycerides PLA 1.27 ± 0.66 1.03 ± 0.47 1.36 ± 1.23 1.23 ± 0.89 1.22 ± 0.13 Time 0.30 
1.7-2.2 
mmol/L 
RTD 2.97 ± 0.86 1.19 ± 0.65 1.16 ± 0.65 1.10 ± 0.59 1.15 ± 0.13 Trt 0.71 
Time 1.21 ± 0.64 1.11 ± 0.56 1.27 ± 1.00 1.17 ± 0.76       I 0.25 
HDL PLA 1.68 ± 0.62 1.58 ± 0.50 2.15 ± 2.88 1.62 ± 0.59 1.75 ± 0.11 Time 0.74 
1-1.55 
mmol/L 
RTD 1.55 ± 0.49 1.63 ± 0.51 1.68 ± 0.55 1.65 ± 0.47 1.61 ± 0.11 Trt 0.49 
Time 1.62 ± 0.56 1.60 ± 0.50 1.93 ± 2.13 1.63 ± 0.54       I 0.49 
Cholesterol PLA 4.92 ± 1.47 4.36 ± 1.02 4.80 ± 1.33 4.58 ± 1.24 4.66 ± 0.12 Time 0.89 
5.18-6.18 
mmol/L 
RTD 4.63 ± 1.10 4.50 ± 1.01 4.60 ± 1.07 4.56 ± 1.08 4.54 ± 0.12 Trt 0.80 
Time 4.78 ± 1.30 4.43 ± 1.01 4.71 ± 1.21 4.57 ± 1.15       I 0.47 
LDL PLA 2.57 ± 0.96 2.28 ± 0.73 2.56 ± 0.75 2.42 ± 0.69 2.47 ± 0.08 Time 0.25 
2.59-4.12 
mmol/L 
RTD 2.62 ± 1.13 2.40 ± 0.83 2.37 ± 0.81 2.45 ± 0.97 2.45 ± 0.08 Trt 0.94 
Time 2.60 ± 1.03 2.33 ± 0.77 2.47 ± 0.77 2.44 ± 0.82       I 0.42 
Nitrates PLA 0.177 ± 0.10 0.181 ± 0.13 0.197 ± 0.15 0.192 ± 0.18 0.19 ± 0.02 Time 0.29 
mmol/L 
RTD 0.163 ± 0.06 0.201 ± 0.07 0.228 ± 0.15 0.227 ± 0.11 0.21 ± 0.02 Trt 0.26 
Time 0.170 ± 0.08 0.191 ± 0.10 0.228 ± 0.15 0.209 ± 0.15       I 0.34 
Values are means ± standard deviations with normal clinical values are included with each variable. Multivariate analysis revealed overall Wilks’ Lambda treatment (p = 0.82), time (p = 
0.44), and treatment x time (p = 0.30).  Greenhouse-Geisser p-levels are reported with univariate analyses for time, treatment, and time x treatment interactions for each variable. 
HDL=high densilty lipoprotein, LDL=low density lipoprotein, PLA=Placebo, RTD=Ready-to-drink Pre-workout supplement 
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Table 4.7. Whole blood chemistry 
Variable Treatment Day 1 Day 2 Day 6 Day 7 Treatment     
    Mean   SD Mean   SD Mean   SD Mean   SD Mean   SE p-value 
WBC PLA 6.60 ± 1.45 6.04 ± 1.34 6.41 ± 1.74 5.72 ± 1.49 6.19 ± 0.15 Time 0.002 
(x10
3
/µl) RTD 6.66 ± 1.59 6.14 ± 1.53 6.22 ± 1.36 5.87 ± 1.36 6.25 ± 0.15 Trt 0.93 
  Time 6.63 ± 1.51 6.09 ± 1.43* 6.31 ± 1.55 5.79 ± 1.41*       I 0.78 
LYM PLA 2.50 ± 0.65 2.33 ± 0.72 2.62 ± 0.79 2.44 ± 0.83 2.47 ± 0.12 Time 0.13 
(%) RTD 2.59 ± 0.74 2.40 ± 1.00 2.61 ± 0.80 2.52 ± 0.85 2.53 ± 0.14 Trt 0.41 
  Time 2.55 ± 0.69 2.36 ± 0.87 2.62 ± 0.78 2.48 ± 0.84       I 0.92 
MID PLA 0.77 ± 0.23 0.66 ± 0.22 0.58 ± 0.25 0.68 ± 0.34 0.67 ± 0.04 Time 0.77 
(%) RTD 0.80 ± 0.64 0.82 ± 0.64 0.79 ± 0.54 0.80 ± 0.52 0.83 ± 0.04 Trt 0.21 
  Time 0.83 ± 0.48 0.75 ± 0.51 0.68 ± 0.42 0.74 ± 0.44       I 0.91 
GRAN PLA 3.33 ± 1.09 3.05 ± 0.82 3.21 ± 0.93 2.60 ± 1.10 3.06 ± 0.11 Time 0.01 
(x10
3
/µl) RTD 3.18 ± 1.43 2.94 ± 1.04 2.87 ± 1.08 2.56 ± 1.10 2.88 ± 0.11 Trt 0.47 
  Time 3.26 ± 1.26 3.00 ± 0.95* 3.04 ± 1.04 2.58 ± 1.09*       I 0.77 
RBC PLA 4.69 ± 0.42 4.66 ± 0.39 4.73 ± 0.57 4.73 ± 0.43 4.72 ± 0.04 Time 0.56 
(x10
6
/µl) RTD 4.83 ± 0.53 4.85 ± 0.58 4.80 ± 0.48 4.84 ± 0.54 4.81 ± 0.04 Trt 0.06 
  Time 4.76 ± 0.48 4.76 ± 0.50 4.77 ± 0.55 4.78 ± 0.44       I 0.50 
HGB PLA 13.92 ± 1.31 13.91 ± 1.14 14.28 ± 1.44 14.03 ± 1.24 14.1 ± 0.12 Time 0.76 
(g/dl) RTD 14.10 ± 1.55 14.42 ± 1.83 14.12 ± 1.43 14.30 ± 1.77 14.2 ± 0.12 Trt 0.32 
  Time 14.16 ± 1.53 14.16 ± 1.53 14.20 ± 1.42 14.16 ± 1.50       I 0.16 
Values are means ± standard deviations. Multivariate analysis revealed overall Wilks’ Lambda treatment (p = 0.61), time (p = 0.052), and treatment x time (p = 0.99).  Greenhouse-
Geisser p-levels are reported with univariate analyses for time, treatment, and time x treatment interactions for each variable.  * represents p<0.05 change from baseline.  
PLA=Placebo, RTD=Ready-to-drink Pre-workout supplement, Trt=Treatment, I=Time x Treatment interaction.  WBC=white blood cells leukocyte count, LYM=lymphocytes, MID=mid-
range absolute count, GRAN=granulocytes, RBC=red blood counts, HGB=hemoglobin, HCT=hematocrit, MCV=mean cell volume, MCH=mean cell hemoglobin, MCHC=mean corpuscular 
hemoglobin concentration, RDW=red blood cell distribution width. 
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Table 4.7. Whole Blood Chemistry 
Variable Treatment Day 1 Day 2 Day 6 Day 7 Treatment     
    Mean   SD Mean   SD Mean   SD Mean   SD Mean   SE p-value 
HCT PLA 43.97 ± 3.72 43.50 ± 3.23 45.17 ± 4.60 44.14 ± 3.77 44.3 ± 0.34 Time 0.63 
(%) RTD 45.10 ± 4.69 45.38 ± 4.87 44.95 ± 4.24 44.90 ± 4.57 44.9 ± 0.34 Trt 0.21 
  Time 44.55 ± 4.35 44.44 ± 4.20 45.06 ± 4.40 44.52 ± 4.16       I 0.20 
MCV PLA 93.89 ± 3.48 93.46 ± 3.81 93.95 ± 3.25 92.36 ± 5.54 93.4 ± 0.37 Time 0.09 
(fL) RTD 93.54 ± 3.29 93.78 ± 3.74 93.82 ± 3.43 92.47 ± 4.75 93.5 ± 0.38 Trt 0.99 
  Time 93.72 ± 3.35 93.62 ± 3.43 93.88 ± 3.31 92.41 ± 5.11       I 0.84 
MCH PLA 29.72 ± 1.32 29.86 ± 1.32 29.70 ± 1.09 29.70 ± 1.29 29.7 ± 0.14 Time 0.89 
(pg/cell) RTD 29.61 ± 1.37 29.75 ± 1.58 29.46 ± 1.38 29.58 ± 1.42 29.6 ± 0.14 Trt 0.68 
  Time 29.66 ± 1.33 29.81 ± 1.44 29.58 ± 1.24 29.64 ± 1.34       I 0.93 
MCHC PLA 31.65 ± 0.82 31.97 ± 0.75 31.64 ± 0.96 31.78 ± 0.76 31.8 ± 0.10 Time 0.79 
(g/dl) RTD 31.67 ± 1.10 31.73 ± 1.32 31.40 ± 1.08 31.82 ± 1.08 31.6 ± 0.10 Trt 0.54 
  Time 31.66 ± 0.96 31.86 ± 1.07 31.52 ± 1.01 31.79 ± 0.93       I 0.72 
RDW PLA 13.14 ± 0.89 13.04 ± 0.63 13.29 ± 0.85 13.09 ± 0.72 13.1 ± 0.08 Time 0.66 
(%) RTD 13.32 ± 0.86 13.52 ± 1.06 13.20 ± 0.85 13.42 ± 0.76 13.4 ± 0.09 Trt 0.20 
  Time 13.23 ± 0.87 13.28 ± 0.90 13.24 ± 0.85 13.25 ± 0.75       I 0.12 
Values are means ± standard deviations. Multivariate analysis revealed overall Wilks’ Lambda treatment (p = 0.61), time (p = 0.052), and treatment x time (p = 0.99).  Greenhouse-
Geisser p-levels are reported with univariate analyses for time, treatment, and time x treatment interactions for each variable.  * represents p<0.05 change from baseline.  
PLA=Placebo, RTD=Ready-to-drink Pre-workout supplement, Trt=Treatment, I=Time x Treatment interaction.  WBC=white blood cells leukocyte count, LYM=lymphocytes, MID=mid-
range absolute count, GRAN=granulocytes, RBC=red blood counts, HGB=hemoglobin, HCT=hematocrit, MCV=mean cell volume, MCH=mean cell hemoglobin, MCHC=mean 
corpuscular hemoglobin concentration, RDW=red blood cell distribution width. 
 118 
 
Table 4.8. Change in blood markers relative to normal clinical limits from Day 1 to 
Day 7 
    Change       
    No 
Change 
Normal 
to High 
High to 
Normal 
High to 
High 
      
Marker Treatment n p-value 
AST PLA 24 0 0 1 25 
Trt 0.31 
2-50U/L 
RTD 25 0 0 0 25 
Time 49 0 0 1 50 
ALP PLA 23 0 2 0 25 
Trt 0.51 
7-60U/L 
RTD 23 0 1 1 25 
Time 46 0 3 1 50 
ALT PLA 22 0 1 2 25 
Trt 0.49 44-147-
U/L 
RTD 24 0 0 1 25 
Time 46 0 1 3 50 
CK PLA 11 8 3 3 25 
Trt 0.62 
0-200 U/L 
RTD 13 4 4 4 25 
Time 24 12 7 7 50 
LDH PLA 2 16 4 3 25 
Trt 0.64 140-280-
U/L 
RTD 2 12 5 6 25 
Time 4 28 9 9 50 
BUN PLA 24 0 0 1 25 
Trt 0.60 2.1-7.1-
mmol/L 
RTD 23 0 1 1 25 
Time 47 0 1 2 50 
Creatinine PLA 18 1 4 2 25 
Trt 0.10 80-115-
umol/L 
RTD 24 0 0 1 25 
Time 42 1 4 3 50 
Glucose PLA 25 0 0 0 25 
Trt 1.00 4.0-6.0-
mmol/L 
RTD 25 0 0 0 25 
Time 50 0 0 0 50 
Data are presented as number of occurrences and were analyzed by Pearson's Chi Square on a marker-by-marker basis.  
Pearson's Chi Square p-values listed for each variable with significance determined at p < 0.05. Data were arranged so that 
values within normal clinical ranges were labelled 'Normal' and values above normal clinical ranges were labelled 'High'.  
They were then assessed as 'Normal/Normal' or 'No Change', 'Normal/High', 'High/Normal', or 'High/High' to address 
values at Day 1 and Day 7. No significant differences were noted.  AST=aminoaspartate transferase, ALP=alkaline 
phosphatase, ALT=aminoalanine transaminase, CK=creatine kinase, LDH=lactate dehydrogenase, BUN=blood urea 
nitrogen, HDL=high densilty lipoprotein, LDL=low density lipoprotein, PLA=placebo, RTD=ready to drink. 
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Table 4.8. Change in blood markers relative to normal clinical limits from Day 1 to 
Day 7 
    Change       
    No 
Change 
Normal 
to High 
High to 
Normal 
High to 
High 
      
Marker Treatment n p-value 
Triglycerides PLA 25 0 0 0 25 
Trt 1.00 1.7-2.2-
mmol/L 
RTD 25 0 0 0 25 
Time 50 0 0 0 50 
HDL PLA 6 13 5 1 25 
Trt 0.09 1.0-1.55-
mmol/L 
RTD 7 11 1 6 25 
Time 13 24 6 7 50 
Cholesterol PLA 16 5 2 2 25 
Trt 0.37 5.18-6.18-
mmol/L 
RTD 19 1 2 3 25 
Time 35 6 4 5 50 
LDL PLA 22 0 2 1 25 
Trt 0.84 2.59-4.12-
mmol/L 
RTD 23 0 1 1 25 
Time 45 0 3 2 50 
Data are presented as number of occurrences and were analyzed by Pearson's Chi Square on a marker-by-marker basis.  
Pearson's Chi Square p-values listed for each variable with significance determined at p < 0.05. Data were arranged so that 
values within normal clinical ranges were labelled 'Normal' and values above normal clinical ranges were labelled 'High'.  
They were then assessed as 'Normal/Normal' or 'No Change', 'Normal/High', 'High/Normal', or 'High/High' to address values 
at Day 1 and Day 7. No significant differences were noted.  AST=aminoaspartate transferase, ALP=alkaline phosphatase, 
ALT=aminoalanine transaminase, CK=creatine kinase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen, HDL=high 
densilty lipoprotein, LDL=low density lipoprotein, PLA=placebo, RTD=ready to drink. 
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PLA RTD PLA RTD PLA RTD PLA RTD PLA RTD PLA RTD PLA RTD PLA RTD
Dizziness 0 22 22 19 18 22 22 20 18 21 19 20 19 22 21 19 16 Trt 0.49
1 0 0 3 4 0 0 1 3 1 2 1 2 0 1 3 4
2 0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 2
3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Headache 0 20 20 21 21 21 21 21 21 21 20 20 19 21 20 18 18 Trt 0.85
1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 3 2
2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1
3 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tachycardia 0 21 21 18 16 22 21 18 15 21 20 17 16 21 19 17 16 Trt 0.89
1 1 1 2 3 0 1 1 3 1 2 2 3 0 3 2 2
2 0 0 1 1 0 0 2 2 0 0 3 2 1 0 3 3
3 0 0 1 1 0 0 1 0 0 0 0 1 0 0 0 1
4 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0
Palpitations 0 21 22 20 20 21 21 19 20 21 21 20 19 22 21 20 20 Trt 0.24
1 1 0 2 1 1 1 2 0 1 0 2 1 0 0 2 0
2 0 0 0 0 0 0 0 1 0 1 0 2 0 1 0 0
3 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 2
4 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Dyspnea 0 20 20 18 17 21 21 17 14 20 20 17 16 21 19 18 13 Trt 0.56
1 2 2 1 2 1 1 2 5 2 2 3 3 1 3 2 5
2 0 0 2 2 0 0 1 1 0 0 1 3 0 0 1 3
3 0 0 1 1 0 0 2 2 0 0 1 0 0 0 1 1
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nervous 0 19 20 19 21 19 20 19 20 21 20 20 21 21 20 20 20 Trt 0.92
1 1 2 1 1 2 2 2 2 1 2 2 1 1 2 2 2
2 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
3 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Blurred 0 22 21 20 20 21 22 21 20 22 21 21 21 22 22 21 21 Trt 0.54
Vision 1 0 1 2 1 1 0 1 2 0 1 1 0 0 0 1 0
2 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 1
3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other 0 22 22 22 19 22 20 22 19 22 20 22 19 22 21 22 20 Trt 0.54
Side Effects 1 0 0 0 3 0 1 0 3 0 0 0 2 0 0 0 1
2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1
5 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0
Table 4.9. Frequency of Self-Reported Side Effects
Variable & 
no. of 
occurrences
Day 1 Day 2 Day 6 Day 7
Post-
p -value
Pre- Post-Pre- Post- Pre- Post- Pre-
Data are presented as number of occurrences and were anaylyzed by Pearson's Chi Square on a question-by-question basis.  Pearson's Chi Square p-
values listed for each variable with significance determined at p < 0.05. Values are as follows: 0=No occurrences, 1=1- to 2-occurrences/wk, 2=3- to 
4- occurrences/wk, 3=5- to 6-occurrences/wk, 4=7 occurrences/wk, 5=More than 7 occurrences/wk.  No significant between-group differences were 
noted.
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Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
PLA 0.00 ± 0.0 0.18 ± 0.4 0.00 ± 0.0 0.14 ± 0.5 0.18 ± 0.7 0.09 ± 0.3 0.00 ± 0.0 0.23 ± 0.7 Time 0.03
RTD 0.00 ± 0.0 0.32 ± 0.7 0.00 ± 0.0 0.45 ± 1.1 0.27 ± 0.7 0.32 ± 0.9 0.14 ± 0.6 0.59 ± 1.0 Trt 0.14
Time 0.00 ± 0.0 0.50 ± 1.1 * 0.00 ± 0.0 * 0.59 ± 1.5 * 0.45 ± 1.4 0.41 ± 1.2 0.14 ± 0.6 ‡ 0.82 ± 1.7 * I 0.58
PLA 0.14 ± 0.5 0.05 ± 0.2 0.05 ± 0.2 0.18 ± 0.7 0.05 ± 0.2 0.09 ± 0.3 0.05 ± 0.2 0.32 ± 0.8 Time 0.46
RTD 0.09 ± 0.3 0.05 ± 0.2 0.00 ± 0.0 0.00 ± 0.0 0.14 ± 0.6 0.36 ± 1.1 0.14 ± 0.5 0.41 ± 0.9 Trt 0.74
Time 0.09 ± 0.3 0.05 ± 0.2 0.00 ± 0.0 0.00 ± 0.0 0.14 ± 0.6 0.36 ± 1.1 0.14 ± 0.5 0.41 ± 0.9 I 0.41
PLA 0.00 ± 0.0 0.45 ± 1.0 0.00 ± 0.0 0.55 ± 1.0 0.05 ± 0.2 0.27 ± 0.7 0.00 ± 0.0 0.18 ± 0.6 Time 0.29
RTD 0.05 ± 0.2 0.59 ± 1.1 0.00 ± 0.0 0.96 ± 1.5 0.23 ± 1.1 0.59 ± 1.2 0.27 ± 1.1 0.64 ± 1.3 Trt 0.26
Time 0.05 ± 0.2 0.59 ± 1.1 0.00 ± 0.0 0.96 ± 1.5 0.23 ± 1.1 0.59 ± 1.2 0.27 ± 1.1 0.64 ± 1.3 I 0.64
PLA 0.05 ± 0.2 0.09 ± 0.3 0.05 ± 0.2 0.09 ± 0.3 0.05 ± 0.2 0.09 ± 0.3 0.00 ± 0.0 0.36 ± 1.5 Time 0.34
RTD 0.00 ± 0.0 0.18 ± 0.7 0.05 ± 0.2 0.36 ± 1.2 0.18 ± 0.9 0.27 ± 0.9 0.23 ± 0.9 0.32 ± 1.0 Trt 0.53
Time 0.00 ± 0.0 0.18 ± 0.7 0.05 ± 0.2 0.36 ± 1.2 0.18 ± 0.9 0.27 ± 0.9 0.23 ± 0.9 0.32 ± 1.0 I 0.54
PLA 0.05 ± 0.2 0.41 ± 1.0 0.05 ± 0.2 0.64 ± 1.1 0.09 ± 0.3 0.27 ± 0.7 0.00 ± 0.0 0.32 ± 0.8 Time 0.06
RTD 0.09 ± 0.3 0.41 ± 0.9 0.00 ± 0.0 0.82 ± 1.3 0.18 ± 0.9 0.55 ± 1.1 0.23 ± 0.9 0.96 ± 1.5 Trt 0.30
Time 0.09 ± 0.3 0.41 ± 0.9 0.00 ± 0.0 0.82 ± 1.3 0.18 ± 0.9 0.55 ± 1.1 0.23 ± 0.9 0.96 ± 1.5 I 0.24
PLA 0.18 ± 0.5 0.05 ± 0.2 0.18 ± 0.5 0.09 ± 0.3 0.05 ± 0.2 0.09 ± 0.3 0.05 ± 0.2 0.09 ± 0.3 Time 0.57
RTD 0.09 ± 0.3 0.05 ± 0.2 0.05 ± 0.2 0.05 ± 0.2 0.00 ± 0.0 0.05 ± 0.2 0.09 ± 0.3 0.09 ± 0.3 Trt 0.50
Time 0.09 ± 0.3 0.05 ± 0.2 0.05 ± 0.2 0.05 ± 0.2 0.00 ± 0.0 0.05 ± 0.2 0.09 ± 0.3 0.09 ± 0.3 I 0.45
PLA 0.00 ± 0.0 0.09 ± 0.3 0.05 ± 0.2 0.05 ± 0.2 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.05 ± 0.2 Time 0.33
RTD 0.05 ± 0.2 0.09 ± 0.4 0.00 ± 0.0 0.18 ± 0.7 0.14 ± 0.6 0.23 ± 0.8 0.14 ± 0.6 0.14 ± 0.6 Trt 0.27
Time 0.05 ± 0.2 0.09 ± 0.4 0.00 ± 0.0 0.18 ± 0.7 0.14 ± 0.6 0.23 ± 0.8 0.14 ± 0.6 0.14 ± 0.6 I 0.51
PLA 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 Time 0.17
RTD 0.00 ± 0.0 0.32 ± 0.9 0.32 ± 1.0 0.46 ± 0.9 0.27 ± 0.9 0.36 ± 0.9 0.14 ± 0.6 0.41 ± 1.1 Trt 0.06
Time 0.00 ± 0.0 0.32 ± 0.9 0.32 ± 1.0 0.46 ± 0.9 0.27 ± 0.9 0.36 ± 0.9 0.14 ± 0.6 0.41 ± 1.1 I 0.19
p-value
Table 4.10. Severity of Self-Reported Side Effects
Day 1 Day 2 Day 6 Day 7
Variable Treatment
Pre-
Blurry Vision
Other side 
effects
Dizziness
Headache
Tachycardia
Mean Data presented as Mean ± SD.  Multivariate  Wilk's Lambda analysis revealed no time (p = 0.12), treatment (p = ), or time x treatment interaction effect (p = 0.42).  Greenhouse-Geisser 
p-values are listed for each variable to show time, treatment, and interaction effects with significance determined at p < 0.05.  A score of 0 means no severity and a score of 4 equals 
maximum severity.  * indicates a significant difference from the prior time point (p < 0.05).  PLA=Placebo, RTD=Ready-to-drink Pre-workout supplement
Dyspnea
Nervous
Pre- Post- Post-Pre- Post- Pre- Post-
Palpitations
  
*Reprinted with permission from “Short-Term Effects of a Ready-to-Drink Pre-Workout 
Beverage on Exercise Performance and Recovery” by Collins, et al., Nutrients, 2017, 
1;9(8), Copyright 2017 by Patrick Blaise Collins 
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CHAPTER V 
CONCLUSIONS* 
 
5.1. Discussion 
This study has been published previously and this discussion is an extended 
explanation of published material [206].  The aim of this study was to examine whether 
acute and/or short-term term ingestion of a commercially available pre-workout RTD 
beverage would affect workout performance, hemodynamic reactivity, and/or 
hematological affects during a 7 days intervention period. Overall, there was some 
evidence of better maintenance of recovery 1-RM and improvement in recovery 
muscular endurance with acute (Day 1) and short-term (Day 6) RTD supplementation. 
These findings suggest that acute and/or short-term ingestion of this RTD beverage 
may provide ergogenic benefit after a short recovery from resistance-training. 
However, ingestion of this RTD had no effects on 4 km cycling time-trial performance. 
Additionally, we observed no evidence that acute or short-term ingestion of this RTD 
negatively affected hemodynamic responses to a standardized hemodynamic 
challenge, fasting blood makers, or perceived side effects. Based on these findings, the 
hypotheses that the RTD studied would improve resistance-exercise strength and 
endurance exhaustive exercise without undue alterations in hepatorenal and muscle 
enzyme function, hemodynamic responses to a postural challenge, or self-reported side 
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effects are accepted. However, there was insufficient evidence that acute and/or short-
term ingestion of this RTD affected 4 km cycling time-trial performance in non-trained 
cyclists. The following discussion provides additional insight as to results observed. 
 
5.2. Performance 
 Caffeine is well-known for improving exercise performance and has been 
extensively reviewed elsewhere [22, 32, 76, 210]. Most recently, Souza et al. performed 
a systematic review and meta-analysis of caffeine containing energy drinks, finding 
significant improvements in muscular strength and endurance (ES = 0.49), endurance 
exercise tests (ES = 0.53), jumping (ES = 0.29) and sport-specific actions (ES = 0.51), but 
not in sprinting (ES = 0.14) [80].  A separate review by Warren, et al. found caffeine to 
have a greater effect on lower body strength (ES = 0.37) and endurance (ES = 0.28) [76]. 
The relative caffeine in this study, calculated from the absolute value of 200 mg 
found in the treatment divided by average weight, was 2.51 ± 0.4 mg/kg for males and 
3.1 ± 0.5 mg/kg for females.  The dose of 2.5 to 3.1 mg of caffeine is on the lower 
portion of the ergogenic range of 3 to 9 mg/kg; however, a number of studies have 
noted ergogenic benefits from as little as 2 mg/kg [22, 30, 66-69, 72, 92, 211].  The data 
in the present study evidenced acute use as well as short-term (6 d) use promoted 
better maintenance of strength and endurance following exhaustive exercise.  These 
findings are in agreement with prior research from our lab [98, 99] as well as the 
literature reviewed showing an ergogenic effect of lower doses of caffeine.  There does 
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exist the possibility that the ergogenic effect of caffeine in this study may have been 
synergistically enhanced by other ingredients; however, there is conflicting evidence.  
In a review, Souza, et al. [210] found energy drinks containing both taurine and caffeine 
to potentially enhance the effects of caffeine whereas Hendrix, et al. [20] found a 
caffeine supplement containing 400 mg caffeine, 67 mg capsaicin, and 10 mg bioprene 
had no effect on bench or leg press one repetition maximum or time to exhaustion at 
80% maximal power output on cycle ergometer. 
Recently, research of nitrates on resistance training and sprint performance has 
received more interest [23-25, 125, 165, 212-214] compared to those investigating 
nitrates in relation to endurance oriented performance variables [102, 164, 215].  The 
literature investigating nitrates and resistance training has consistently evidenced 
safety as well as an ergogenic effect at doses of approximately 4.8 mmol (300 mg) 
similar to the 5.7 mmol (353 mg) found in the current work [27, 28, 111, 112, 164].  In 
the studies found regarding nitrates by themselves, significant increases were seen in 
repetitions to failure and total lifting volume [26, 111, 126, 216] as well as showing 
increased muscle firing rates via EMG [217] with no effect on heart rate which is in line 
with the findings from the current work.  These studies generally demonstrate that 
nitrate supplementation prior to exercise can enhance endurance and high-intensity 
intermittent exercise performance.  For this reason, addition of nitrates to pre-workout 
supplements has received increasing interest [23, 26, 98-100, 111, 121, 130, 157, 214].  
The results of the present work evidenced an ergogenic effect of concomitant use of 
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caffeine and nitrates to promote maintenance of muscular strength and/or endurance; 
however, the data do not support an ergogenic effect on time trial performance which 
is in contrast to recent findings [26, 98, 100, 101, 111, 121, 157].  These conflicting 
results could potentially be a function of greater variability in non-trained cyclists, 
differences in the dosages and/or timing of ingestion of the nitrate-containing RTD, or 
use of arginine nitrate as opposed to other forms of nitrates. 
 
5.3. Safety 
Concerns have been presented previously related to the effects of caffeine or 
nitrates on cardiovascular health and hemodynamic response to exercise [21, 204, 205, 
218, 219]; this is the primary reason for assessing responses to the hemodynamic 
challenge test before and after strength testing.  The hemodynamic challenge test was 
appropriate as a normal exercise bout involves multiple postural changes from supine 
to standing which may increase the chance of occurrence of orthostatic hypotension, 
particularly when supplementation with ingredients thought to increase the risk is 
undertaken.  As hypothesized, there was no evidence of a negative effect on 
hemodynamic response associated with the RTD.  In addition, the present work yielded 
no evidence of negative effects on blood chemistry or side effects.  Overall, these data 
are in agreement with previous work from our lab [98-100] and other studies [220, 
221]. 
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5.4. Strengths and Limitations 
A strength of the current work was the use of a fairly large cohort comprised of 
men and women who ingested their respective treatments in addition to their normal 
diet in a randomized double blind, cross-over manner.  While this does not discount the 
possibility that gender differences may exist when using a larger or single-gender study 
protocol, gender served as a covariate to account for gender differences.  Additionally, 
the muscular performance protocol was vigorous with regard to the number of 
exercises performed during testing and applicable as typical resistance-training sessions 
are comprised of multiple sets of multiple exercises; thus, the design allowed for a 
practical assessment of the ability of resistance-trained participants to maintain 
performance throughout a rigorous workout. 
Finally, a strength of this study was the concerted effort to examine several 
parameters associated with safety by examining potential hemodynamic changes 
accompanying supplementation and exercise as well as a thorough analysis of 
hepatorenal and muscle enzyme function associated with the supplementation 
protocol.  Assessment of the cardiovascular and hemodynamic responses to a postural 
challenge represents a similar pattern of movement as would take place during 
resistance training, as athletes often go from supine to standing positions throughout a 
workout and may experience orthostatic hypotension.  Furthermore, a further strength 
of this study was an extended reporting schema to include potential changes out of 
normal clinical ranges, without adverse consequence. 
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Potential limitations in the present study included the utilization of 
recommended absolute serving sizes rather than relative doses to body weight or fat-
free mass. It is possible that more consistent performance results would have been 
observed if relative doses were used; however, this is not how these types of 
supplements are consumed so normal serving sizes were controlled for by using 
relative caffeine intake as a covariate in the analysis.  Additionally, although prior 
research in our lab has examined the effects of ingesting pre-workout supplements for 
up to 8 weeks, this study only assessed the acute and short-term effects.  It is possible 
that the ergogenic benefits may lessen with longer periods of supplementation due to 
habituation, but research in this area is limited.  Of note, RTD products are marketed as 
having an immediate effect on performance without requiring a loading period or 
alterations in diet; this design was a practical analysis of how individuals may use this 
type of supplement. 
Another potential limitation was the examination of the effects of this RTD on 
recreationally-active resistance-trained participants.  While this population was well-
prepared to assess changes in muscular strength and endurance performance, they 
were not trained cyclists accustomed to performing sprints. Thus, it is conceivable that 
the lack of effect observed on 4 km cycling time-trial performance may have been 
affected by a lack of familiarity with cycling, regardless of partaking in a familiarization 
session.  Additional research should examine whether ingestion of this type of RTD may 
affect sprint and/or high-intensity short-duration sprint performance.  
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5.5. Conclusions 
Based on the collective findings and within the limitations of the current work, 
the RTD treatment used in this study appears to acutely improve indices of strength 
training via the observed improvement in bench press, leg press, and total lifting 
volume, as well as an attenuated decrease in one repetition maximum.  Consumption 
of the RTD did not have an effect on 4 km time trial performance on the cycle 
ergometer in non-cycling trained participants.  The RTD also appears to be safe in 
resistance-trained, college-aged males and females; however, additional research 
should assess the safety and efficacy of nutrients found in pre-workout supplements so 
that active individuals may make an informed decision concerning the use of 
supplements during training and/or competition. 
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